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Abstract 
 
Members of the phosphoinositide-specific phospholipase C (PI-PLC) enzyme family 
play a fundamental role in cell signalling pathways by regulating cytosolic calcium 
and/or the activity of several protein kinases. This thesis reports the identification, 
molecular cloning and characterisation of a potential seventh sub-class of the PI-PLC 
enzyme family, the phospholipase C X-domain containing proteins (PLCXDs), which 
contain only an X domain in their structure. Comparative sequence analysis has 
identified at least three PLCXD isoforms in the human and mouse genomes (PLCXDs 1, 
2 and 3), and at least four isoforms in the European eel (PLCXDs 1-4). Key amino acid 
residues responsible for the catalytic properties of PI-PLCs were found to be conserved 
in human, mouse and eel PLCXDs 1, 2 and 3, but were absent in the sequence of eel 
PLCXD4. PLCXD isoforms displayed unique tissue-specific expression profiles and some 
similarities between species. Interestingly, in mouse PLCXD1-3 mRNA were found to 
be predominantly expressed in the brain, however this is yet to be confirmed in 
humans. Analysis of in situ hybridisation data in mice revealed each PLCXD to be 
localised in neurons within different brain regions, highly suggestive of unique roles in 
brain function. Furthermore, the levels of PLCXD3 protein were reduced by more than 
99% in cerebella samples from a mouse model of neurodegeneration (Harlequin 
mouse) compared to control mice. Human PLCXD1, 2 and 3 were found to increase 
phosphoinositide turnover when overexpressed in the HeLa cell line, and recombinant 
PLCXD3, purified to homogeneity from E. coli, was found to interact with various 
phosphoinositides including PI(4,5)P2. 31P-NMR analysis of PI(4,5)P2 and PI before and 
VIII 
 
after the addition of PLCXD3 purified from HeLa cells and E. coli revealed no difference 
in the 31P spectra whereas expected chemical shifts were seen following the addition 
of purified bacterial PI-PLC. Significant formation of inclusion bodies was noted when 
human PLCXDs 1, 2 and 3 were expressed as recombinant proteins in E. coli. Different 
strategies aimed at optimising the expression of recombinant PLCXD1, 2 and 3, 
including the use of different fusion proteins and screening expression in E. coli, 
mammalian and insect cells had limited success, with the best soluble expression only 
seen with PLCXD3 in insect cells.  Attempts to scale-up the purification of PLCXD3 from 
insect cells to provide sufficient protein for enzyme assays and crystal screens were 
unsuccessful. The results presented herein suggest that these novel proteins possess 
distinct and as yet uncharacterised tissue-specific roles in cell physiology. 
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CHAPTER 1: INTRODUCTION 
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1.1. Signal transduction 
The survival of all organisms is governed by their dynamic ability to coordinate 
constantly their activities with environmental changes. Successful communication 
with the environment is achieved through a number of signal transduction pathways 
that receive and process signals from the external environment, from other cells 
within the organism and also from different regions within the cell. Signal transduction 
pathways coordinate a wide range of physiological activities including: cell growth and 
division; differentiation and development; cell motility and morphology; and cell 
metabolism. A deep appreciation and understanding of the different signal 
transduction pathways and the interplay between them is therefore essential for the 
development of approaches to correct abnormal cell functions. 
1.2. Discovery of phosphoinositides 
Inositol-containing phospholipids, also known as phosphoinositides, comprise a group 
of membrane lipids with different arrangements of phosphate groups attached to the 
polar inositol head-group. Although together they only represent a small fraction of 
the total cellular phospholipid pool, enzymatic regulation of the abundance of the 
different inositol phospholipids is a fundamental component of one of the many signal 
transduction pathways found in animal cells (Balla, 2013). Initial identification and 
characterisation of the various phosphoinositides began with the observation that 
inositol can be incorporated into some lipids present within mycobacteria (Anderson 
and Roberts, 1930). Furthermore, analysis of lipid extracts prepared from bovine brain 
identified inositol phospholipids that contain phosphate groups in approximate ratio 
of 2:1 with inositol. These lipids were named diphosphoinositides and were found to 
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be present in a number of different cells and tissues (Folch, 1949). Our understanding 
of the complexity of the inositol phospholipid family was extended following the 
identification of mono and tri-phosphorylated derivatives of inositol phospholipids in 
lipid extracts, giving a total of three major classes known as the mono-, di-, and tri-
phosphoinositides. Characterisation of these lipids revealed that they all had similar 
chemical structures consisting of a diacyglycerol backbone (two fatty acids esterified 
onto glycerol) attached through a diester phosphate to the 1-hydroxyl of the inositol 
ring (Mitchell, 1975). Cartoon structures of these lipids are shown in Figure 1.1.  
 These lipids were also found to be present in many types of cells and 
tissues and were therefore thought to be essential for the normal functions of most 
cells. These lipids are now more correctly referred to as phosphatidylinositol (PI), 
phosphatidylinositol 4-phosphate (PI(4)P) and phosphatidylinositol 4,5-bisphosphate 
(PI(4,5)P2) (Mitchell, 2008; Figure 1.1).  The physiological importance of these lipids 
began to be revealed in 1953 following the observation of that acetylcholine could 
induce rapid changes in the abundance of certain lipids within this phosphoinositide 
pool in rat pancreatic slices (Hokin, 1953). The discovery of the further phosphorylated 
versions of phosphatidylinositol, including phosphatidylinositol 3-phosphate  (PI(3)P), 
phosphatidylinositol 3,4-bisphosphate PI(3,4)P2 and phosphatidylinositol 3,4,5-
trisphosphate PI(3,4,5)P3 in 1988 (Traynor-Kaplan et al., 1988; Whitman et al., 1988) 
and phosphatidylinositol 5-phosphate (PI(5)P) and phosphatidylinositol 3,5-
bisphopshate (PI(3,5)P2) in 1997 (Dove et al., 1997; Rameh et al., 1997) gave 
phosphoinositide research a new focus. There are now seven phosphorylated 
derivatives of phosphatidylinositol known to exist in mammalian cells. These are 
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derived through phosphorylation and de-phosphorylation of the inositol head-group 
by a variety of lipid kinases and phosphatases at three positions, 3, 4 and 5 (Kadamur 
and Ross, 2013; Figure 1.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Schematic depiction of the chemical structures of the eight 
phosphoinositides found in mammalian cells. Each of the 8 phosphoinositides has a 
similar chemical structure which consists of two fatty acids esterified onto glycerol 
(Diacylglycerol) which is attached, through a diester phosphate, to the 1-hydroxyl of 
the inositol ring. The inositol moiety can be reversibly phosphorylated at positions 3, 
4 and 5 of the inositol ring. Taken from Hawkins et al., 2006.  
 
1.3. Pathways for phosphoinositide biosynthesis 
The synthesis of phosphoinositides involves the formation of the six carbon cyclitol, 
inositol. In nature a total of nine possible stereoisomers of inositol have been 
identified to date. In eukaryotic cells myo-inositol is physiologically the most important 
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stereoisomer and is used for phospholipid synthesis (Mitchell, 2008). The biosynthesis 
of myo-inositol can occur through two pathways: the de novo pathway and the salvage 
pathway. In all organisms studied to date, the de novo synthesis of myo-inositol follows 
a common pathway. The NAD+-dependent myo-inositol 3-phosphate synthase (MIPS) 
converts glucose 6-phosphate (G 6-P) to myo-inositol 3-phosphate (MIP), which is 
subsequently dephosphorylated to myo-inositol by inositol monophosphatase (IMPA; 
Nuwayhid et al., 2006). Alternatively, myo-inositol can be regenerated from any myo-
inositol 1-phosphate recycled from the membrane phospholipid pool through the 
action of IMPA (Mitchell, 2008). 
Once synthesized perhaps the best know fate of myo-inositol is as a precursor for the 
biosynthesis of phosphatidylinositol. In this pathway phosphatidylinositol synthase 
catalyses attachment of cytidine diphosphate diacylglycerol (CDP-DAG) to the D1-
hydroxyl group of myo-inositol, forming phosphatidylinositol and releasing cytidine 
monophosphate (CMP; Shen and Dowhan, 1996). As with myo-inositol, the 
biosynthesis of CDP-DAG can occur through de novo synthesis and a salvage pathway. 
The former uses dihydroxyacetone phosphate derived from glucose to make glycerol 
3-phosphate, which becomes acylated at carbon-1 and carbon-2 to yield phosphatidic 
acid (PA; Nuwayhid et al., 2006). Subsequently, the enzyme CDP-diacylglycerol 
synthase then catalyses the condensation of PA and cytidine triphosphate (CTP), 
eliminating pyrophosphate and forming CDP-DAG (Heacock and Agranoff, 1997). The 
latter involves DAG derived from the phosphatidylinositol-specific phospholipase C (PI-
PLC)-mediated PIP2 hydrolysis, which subsequently becomes converted to PA through 
the action of DAG kinase which is used to form CDP-DAG as described above (Li et al., 
6 
 
2013). Phosphatidylinositol can then be reversibly phosphorylated at one or a 
combination of positions (3, 4 or 5) on the inositol head-group, which results in a total 
of eight phosphoinositide species. The levels and turnover of the different 
phosphoinositides are tightly regulated by families of lipid kinases and phosphatases 
and also phosphatidylinositol-specific phospholipase Cs (Mitchell, 2008; PI-PLCs).  
1.4. The evolving physiological significance of PIP2 
Although PIP2 represents only 1% of the total cellular phospholipid pool, it has 
important regulatory roles in many cellular processes. PIP2 is mainly found in the inner, 
cytoplasmic leaflet of the plasma membrane but is also present in Golgi, ER and the 
nuclear membranes (McLaughlin et al., 2002). The main route leading to the 
production of PIP2 is through phosphorylation of phosphatidylinositol-4-phosphate by 
the action of PIP5 kinase (PIP5K). However, PIP2 can also be produced through the 
phosphorylation of PI(5)P by through the action of PIP4 kinase (PIP4K). The kinase 
involved in PIP2 synthesis depends on the cellular location as PIP5K is mainly found at 
the plasma membrane whereas PIP4K is found in the cytosol, ER and the nucleus 
(Mitchell, 2008).  
1.4.1. Phosphoinositide-specific phospholipase C-mediated PIP2 hydrolysis 
Early studies into the physiological roles of PIP2 established a role for this lipid in the 
production of two second messenger molecules in the cell, diacylglycerol (DAG) and 
inositol trisphosphate (IP3). An enzyme central to this process, and therefore a major 
regulator of PIP2 metabolism is known as phosphatidylinositol-specific phospholipase 
C (PI-PLC). Following PI-PLC activation, the levels of these two second messengers 
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transiently rise, which themselves have a myriad of regulatory functions in mammalian 
cells (Kadamur and Ross, 2013). These are summarised in Figure 1.2. 
 
 
Figure 1.2: Hydrolysis of PIP2 by phosphatidylinositol-specific phospholipase C (PI-
PLC).  This reaction generates both IP3 and DAG and these second messenger 
molecules are known to play diverse roles in signalling pathways within mammalian 
cells. They also act as substrates for the formation of further signalling molecules, such 
as inositol phosphates and phosphatidic acid. In the above figure, the site of PI-PLC 
cleavage on PIP2 is indicated with the orange arrow, the other signalling metabolites 
are blue, and effector molecules are green. 
 
DAG recruits and often activates a variety of proteins containing cysteine-rich, C1 
domains, and thereby influences multiple cellular processes (Hurley and Misra, 2000). 
Although several proteins are known to contain a DAG-binding C1 domain, protein 
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kinase C (PKC) isoforms have received the most attention with regards to PI-PLC-
mediated signalling pathways. Activation of PKC and subsequent phosphorylation of 
many different proteins such as ion channels, cytoskeletal proteins and other enzymes 
is known to be involved in a multitude of physiological processes including cell growth, 
cytoskeleton reorganisation and apoptosis (Pears, 1995). In addition, a number of 
other C1-domain containing proteins are known to be effectors for DAG produced 
through PI-PLC-mediated PIP2 metabolism. These include the chimerin family of Rho 
GTPase-activating proteins; the large neuronal protein Munc 13-1, which is essential 
for DAG-dependent augmentation of neurotransmitter release; and the serine-
threonine kinase, protein kinase D, which phosphorylates numerous proteins (Brose 
and Rosenmund, 2002). Furthermore, DAG directly binds with DAG kinase and 
becomes phosphorylated to PA, which itself is an example of a signalling metabolite 
with far-reaching regulatory effects (Shulga et al., 2011). It is therefore clear from 
these data that the physiological effects of DAG produced through PI-PLC-mediated 
PIP2 metabolism are not restricted to PKC activation, but can be mediated through 
many different effector molecules.  
The other signalling molecule generated directly from the activation of PI-PLC is IP3, 
which is known to bind and activate receptors present on intracellular calcium stores, 
allowing calcium to be released into the cytosol (Berridge, 2009). IP3 mediated 
elevation of cytosolic calcium levels leads to the stimulation of a variety of calmodulin-
dependent enzymes, such as protein kinases and phosphoprotein phosphatases (Kirk, 
1990). Through its influence on intracellular calcium levels, IP3 regulates many cellular 
processes, including fertilisation, apoptosis, exocytosis, cell proliferation, smooth 
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muscle contraction and secretion (Berridge et al., 2000). The ability of cells to produce 
a wide range of calcium signals with different spatial and temporal characteristics is 
not only necessary for the control and multiple functions and but underscores the 
versatility and importance of the calcium signalling system in physiology (Bootman, 
2012). 
1.4.2. Additional functions of PIP2. 
The importance of PIP2 in cellular physiology is not restricted to its ability to produce 
second messengers. Recently it has become clear that PIP2 is able to bind and regulate 
the molecular function of many signalling proteins, and also act as the substrate for 
the production of other signalling metabolites, in addition to IP3 and DAG. PIP2 has a 
number of functions in cells related to its ability to bind with signalling proteins 
(McLaughlin et al., 2002).  
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Figure 1.3: A summary of the diverse cellular functions of intact PIP2 in mammalian cells. 
In addition to the production of second messenger molecules, PIP2 has various 
additional cellular functions, including vesicular trafficking, cytoskeleton remodelling 
and regulation of ion channel activity. Clathrin assembly lymphoid myeloid leukemia 
protein, CALM; actin-depolymerizing factor, ADF; Neural-Wiskott Aldrich Syndrome 
Protein, N-WASp; actin-realted protein, Arp2/3; Adapter protein, AP180; Inwardly 
rectifying potassium channel, Kir; Transient receptor potential channel, Trp; Epithelial 
sodium channel, ENaC. 
 
Several integral plasma membrane proteins such as ion channels and transporters are 
thought to be directly regulated by PIP2 (Hilgemann et al., 2001). The first channel 
found to be regulated by PIP2 was the inwardly rectifying potassium (Kir) channels 
(Hilgemann and Ball, 1996). PIP2 activates Kir channels by stabilising its open state. A 
cluster of basic amino acid residues, including a highly conserved arginine, is thought 
to mediate the affinity of Kir channels for PIP2, as mutation within this region prevent 
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normal channel activation (Huang et al., 1998). PIP2 is also known to activate 
amiloride-sensitive epithelial Na+ channels (ENaC), and therefore play a role in Na+ 
reabsorption across the nephron with consequential effects on body Na+ homeostasis 
(Ma et al., 2002). Although the PIP2 binding site has yet to be clearly mapped, mutation 
of several lysine and arginine residues within the cytoplasmic N-terminal loops caused 
a severe reduction in channel activity, with no effects on surface expression (Chalfant 
et al., 1999).  
Intact PIP2 is also thought to be important in vesicular trafficking. For example, plasma 
membrane PIP2 is directly implicated in clathrin-mediated endocytosis (De Camilli et 
al., 1996). This form of endocytosis is the main pathway for endocytic entry of lipids 
and proteins at the plasma membrane (Takei and Haucke, 2001). PIP2 is thought to be 
crucial for this process as several of the proteins implicated in clathrin-mediated 
endocytosis are recruited to the plasma membrane through binding PIP2. These 
include the brain-specific CALM (clathrin assembly lymphoid myeloid leukemia protein) 
homologue AP180, which mediates the assembly of clathrin coats (Ford et al., 2001). 
Other PIP2-binding proteins involved in clathrin-mediated endocytosis include the 
GTPase dynamin, which is known to be crucial for the release of clathrin-coated 
vesicles from the plasma membrane (Bottomley et al., 1999). Moreover, disruption of 
PIP2 levels by sequestration or recruitment of a 5’-inositol phosphatase to the plasma 
membrane prevented the formation of clathrin-coated vesicles (Antonescu et al., 
2011). PIP2 is also thought to influence exocytosis in a number of cells, including 
calcium-triggered vesicle exocytosis at nerve terminals (Kabachinski et al., 2014). 
ARF6-regulated membrane trafficking is dependent on the metabolism of PIP2. 
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Reduction in the PIP2 level through inhibition of PIP5K prevents the recycling of ARF6-
containing vesicles back to the plasma membrane and therefore alters exocytosis 
(Brown et al., 2001). The regulated secretion of insulin has also been shown to be 
negatively regulated by the inhibition of PIP2 synthesis in pancreatic beta cells (Tomas 
et al., 2009). 
A major role that has been assigned to PIP2 is the regulation of actin cytoskeleton 
remodelling (Yin and Janmey, 2002). PIP2 is known to influence actin polymerisation in 
a number of ways: recruiting and inhibiting the actin-severing proteins, gelsolin and 
ADF (actin depolymerising factor) (Sechi and Wehland, 2000); activating the branching 
of actin by binding N-WASp and Arp2/3 (Higgs and Pollard, 2000); mediating the 
removal of the caps from actin filaments and thus facilitating the addition of new actin 
monomers to the growing chain (Yin and Janmey, 2002). PIP2 also binds with many 
other cytoskeletal proteins such as talin and vinculin and therefore facilitates the 
anchoring of the cytoskeleton to the plasma membrane (Chandrasekar et al., 2005). 
1.5. Phosphatidylinositol-specific phospholipase C isozymes 
Signalling pathways involving PI-PLCs have a long history that began with the 
observation that treatment of pancreatic slices with various cholinergic agents could 
induce a rapid turnover of phosphoinositides (Hokin and Hokin, 1953). Subsequently, 
direct hydrolysis of phosphoinositides was first observed following incubation of 
purified phosphoinositides with rat brain homogenates (Sloane-Stanley, 1953). A 
similar PI-PLC activity was observed by various other groups, and this led to the 
eventual partial purification of the first PI-PLC (Dawson et al., 1959). Currently, 13 
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distinct PI-PLC isoforms have been identified in mammalian cells, which have been 
grouped into 6 subtypes, PLCβ (β1-β4), PLCδ (δ1-δ4), PLCγ (γ1 and γ2), PLCε (ε1 and 
ε2), PLCη (η1- η2) and PLCζ. This classification is based on amino acid sequence 
homologies, overall domain structures, and the mechanisms of regulation. In addition 
to the presence of a number of different PI-PLC isoforms, further molecular diversity 
is generated by the presence of alternative splicing variants for several of these PI-PLC 
isoforms (Suh et al., 2008).  
1.5.1. Domain structure of mammalian phosphatidylinositol-specific phospholipase C 
subtypes 
The amino acid sequences of each mammalian PI-PLC subtype contain distinct modular 
domains that are organised around the characterised X- and Y- catalytic domain 
regions. They include: a pleckstrin homology (PH) domain and EF-hand like motifs, 
which precede the X-domain; and a single C2 domain that occurs immediately after 
the Y-domain. Additional subtype-specific regulatory motifs are present in γ-, ε-, β- 
and η- subtypes, which are thought to contribute towards specific regulatory 
mechanisms (Suh et al., 2008). These include the Ras-association (RA) and the Ras-
GDP/GTP exchange factor (Ras-GEF) domains in PLCε-isoforms, the C-terminal 
extension region in PLCβ-isoforms, and the Src homology domains in PLCγ-isoforms 
(Kadamur and Ross, 2013). The domain structures of each of the 6 sub-types of PI-PLC 
are shown in Figure 1.4. 
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Figure 1.4: Diagrammatic representation of the domain structures of the six different 
mammalian PI-PLC subtypes. Each mammalian PI-PLC subtype contains distinct 
modular domains. The domains are abbreviated as follows: PH, pleckstrin homology; 
EF, EF hand domains; X and Yindicate the N and C terminal portions of the catalytic 
domain; SH2/SH3, Src homology 2/3; RA, Ras association; Ras GEF, Ras GDP/GTP 
exchange factor; CC, coiled coil.   
 
1.5.1.1. Pleckstrin homology domain 
The pleckstrin homology (PH) domain was first discovered as a short amino acid 
sequence occurring in various intracellular signalling proteins which showed limited 
homology to a region that is duplicated in the protein pleckstrin (Haslam et al., 1993; 
Mayer et al., 1993) Many of these proteins that contain PH domains are known to be 
important in cellular processes that require association with the cell membrane, 
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including cell signalling and organization of the cytoskeleton. Furthermore no obvious 
catalytic properties have yet to be assigned to any PH domain, and therefore these 
domains are thought to mainly function as adaptor motifs, to recruit their host 
proteins to the membrane surface (Lemmon, 2007). Structural studies, involving 
several proteins, including PLCδ1, demonstrate that all known structural 
representations of the PH domain show a common fold consisting of two 
perpendicular anti-parallel β sheets, closed off at one end by a C-terminal α helix 
(Figure 1.5; Ferguson et al., 1995).  
 
                                                                                            
 
 
 
 
Figure 1.5: Cartoon diagram of the pleckstrin homology domain structure from 
Phospholipase Cδ1. The canonical structure of the PH domains consists of two 
perpendicular anti-parallel β sheets, occluded at one end by a more C-terminal α helix. 
Image from the RCSB PDB of PDB ID 1MAI (Ferguson, K.M et al., 1995). 
 
With the exception of PLCζ isoforms, all PI-PLCs contain at least one PH domain at the 
N-terminus. PLCγ contains an additional PH domain, which is split by two 
SH2 domains and a single SH3 domain (Suh et al., 2008). The PH domains of PLC-
subtypes can bind phosphoinositides within biological membranes and also certain 
proteins including the βγ subunits of heterotrimeric G proteins, and PKC (Varnai et al., 
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2002; Wang et al., 2000). The PH domains of different PI-PLC subtypes exhibit 
disparate ligand binding specificities and therefore diverse modes of membrane 
interactions. Through these domain interactions, PLC-subtypes are recruited to 
different membranes, enabling them to interact with appropriate cellular 
compartments or allowing them to interact with other components of signalling 
pathways (Singh and Murray, 2003). These disparate interactions and how they 
regulate the catalytic function of individual PLC-subtypes will be discussed in Section 
1.5.2. 
1.5.1.2. The C2 domain 
The C2 domain is a calcium-binding motif found within more than 100 proteins 
involved in signal transduction and the cytoskeleton, including PKC, synaptotagmin 
and various phospholipases. The C2 domain is thought to be involved in calcium-
dependent phospholipid binding and membrane targeting processes such as 
subcellular localisation (Nalefski and Falki, 1996). The three-dimensional structure of 
the C2 domain of PLCδ1 has been reported, and consists of a β-sandwich composed of 
two four-stranded anti-parallel β-sheets, with a variable loop linking each of the β-
strands (Essen et al., 1997). A schematic depiction of this structure is shown in Figure 
1.7. Two of the loops (highlighted in green; Figure 1.6) contain conserved aspartate 
residues which co-ordinate the binding of Ca2+ to the C2 domain (Rizo and Sudhof, 
1998). At least two Ca2+ ions have been shown to bind to the C2 domain of PLCδ1, 
however the exact number is still unknown (Lomasney et al., 2012).    
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Figure 1.6: Schematic representation of the structure of the C2 domain from PLCδ1. 
The atomic structure of the PLCδ1 consists 8 anti-parallel β-sheets which are linked by 
intervening amino acid loops. The Ca2+ binding regions are highlighted in green. The 
arrows represent each of the eight β-strands. Adapted from Essen et al., 1997. 
 
A single C2 domain, of around 130 amino acids, is present in all six mammalian PI-PLC 
isoforms (Suh et al., 2008). Studies of PLCδ1 suggest that Ca2+ binding to the C2 domain 
can induce a conformational change within this region, which may permit the 
subsequent binding of the protein to phospholipids. Also, the calcium binding loops of 
PLCδ1 are negatively charged due to the presence of a number of acidic residues and 
therefore the binding of Ca2+ ions is thought to confer a switch in the electrostatic 
characteristics of this region so that it can attract negatively charged membranes 
(Grobler et al., 1996). As with the PH domain, evidence suggests that the C2 domains 
of different PLC-subtypes show disparate ligand binding specificities, reflecting their 
unique modes of regulation (Suh et al., 2008). The importance of the C2 domains in 
the regulation of the catalytic activities of PLC-subtypes is considered further in 
Section 1.5.2.  
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1.5.1.3. The EF-hand domain 
Many calcium-binding proteins are evolutionary related and share a specific type of 
calcium-binding domain known as the EF-hand motif (Nelson et al., 2002). This 
structural motif was first discovered by Krestinger, following derivation of the crystal 
structure of parvalbumin (Krestinger and Nockolds, 1973). In this structure, the EF-
hand is a 29-residue polypeptide calcium-binding motif consisting of two α-helices 
(helices E and F in parvalbumin) flanking an inter-helical Ca2+-chelation loop (Figure 1.7) 
(Moews and Kretsinger, 1975). The secondary structure and the putative calcium-
coordinating residues are highly conserved across EF-hand proteins such as troponin 
C and calmodulin (Nelson et al., 2002).  
 
 
 
 
 
Figure 1.7: A single EF hand domain from calmodulin demonstrating the canonical 
structure of a single EF hand domain. The EF hand consists of an N-terminal 9-residue 
helix, a 9-residue calcium-binding loop and an 11-residue C-terminal loop. The yellow 
ball represents a calcium ion. The N- and C-terminal regions of the domain are also 
shown. Figure adapted from Gifford et al., 2007 
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The first description of EF-hand motifs in PI-PLC subtypes occurred following analysis 
of the crystal structure of PLCδ1, which revealed the presence of the characteristic 
helix-loop-helix motifs (Essen et al., 1996). Subsequent sequence analysis revealed the 
presence of a total of four EF-hand motifs (EF1-4) in all mammalian PI-PLC subtypes. 
In these enzymes, the EF-hand domain forms part of the catalytic core, which consists 
of the EF-hand motif, X and Y catalytic domains and the C2 domain. In contrast to other 
proteins, the EF-hand domains of many PI-PLC subtypes may have limited or no ability 
to bind calcium (Suh et al., 2008). Key exceptions include PLCζ and PLCη isozymes, both 
of which exhibit high sensitivities to calcium, which is thought to be directed by their 
EF-hand domains (Nominkos et al., 2005; Popovics et al., 2014).  
1.5.1.4. The catalytic domain 
The catalytic properties of PI-PLCs have been extensively studied and reveal many 
common characteristics shared by all mammalian enzymes (Kadamur and Ross, 2013). 
These studies reveal that all mammalian PI-PLCs can hydrolyse many 
polyphosphoinositides with a preference for PIP2, and that their catalytic activity is 
entirely dependent on the presence of a calcium cofactor. The central catalytic core of 
PLC is composed of an X-box and Y-box domain separated by a short sequence known 
as the X-Y linker. Although the overall sequence similarity between PI-PLC isoforms is 
low, the X-box and Y-box domains are well conserved across the different subtypes, 
with an overall amino acid sequence homology of ~60% among all the isozymes. An 
even greater homology is seen within individual PLC-subtypes (Kadamur and Ross, 
2013). X-ray crystallographic studies of PLCδ1 revealed the catalytic core to consist of 
alternating α-helices and β-strands resembling an incomplete triose phosphate 
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isomerase (TIM) α/β-barrel (Figure 1.9). This barrel is composed of two lobes, which 
are formed from the X-box and Y-box domains (Suh et al., 2008).  Additionally, 
structural analysis reveals a cluster of hydrophobic amino acids at the entrance to the 
active site, forming a spout like structure, which enables the enzyme to penetrate into 
the phospholipid bilayer, facilitating membrane interaction and introduction of the 
substrate into the catalytic core. The catalytic activity of all eukaryotic PI-PLCs is 
dependent on the presence of calcium as a cofactor (Essen et al., 1996). 
 
 
 
 
 
 
 
Figure 1.8: Depiction of the structure of the catalytic domain of rat phospholipase 
Cδ1 in the presence of IP3. The catalytic domain folds as a TIM barrel. The active site, 
all catalytic residues, and a Ca2+ binding site are found within the TIM barrel. Bound 
calcium is shown as a sphere, and IP3 is represented in ball-and-stick form. Depicted 
also is the “spout” which represents a clutch of hydrophobic residues that allows PIP2 
to penetrate the active site. Taken from Essen et al., 1996. 
 
These crystallographic studies together with supporting data from mutational and 
kinetic studies have identified key residues within the catalytic core of PLCδ1 that are 
involved in substrate binding, interactions with calcium and have provided a structural 
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model for the mechanism of calcium-dependent hydrolysis (Figure 1.11). These data 
support a two-step, sequential mechanism that involves general acid-base catalysis. 
The first step is a phosphotransferase step that involves de-protonation of the 2-OH 
group of inositol by residue able to accept hydrogen ions (general base) which leaves 
an oxyanion which nucleophillically attacks the phosphate group attached at position 
1 of the inositol ring forming a pentacovalent transition state intermediate. This is 
followed by protonation of the 1-phosphate of inositol by a residue able to donate 
hydrogen ions (general acid) and release of DAG and the more stable substrate 
intermediate cyclic inositol phosphate (Ins (1:2cyc)P; Heinz et al., 1998). In mammalian 
PI-PLCs, His356 has been identified as the general acid whereas the identity of the 
general base remains unclear, with Glu341 and Glu390 as the most likely candidates 
(Figure 1.11; Heinz et al, 1998)). The crystal structure of PLCδ1 shows that His311 
forms a hydrogen bond with the 1-phosphate of inositol and this is thought to stabilise 
the Ins(1:2cyc)P intermediate. In mammalian PI-PLCs, calcium is also present within 
the active site and interacts with the 1-phosphate and 2-OH group of inositol. These 
interactions are thought to stabilise the Ins(1:2cyc)P intermediate and lower the pKa 
of the 2-OH group of inositol (Heinz et al., 1998). The side-chains of Asn312, Asp343, 
Glu341 and Glu390 (Human PLCδ1 numbering) are also known to co-ordinate the 
binding of calcium within the active site and mutation of any of these result in an 
increase in the concentration of calcium required for catalysis (Essen et al., 1996; Ellis 
et al., 1998). The second step (phosphodiesterase step) results in the hydrolysis of the 
cyclic intermediate forming the acyclic inositol phosphate product. This reaction is 
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much slower than the phosphotransferase step and the roles of the general base and 
acid are reversed resulting in the formation of an acyclic IP3 (Heinz et al., 1998). 
Given the highly conserved nature of the X- and Y- catalytic domain, the catalytic 
mechanism of substrate hydrolysis deduced for PLCδ1 is expected to be common to 
all mammalian PI-PLC isoforms. All the residues identified in PLCδ1 as forming 
important contact with the substrate and binding calcium (described above) are 
strictly conserved in all mammalian PI-PLCs and mutation of any one of these severely 
reduces the catalytic activity of PLCδ1 towards substrate PIP2 (Kadamur and Ross, 
2013).  
1.5.1.5. X-Y linker region 
The X and Y domains are joined by a highly disordered intervening sequence, known 
as the X-Y linker region. As the X-Y linker is known to act as an auto-inhibitor of PLC-
subtypes, with activation of these enzymes requiring removal of the X-Y linker from 
the active site. This linker varies in length between different PLC-subtypes, consisting 
of 40 to 110 residues in β and δ-subtypes, 190 residues in PLCε and the much longer 
sequence in PLCγ isoforms (~400 residues) as it also includes two Src homology 2 (SH2) 
domains and one SH3 domain (Suh et al., 2008). 
1.5.2. Regulation and physiological functions of mammalian PI-PLCs 
Given the sheer number of physiological processes that rely on the activity of PLC it is 
not surprising that a number of PI-PLC subtypes have evolved, each with a different 
number of isoforms and associated spliceforms. While all isozymes have similar 
catalytic properties, different subtypes are characterised by distinct modes of 
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regulation. This distinctiveness is in part due to the presence of subtype-specific 
domains but also due to differences in the binding specificities of common domains. 
1.5.2.1. PLCβ isoforms 
Currently four mammalian β-isoforms (PLCβ1-4) and additional spliced variants are 
known to exist (Rebecchi and Pentyala, 2000). Analysis of expressed sequence tags 
and subsequent experimental verification by in situ hybridisation and quantitative 
RT-PCR reveals PLCβ1 mRNA to be widely expressed, with the highest levels being 
detected in the cerebral cortex and hippocampus (Homma et al., 1989). In contrast, 
the expression of PLCβ2 mRNA is restricted to cells of hematopoietic origin (Sun et 
al., 2007). PLCβ3 mRNA is expressed in the brain, liver and parotid gland (Jhon et al., 
1993) and PLCβ4 is predominantly expressed in cerebellar Purkinje and granule cells, 
and the retina (Adamski et al., 1999). Activation of the different PLCβs can take place 
through the absorption of photons or by the binding of certain odorant molecules or 
numerous hormones to a variety of G-protein coupled receptors (GPCRs) that are 
linked to the activation of specific isoforms (Kadamur and Ross, 2013). Figure 1.9 
shows a diagrammatic representation describing the standard model of G protein 
activation of PLCβ isoforms.  
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Figure 1.9: Schematic representation of the regulation of PLCβ by G protein-coupled receptors (GPCRs). Gαq stimulates PLCβ and Gβγ-
subunits released from Gi/o can also activate PLCβ. Green arrows represent the known sites on PLCβ that mediate regulation by G proteins. 
The black dashed line points to the potential site on PLCβ that interacts with Gβγ. Recent evidence also suggest that PLCβ can be directly 
activated by the small GTPases Rac 1/2, and the solid black line represents the PLCβ domain responsible for these interactions. PH, 
pleckstrin homology; EF, EF hand domains; X and Y indicate the N- and C-terminal portions of the catalytic domain; CC, coiled coil domain.
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GPCRs are associated with heterotrimeric G proteins and upon agonist binding they 
facilitate the exchange of bound GDP for GTP on the α-subunit of the G protein. Once 
charged with GTP, the α-subunit separates from the Gβγ heterodimer in the plane of 
the membrane and the α-subunit, the βγ heterodimer or both increase the catalytic 
activity of PLCβ (Kadamur and Ross, 2013). The Gq class of α-subunits, which consists 
of five different isoforms (αq, α11, α14, α15 and Gα16), are known to activate PLCβ 
isoforms (Taylor and Exton, 1991; Lee et al., 1992). Recent derivation of the crystal 
structure of PLCβ3 in complex with Gαq has provided a greater understanding of the 
mechanism whereby Gαq activates PLCβ isoforms. This structure highlighted the EF 
hand domain, the region between the catalytic domain and the C2 domain, and the 
coiled coil (CC) motif C-terminal to the C2 domain of PLCβ3 as forming contact points 
with Gαq (Waldo et al., 2010). Interestingly, comparison of this high-resolution 
structure of activated PLCβ3 with that of non-activated PLCβ3 revealed no 
conformational rearrangements within the core structure of PLCβ3. It has therefore 
been proposed that Gαq-mediated activation of PLCβ isoforms does not involve any 
conformational changes to the core of the protein but instead Gαq acts to anchor and 
orient PLCβ at the surface of the membrane. Owing to the negative charge of the 
membrane, such interactions are thought to push the X-Y linker away from the 
catalytic core effectively removing its auto-inhibitory effect (Hicks et al., 2008). PLCβs 
1, 2 and 3 can also be activated by Gβγ subunits and are therefore responsive to Gi-
coupled GPCRs. PLCβ4 is however, not activated by Gβγ subunits (Park et al., 1993). 
The PH domains of PLCβ1-3 are thought to mediate the activation by Gβγ subunits 
(Wang et al., 1999). This is based on evidence that removal of the PH domain blocks 
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activation by Gβγ and a chimeric form of PLCδ1 containing the PH domain of PLCβ2 
can be activated by Gβγ (Wang et al., 2000A). To date, no X-ray structure of PLCβ in 
complex with Gβγ exists and therefore the ability of the PH domain to directly bind 
Gβγ is unknown. 
Individual PLCβ isoforms are also activated by various other regulatory ligands, such 
as phosphatidic acid and the small GTP-binding protein, Rac (Illenberger et al., 1998). 
PLCβ2 is directly activated by multiple, small-GTP-binding proteins such as Rac1, Rac2 
and Cdc42 (Illenberger et al., 1997). Both biochemical and structural studies have 
suggested that the PH domain of PLCβ2 mediates the binding of Rac. The core 
structure of PLCβ2 bound to Rac1 is essentially identical to that of PLCβ2, and 
therefore it has been suggested that the binding of Rac does not involve any 
conformational changes in PLCβ2 (Jezyk et al., 2006). The exact mechanism by which 
PLCβ2 becomes activated by Rac remains to be fully characterised.  
Phenotypes associated with transgenic mice and flies lacking individual β-isoforms 
have revealed important insights into how these enzymes are integrated into normal 
physiology. Mice lacking PLCβ1 experience epileptic-like seizures leading to sudden 
death. These mice are also much more sensitive to drugs that induce convulsions, 
which together with the spontaneous seizure phenotype, suggest that PLCβ1 is 
involved in brain inhibitory pathways (Kim et al., 1997). Owing to the predominant 
expression in immune cells, phenotypes associated with the lack of PLCβ2 are entirely 
different. Within immune cells, PLCβ2 couples to GPCRs for a number of chemokines, 
including those for C5a, fMLP and interleukin-8 (Jiang et al., 1996A). In line with these 
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biochemical characteristics, chemokine signalling pathways are disrupted in mice 
lacking PLCβ2, however the outcomes are different depending on the specific immune 
cell involved (Jiang et al., 1997). Neutrophils from mice lacking PLCβ2 are insensitive 
to the chemoattractant fMLP and chemotaxis is inhibited (McNeill et al., 2007). In 
eosinophils from these animals, chemotaxis is enhanced suggesting in these cells 
PLCβ2 actually inhibits chemotaxis and that alternative pathways couple chemokines 
receptors to cell locomotion (Sano et al., 2001). Mice lacking PLCβ4 showed ataxia that 
was linked to defects in the normal development of the cerebellum (Jiang et al., 1996). 
The authors suggest that this phenotype was due to attenuated glutamate signalling 
through metabotropic glutamate receptor 1 (mGluR1) in cerebellar Purkinje cells 
(Jiang et al., 1996) In contrast to other β-isoform-knock-outs, PLCβ3-null mice die very 
early on in their development (Xie et al., 1999). It is therefore clear that the individual 
absences of each β-isoform gives rise to different phenotypes reflecting their unique 
roles in cell physiology. Further studies are required to unravel the physiological roles 
of the alternatively spliced variants of the each β-isoform. 
1.5.2.2. PLCγ isoforms 
The PLCγ family of mammalian PI-PLCs consists of two members known as PLCγ1 and 
2 (Kadamur and Ross, 2013).  PLCγ1 mRNA is expressed in various tissues. It is highly 
expressed in the brain where it is found in neurons, oligodendrocytes and astrocytes 
(Mizuguchi et al., 1991). In contrast, PLCγ2 mRNA is expressed primarily in immune 
cells with expression also being found in the Purkinje and granule cells found in the 
cerebellum (Tanado and Kondo, 1994).  For PLCγ1 two alternative splicing variants 
have been identified thus far, and these differ in their C-terminal sequences. To date, 
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a single spliced variant of PLCγ2 has been identified in mouse. PLCγ isoforms are 
unique among other mammalian PI-PLCs in that they contain two tandem SH2 
domains, a SH3 domain, and a split PH domain in region between the X and Y domains 
(Suh et al., 2008).  
PLCγ isoforms can be activated downstream of receptors which possess intrinsic 
tyrosine kinase activity, such as those for platelet-derived growth factor (PDGF), 
epidermal growth factor (EGF) and nerve growth factor (NGF) (Kadamur and Ross, 
2013). Figure 1.10 shows a schematic diagram summarising the pathways leading to 
activation of PLCγ isoforms. 
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Figure 1.10: PLCγ-isoforms are regulated by tyrosine phosphorylation mediated by various different tyrosine kinases, included receptor 
tyrosine kinases (RTKs) and non-receptor (soluble) tyrosine kinases (NRTKs). Some NRTKs are recruited to the membrane following 
activation of the B cell receptor by multiprotein complexes (MPCs) that assmeble on the cytoplasmic tails of the activated receptor. 
Critical tyrosine residues present within the SH2 are the site of phosphorylation of PLCγ isoforms and when phosphorylated, the SH2 
recruits PLCγ to the membrane. Interestingly, GPCRs are also able to regulate PLCγ functions by recruiting NRTKs to the membrane. Green 
arrows indicate the PLCγ domains that experimentally indicated to mediate interactions with the different regulatory inputs.  
30 
 
These receptors dimerize upon binding of their ligand, triggering autophosphorylation 
on specific tyrosine residues. These phosphorylated residues subsequently act as 
docking sites to recruit various SH2 containing proteins, such as PLCγ isoforms to the 
cell surface (Suh et al., 2008). A receptor may contain one or more docking sites for 
the recruitment of PLCγ isoforms, and mutation of these residues prevents PLCγ 
activation (Rebecchi and Pentyala, 2000). For the PDGF receptor, PLCγ1 specifically 
binds to phosphorylated Tyr-1021 (Valius et al, 1993) whereas PLCγ2 can bind with five 
preferred autophosphorylated tyrosine residues on the EGF receptor (Sorkin et al., 
1991). Subsequently PLCγs can be phosphorylated on a number of tyrosine residues 
within the N-terminal SH2 domain (nSH2), but only one (Tyr-783 in PLCγ1 and Tyr-759 
in PLCγ2) is essential for the stimulation of activity (Sekiya et al., 2004). The 
phosphorylated Tyr-783/Tyr-759 has been shown to associate with the C-terminal SH2 
(cSH2) domain within the same PLCγ1 molecule and this interaction is thought to cause 
significant conformational changes resulting in the re-orientation of the X-Y linker with 
respect to the core enzyme (Poulin et al. 2005). This conformational change is thought 
to remove the auto-inhibition caused by the X-Y linker (Kadamur and Ross, 2013).  
PLCγ isoforms are also activated downstream of receptors that lack intrinsic tyrosine 
kinase activity, including the angiotensin II receptor-type 1 (AT1) and the B-cell 
receptor (BCR). As with the receptor tyrosine kinases (RTKs; described above), PLCγ1 
and PLCγ2 activation is also mediated by tyrosine phosphorylation at Tyr-783 or Tyr-
759 respectively but this time by non-receptor tyrosine kinases. In the case of the AT1 
receptor (a GPCR), coupling of PLCγ to the activated receptor and subsequent tyrosine 
phosphorylation is likely to occur in the context of a membrane-bound, multiprotein 
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complex containing a soluble tyrosine kinase (Marrero et al., 1994). The exact 
molecular identities of the proteins involved are yet to be fully characterised.  In the 
case of the BCR, antigen binding is known to recruit and activate the catalytic activity 
of PLCγ2. Activation of the BCR receptor by antigen binding induces the recruitment 
of the Src family of protein tyrosine kinases (PTKs) to the two immunoreceptor 
tyrosine-based activation motifs (ITAMs) present in each of BCR accessory protein 
molecules Igα and Igβ (Avalos and Ploegh, 2014). Src PTKs such as Lyn, Fyn and Blk are 
subsequently activated which then phosphorylate all tyrosine residues present in each 
ITAM. These phosphotyrosine residues then recruit the SH2 domains of the PTK, Syk, 
which then phosphorylates a number of adapter proteins, such as BLINK (B-cell linker 
protein; Kim et al., 2004). Phosphorylated BLINK is known to recruit the C2 domain of 
PLCγ2, and the BCR-associated PLCγ2 becomes phosphorylated at Tyr-759 and 
subsequently activated; however the PTK responsible for this phosphorylation is 
currently unknown (Kim et al., 2004). 
PLCγ isoforms respond to multiple regulatory inputs in addition to tyrosine 
phosphorylation. Piechulek et al. 2005 showed that PLCγ2 could be stimulated through 
binding to the small GTPases, Rac1 and Rac2, and that this stimulation does not involve 
phosphorylation of any tyrosine residues on PLCγ2 (Piechulek et al., 2005). Structural 
and biochemical studies of PLCγ2 in the presence of Rac2 identified the split PH (sPH) 
domain of PLCγ2 as the Rac-binding surface (Bunney et al., 2009). Whether or not the 
binding of Rac to PLCγ2 moves the X-Y linker away from the catalytic site remains to 
be determined.  
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Loss of function in PLCγ1 and PLCγ2 gene-deficient mice has revealed the function of 
these isoforms in vivo. Consistent with its high expression in immune cells, PLCγ2-
deficient mice have defects in the normal physiology of many cells of the immune 
system, including B lymphocytes, platelets, mast cells and natural killer cells (Suh et al., 
2008). Furthermore, loss of PLCγ2 activity in human B lymphocytes has been observed 
in immunodeficiency syndromes such as X-linked agammaglobulinaemia (Satterwaite 
et al., 1998). In contrast, the PLCγ1 is more widely expressed and is thought to regulate 
numerous cellular functions. Consistent with these findings, transgenic mice lacking 
PLCγ1 die early on in development, stressing the widespread importance of this 
enzyme (Ji et al., 1997). PLCγ1 has been shown to be required for the terminal 
differentiation of normal human keratinocytes from the oral cavity (Oh et al., 2003), 
and is known be important for the survival of cardiomyocytes in response to oxidative 
stress (Mangat et al., 2006). As mentioned previously, PLCγ1 mRNA is highly expressed 
within the brain and this isoform is thought to be important for brain function. 
Consistent with the ability of PLCγ isoforms to be activated through growth factor 
stimulation, in neurons PLCγ1 activity is stimulated by signalling through the fibroblast 
growth factor receptor and the Trk family of RTKs and this is thought to be involved in 
neuronal differentiation and neurite outgrowth (Bae et al., 1998; Lin et al., 1998). 
Furthermore, there is evidence that PLCγ1 activity is important for neural networks 
that underlie features of brain function such as memory and motor activity (Blum and 
Dash, 2004; Bolanos et al., 2005), and polymorphisms in the human PLCγ1 gene have 
been linked to the pathogenesis of bipolar disorder (Turecki et al., 1998).  
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1.5.2.4. PLCδ isoforms 
In general, the single polypeptide chain of PLCδ isoforms consists of a PH domain, an 
EF-hand region, a catalytic X/Y domain and a C2 domain (Suh et al., 2008). Simple 
organisms such as yeast and slime moulds contain at least one PLCδ isoform, whereas 
three δ-isoforms (δ1, 3 and 4) have been identified in higher plants and mammals 
(Kadamur and Ross et al., 2013). A number of alternative splicing variants exist for 
mice PLCδ genes, increasing the number of specific isoforms. Two alternative splicing 
variants exist for mouse PLCδ1, known as PLCδ1a and PLCδ1b. Compared with PLCδ1a, 
mouse PLCδ1b has a deletion of 274 residues which results in a truncated Y domain, 
potentially rendering it catalytically inactive. There are two alternative splicing variants 
of mouse PLCδ3 (PLCδ3a and PLCδ3b), with PLCδ3a containing an additional 18 
residues between the PH and EF-hand domains. Three alternative splicing variants 
exist for PLCδ4 (δ4a, δ4b and δ4c), with PLCδ4a containing an extra 32 amino acid 
residue in the linker region between the catalytic X and Y domains (Suh et al., 2008).  
RT-PCR experiments show PLCδ1 mRNA to be mainly expressed in brain, heart, lung, 
skin and testes (Lee et al., 1999). Furthermore, using In situ hybridisation, the same 
researchers found mouse PLCδ1 to be present in almost all regions of the brain, and 
to be particularly enriched in spermatogonia. Northern blot analysis revealed PLCδ3 
mRNA to be predominantly expressed in the heart and skeletal muscle, followed by 
brain and placenta (Lin et al., 2001). PLCδ4 mRNA is predominantly expressed in the 
brain, skeletal muscle, testis and kidney (Lee et al., 1996).  
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Following the homogenisation of tissues and cultured cells, PLCδ1 is mainly present in 
the cytoplasmic fraction. Given that PIP2 is enriched in membranes, translocation of 
PLCδ1 from the cytosol to the membrane is necessary for enzyme activation and this 
is driven by PIP2 binding by the PH domain and calcium by the C2 domain (Kadamur 
and Ross, 2013).  Several studies have highlighted the functional role of the PH domain 
in the activation of PLCδ1 (Lemmon et al., 1995; Ferguson et al., 1995).  In cells 
depleted of PIP2, PLCδ1 is localised in the cytoplasmic fraction, and deletion of the N-
terminal residues corresponding to the PH domain prevents membrane association 
and abolishes the catalytic activity of PLCδ1 (Cifuentes et al., 1993). In addition to the 
PH domain-dependent PIP2-mediated membrane association, the binding of calcium 
by the C2 domain is also required for membrane association and stimulation of the 
catalytic activity of PLCδ1 (Lomasney et al., 1999). Although substrate hydrolysis by all 
eukaryotic enzymes is dependent on the presence of calcium as a cofactor within the 
active site, the crystal structure of PLCδ1 reveals the presence of three calcium-binding 
sites in the C2 domain (Essen et al., 1997). Membrane binding studies with the isolated 
C2 domain of PLCδ1 show that calcium promotes membrane association through 
electrostatic interactions with the anionic lipid phosphatidylserine (PS) (Lomasney et 
al., 1999). Whether these interactions regulate enzyme activity by stabilising 
membrane-targeted PLCδ1, by directly stimulating enzyme activity or a combination 
of both is currently unclear. No other regulators of PLCδ1 activity have been identified 
to date and given that these enzymes are regulated by calcium, PLCδ1 may serve to 
amplify rather than initiate calcium mobilising signals (Kadamur and Ross, 2013). 
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Phenotypes associated with mice deficient in PLCδ isoforms, and human diseases 
associated with these isoforms have provided important insights regarding the 
physiological functions of these subtypes. Lack of PLCδ1 in mice is associated with the 
induction of skin inflammation (Ichinohe et al., 2007). PLCδ1 null mice show an 
increased expression of the pro-inflammatory cytokines IL-1β and IL-6, and the 
epidermis becomes infiltrated with a number of white blood cells, including 
macrophages, granulocytes and T lymphocytes. These defects could be cancelled by 
treatment with anti-inflammatory drugs. These results suggest that PLCδ1 is involved 
in the regulation of the immune system in the skin (Ichinohe et al., 2007).  
PLCδ1 has also been implicated in some neurodegenerative disorders. PLCδ1 protein 
levels are elevated in Alzheimer’s patients, and abnormally accumulate in the 
neurofibrillary tangles (Shimohama et al., 1995). Western blot analysis has also 
confirmed the presence of PLCδ1 in filamentous plaques of other neurodegenerative 
disorders, including Picks disease and Lewy body disease (Shimohama et al., 1993). 
PLCδ1 may therefore play a role in the formation of filamentous plaques in human 
neurodegenerative disease. 
Disruption of PLCδ4 expression leads to male infertility, whereas female mice remain 
fertile. Immunohistochemical analysis of the sperm from wild-type mice reveals that 
PLCδ4 is located at the tip of the sperm, a region known as the acrosome (Fukami et 
al., 2001). The primary function of this region is to allow the sperm to penetrate the 
outer covering of the egg, known as the acrosome reaction (Wassarman et al., 1999). 
The zona pellucida and progesterone are known to stimulate and maintain a sustained 
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influx of calcium, which is essential for the normal acrosome reaction (Jackson et al., 
2002). Interestingly, calcium transients associated with fertilisation are absent or 
delayed in sperm from PLCδ4 null mice, and fewer eggs become activated when 
inseminated with these sperm (Fukami et al., 2003). Together, these data indicate that 
PLCδ4 has an essential role in the acrosome reaction during natural fertilisation. 
1.5.2.3. PLCε isoforms 
PLCε was first discovered in 1998 during a yeast two-hybrid screen of a Caenorhabditis 
elegans library to identify novel Ras-binding proteins. The nematode protein, called 
PLC120, was shown to bind to the C. elegans Ras homologue, LET-60, resulting in the 
activation of its PLC activity (Shibatohge et al., 1998). A mammalian PLCε orthologue 
was later cloned and identified by three independent research groups (Song et al., 
2001; Lopez et al., 2001; Kelley et al., 2001). PLCε is the largest of the PLC family 
members discovered to date, with a calculated molecular mass of 250 kDa and 
contains two domains that are not found in other PLC family members. The N-terminal 
CDC25-homology domain functions as a guanine nucleotide exchange factor for Ras, 
whereas the two C-terminal RA domains (RA1 and RA2) mediate a GTP-dependent 
interaction with Ras (Kadamur and Ross, 2013). The expression of mRNA coding for 
PLCε is highest in the heart, with expression also present in the brain, colon and lung 
(Lopez et al., 2001). Two alternative splicing variants of PLCε exist in humans, known 
as PLCε1a and PLCε1b, which differ at the amino terminus (Suh et al., 2008). Northern 
blot and RT-PCR analysis suggests that PLCε1a and PLCε1b mRNA have different tissue 
distributions. PLCε1a was found to be present in most tissues tested, except for 
peripheral blood leukocytes, whereas PLCε1b could only be detected in the spleen, 
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lung and placenta. These differences in the expression of PLCε1a and PLCε1b are also 
mirrored in cell lines (Smrcka et al., 2012). Sorli et al. 2005 detected PLCε1a mRNA in 
most cell lines that they tested, including SKOV3 (derived from human ovary 
adenocarcinoma), Saos2 (dervived from a primary osteosarcoma), 293A (Human 
Embryonic Kidney; HEK), and 293T (HEK), whereas PLCε1b mRNA was only detected in 
293T cells.  
PLCε is activated by GTP-bound members of the Ras family such as Ras, Rap1, Rap2, 
Ral, and Rho (Kadamur and Ross, 2013). These proteins are a related group of small 
GTP-binding proteins that regulate crucial cellular processes such as proliferation, 
differentiation, apoptosis, migration and adhesion (Takai et al., 2001). Various ligands 
that regulate these GTP-binding proteins, including growth factors, adrenaline, 
thrombin, lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P), are known 
to stimulate PLCε (Smrcka et al., 2012). Structural and biochemical analyses have 
shown the second C-terminal RA domain, RA2, to be predominantly responsible for 
the binding of Ras, Rap and Ral to PLCε (Kelley et al., 2001). Rho-dependent PLCε 
activation does not involve the RA domains, but instead requires an amino acid motif 
within the catalytic domain, which is unique to PLCε (Wing et al., 2003; Seifert et al., 
2004). Recently, PLCε has been shown to be activated by Gα12 and Gα13 subunits 
released from activated G protein-coupled receptors. This mode of regulation is 
indirect in that Gα12 and Gα13 firstly activate RhoA, which subsequently stimulates 
PLCε. The molecular mechanism linking the binding of members of the Ras family of 
GTPases to PLCε activation is currently unclear (Harden et al., 2009). Given that these 
small GTPases are membrane-associated proteins, this mechanism could involve 
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translocation of PLCε from the cytosol to the membrane. Based on the structural 
information for PLCβ, this membrane association could potentially remove the auto-
inhibitory loop from the catalytic core of PLCε, leading to enzyme activation (Kadamur 
and Ross, 2013). 
Important insights regarding the physiological functions of PLCε have been made 
following the analysis of the phenotypes associated with transgenic mice lacking PLCε.  
In line with their predominant expression in the heart, PLCε null mice develop many 
heart cardiac defects, including abnormal semilunar valve development, associated 
ventricular dilation and heart enlargement, and abnormal cardiac contraction in 
response to β-adrenergic stimulation (Tdano et al., 2005). In addition, PLCε null mice 
are less susceptible to carcinogen induced tumour formation (Bai et al., 2005). Further 
insights into how PLCε is integrated into animal physiology have also been provided by 
genome-wide association (GWAS) studies and human genetic analysis. PLCε mutations 
are associated with childhood nephritic syndrome and may cause abnormal 
glomerular development (Hinkes et al., 2006). Furthermore, PLCε single nucleotide 
polymorphisms (SNPs) have been associated with oesophageal squamous cell 
carcinomas (Abnet et al. 2010). 
1.5.2.5. PLCζ isoforms 
PLCζ contains the core domains common among mammalian PI-PLCs but lacks a PH 
domain (Suh et al., 2008). PLCζ was initially identified as the mammalian sperm-
induction factor that initiates calcium oscillations necessary for the maturation and 
subsequent development of a fertilised egg (Saunders et al., 2002). Three alternative 
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splice variants have since been reported for PLCζ, known as ζ1a, ζ1b and ζ1c (Suh et 
al., 2008; Kouchi et al., 2004). Northern blot analysis of mouse tissues revealed PLCζ 
mRNA (all isoforms) to be only detectable in the testes. RT-PCR detection of PLCζ in 
cDNA prepared from mouse testis devoid of spermatids suggested that PLCζ 
expression is specific to sperm and not another part of the testis (Kouchi et al., 2004).  
Calcium is the only known regulatory ligand of PLCζ activity identified to date, with the 
purified enzyme exhibiting an EC50 for calcium-dependent PIP2 hydrolysis of around 30 
nM (Kadamur and Ross, 2013). Experimental evidence has highlighted the EF-hands 
and the C2 domain as being important for PLCζ activation as deletion of either one of 
these domains prevents calcium-dependent PIP2 hydrolysis (Kouchi et al., 2005; 
Nomikos et al., 2005). As mentioned previously, the association of PLC subtypes with 
the membrane fraction is essential for substrate interaction and subsequent PIP2 
hydrolysis. In other PLC family members, membrane association is either driven by 
protein-protein and/or protein-lipid interactions mediated by the PH domains of these 
proteins. Given that PLCζ lacks a PH domain, it is currently unclear how this PLC family 
member interacts with membranes and anchors to PIP2.  
In addition to the lack of a PH domain, PLCζ differs from other PLC family members in 
that its X-Y linker carries a positive charge, due to the presence of a cluster of basic 
residues not present in other PLC family members (Kadamur and Ross, 2013). 
Experimental evidence suggests that these residues may target PLCζ to PIP2-enriched 
membranes as they have significant affinity for PIP2 and reduction of the net positive 
charge of the X-Y linker significantly affects calcium-oscillation-inducing activity in vivo 
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and interaction of PLCζ with PIP2 in vitro (Nomikos et al., 2007). In contrast, the 
negatively charged X-Y linkers of other PLC family members are thought to repel the 
negatively charged plasma membrane. This is thought to induce movement of the X-Y 
linker away from the catalytic domain, opening up the catalytic cleft. Removal of the 
X-Y linker region of PLCζ causes inhibition (Nomikos et al., 2007). 
Prior to fertilisation, mature oocytes are halted in the second meiotic metaphase stage 
(M11) of the cell cycle. Upon binding of a single sperm, IP3-mediated calcium release 
from intracellular calcium stores alleviates oocytes from M11 arrest, a process known 
as oocyte activation (Jones, 2005). A number of studies support the notion that PLCζ 
is responsible for IP3-mediated calcium release and oocyte activation. Injection of 
complementary RNA (cRNA) encoding mouse and human PLCζ into mouse eggs 
initiates calcium oscillations (Saunders et al., 2002). Furthermore, human sperm 
extracts devoid of PLCζ fail to induce calcium release and are unable to initiate the first 
steps of embryogenesis (Yoon et al., 2008). Given the proposed importance of PLCζ as 
the mammalian sperm-inducing factor, defects in sperm PLCζ may underlie certain 
types of male infertility and oocyte activation failure. Recently it has been shown that 
sperm from men, which fail IVF, are unable to produce calcium oscillations following 
intracytoplasmic injection into mouse oocytes. These sperm exhibited reduced levels 
of PLCζ expression (Heytens et al. 2009).  Currently, a PLCζ-deficient mouse model is 
yet to be established. 
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1.5.2.6. PLCη isoforms 
Two PLCη isozymes, PLCη1 and PLCη2, were simultaneously identified by two 
independent research groups in 2005 (Hwang et al., 2005; Stewart et al., 2005). 
Currently, four alternative splice variants of PLCη1 have been identified in both 
humans and mice. These variants have been denoted η1a-d and display sequence 
variations at the C-terminal region (Hwang et al., 2005; Suh et al., 2008). For PLCη2, a 
total of five splicing variants have been reported in humans, and three splicing variants 
in mice (Zhou et al., 2005). RT-PCR experiments show PLCη1 mRNA to be highly 
expressed in the brain and kidney, with expression levels also detectable in the lungs, 
spleen, intestine, pancreas and thymus (Hwang et al., 2005). PLCη2 mRNA levels are 
restricted to the brain and intestine (Zhou et al., 2005; Nakahara et al., 2005). In 
common with other PLC family members, primary sequences of PLCη isozymes contain 
a PH domain, four EF-hand motifs, the C2 domain and the catalytic X and Y domains 
(Suh et al., 2008). 
Recent studies suggest that PLCη isoforms are activated through GPCR stimulation. Co-
expression of PLCη2 with Gβ1 and Gγ2 caused an increase in PLC activity in COS-7 cells 
(Zhou et al., 2005). Furthermore, purified extracts of PLCη2 were stimulated by G 
protein βγ subunits through interaction with the PH domain (Drin et al., 2006). In vitro 
experiments demonstrate that all PI-PLCs can be stimulated by Ca2+, however PLCη1 
and PLCη2 are more sensitive to Ca2+ compared to other isozymes, with maximal 
activity of both enzymes being achieved at Ca2+ concentrations of 1μM (Hwang et al., 
2005). PLCη1 and PLCη2 may act to amplify the signalling events of other PI-PLCs with 
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the C2 domain thought to direct the calcium sensitivity of these enzymes (Popovics et 
al., 2014). 
1.6. Bacterial (b)PI-PLCs: Phospholipase C X-domain containing proteins (PLCXDs) 
Bacterial PI-PLCs have been isolated from various pathogenic species, including 
Bacillus cereus (Kuppe et al,, 1989) B. anthracis (Klichko et al., 2003) B. thuringiensis 
(Volwerk et al., 1989) and L. monocytogenes (Mengaud et al., 1991), and also non-
pathogenic species, including Streptomyces antibioticus (Yugo et al., 1994). Bacterial 
PI-PLCs have much smaller molecular masses (30-35 kDa) than mammalian PI-PLCs and 
consist of only an X-domain and hence are also known as phospholipase C X-domain 
containing proteins (PLCXDs). Furthermore, the bacterial PI-PLCs are secreted while 
mammalian PI-PLCs are intracellular enzymes and biochemical studies suggest that 
bPI-PLC has a role in calcium independent cleavage of PI and not its 
polyphosphorylated derivatives (Essen et al., 1998). Many bacterial PI-PLCs, including 
B. cereus, B. anthracis and S. aurues are also able to hydrolyse 6-glycosylated PI which 
can cause the release of proteins tethered to the membrane by 
glycosylphosphatidylinositol (GPI) anchors (Low, 1989; Low 1990). The catalytic 
activity of PI-PLC is thought to be important for the virulence of many pathogenic 
bacteria. B. thuringiensis is an important insect pathogen, and previous work has 
identified mutants lacking PI-PLC as avirulent (Camilli et al., 1991). L. monocytogenes 
are intracellular pathogenic bacteria that infect and multiply within macrophages. As 
an important part of their virulence, L. monocytogenes must escape from the 
phagosome and enter the cytoplasm of the macrophage (Pamer, 2004). Studies 
43 
 
demonstrate the importance of the L. monocytogenes PI-PLC activity in facilitating this 
escape through the production DAG and subsequent activation of PKC (Poussin et al., 
2009).  
With regards to the three-dimensional structure of bacterial PI-PLCs, B. cereus and B. 
thuringiensis have received the most attention. Sequence alignment analysis shows 
around 98% similarity between the two Bacillus PI-PLCs. Structural analysis using X-ray 
crystallography shows both enzymes consist of a single domain which folds as a 
distorted βα-TIM barrel, similar with to the catalytic domain of mammalian PI-PLCs. 
The enzymes are thought to co-ordinate substrate binding through the formation of 
hydrogen bonds with hydroxyl groups at positions 2, 3, 4 and 5 of the inositol ring. No 
hydrogen bonds are present between the protein and the hydroxyl groups at positions 
1 or 6 of the inositol ring (Essen et al., 1998).  
1.6.1. Mechanistic comparison of bacterial and eukaryotic PI-PLC 
Bacillus PI-PLCs follow a general acid-base catalytic mechanism, similar to that for 
mammalian PI-PLCs, that involves two conserved histidine residues. In the Bacillus 
enzymes, these histidine residues are His32 and His82, which are conserved in other 
bacterial PI-PLCs. Similar to mammalian PI-PLCs, catalysis proceeds in two steps: a 
stable cyclic phosphodiester intermediate is created following a phosphotransfer 
reaction which is followed by a phosphohydrolysis reaction which creates acyclic 
inositol phosphate. In bPI-PLCs, His32 and His82 were identified as the general base 
and general acid, respectively (Heinz et al., 1998). The essential roles for His32 and 
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His82 in this catalytic mechanism have been confirmed by mutagenesis studies 
(Hondal et al., 1997).  
Bacillus cereus 
 
 
 
 
                 
Mammalian PLCδ1 
 
 
 
 
 
 
 
 
Figure 1.11: Comparison of the catalytic mechanism of the calcium-independent 
bacterial PI-PLCs (bPI-PLC) and the calcium-dependent mammalian PI-PLCs. This 
mechanism is based on structural data of PI-PLC from Bacillus cereus (bacterial; top on 
diagram) and human PLCδ1 (bottom on diagram) in complex with a number of 
substrate analogues. For Bacillus, His32 and His82 act as the general base and general 
acid, respectively and Arg69 stabilises the pentacovalent and cyclic inositol phosphate 
substrate intermediates. For PLCδ1, His356 acts as the general acid whereas the 
identity of the general base (B-) is currently unclear. PI, phosphatidylinositol; TS, 
pentacovalent transition state; IcP, Ins(1:2cyc)P. Adapted from Heinz et al., 1998. 
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A striking difference between the catalytic mechanism of bacterial and eukaryotic PI-
PLCs is the utilisation of calcium within the active site. The presence of calcium is a 
hallmark of the active site of eukaryotic PI-PLCs, and it is co-ordinated by the side-
chain of a number of different amino acids (Section 1.4.1.4). These residues are not 
conserved in Bacillus PI-PLC enzymes, which have been confirmed to be calcium-
independent enzymes. Calcium is thought to stabilise the cyclic inositol phosphate 
substrate intermediate within the active site of mammalian PI-PLCs. This stabilisation 
of the cyclic inositol intermediate by calcium is thought to provide an explanation why 
mPI-PLCs are able to bind this substrate intermediate with high affinity and therefore 
produce the acyclic inositol phosphate as the primary product of catalysis. In contrast, 
electrostatic stabilisation of the substrate intermediate is achieved by a basic residue, 
Arg69, and not calcium in Bacillus PI-PLCs and is much weaker than that of mPI-PLCs. 
Due to this lower affinity for the substrate intermediate, bPI-PLCs release most of the 
bound Ins(1:2cyc)P before the second reaction (phosphodiesterase) is complete, 
which is therefore the principal product of catalysis (Heinz et al., 1998). The basic 
residue, Arg69, is well conserved among bPI-PLCs, and mutational studies 
demonstrate its essential role in catalysis (Essen et al., 1998). 
1.7. Phospholipase C X-domain containing proteins (PLCXDs) 
Much of the available literature on the existence and molecular functions of PLCXD 
proteins exist only for bacterial orthologs. It is, however, becoming increasingly clear 
that genes encoding PLCXD proteins are present in the genomes of eukaryotes. The 
first evidence of this came following the isolation and characterisation of a 
glycosylphosphatidylinositol-specific PLC (GPI-PLC) from the human parasite 
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Trypanosoma brucei (Webb et al., 1994). In contrast to other eukaryotic PI-PLCs, this 
enzyme is only 39 kDa and consists of only an X-domain. Like bacterial PI-PLCs it is also 
metal independent and can hydrolyse GPI anchored proteins and PI, but not PIP2, using 
a similar catalytic mechanism. When using PI as a substrate, GPI-PLC generates DAG 
and a cyclic inositol-phosphate (Webb et al., 1994). The cell surface of T. brucei found 
in the mammalian bloodstream, has a densely packed protein coat composed of a 
single polypeptide, the variant surface glycoprotein (VSG), anchored to the exterior 
surface of the plasma membrane by a GPI anchor. Cleavage of this anchor by the GPI-
PLC causes a rapid release of VSG from the plasma membrane (Hanrahan et al., 2009). 
Although a definitive function for GPI-PLC has yet to be identified, evidence suggests 
that the release of VSG from the plasma membrane by the GPI-PLC may be important 
for the pathogenicity of T. brucei (Webb et al., 1997; Sharom and Lehto, 2002). 
Recently, the presence of PLCXD proteins in higher vertebrates and mammals has been 
confirmed. As a result of a microarray screen, a PLCXD was identified as a candidate 
gene showing differential expression between the different developmental stages of 
the European eel (Anguilla anguilla) (Kalujnaia and Cramb, unpublished). Comparative 
analysis with available databases revealed the presence of PLCXD orthologs in the 
genomes of virtually all species sequenced to date, including at least three isoforms in 
the human genome. What is more interesting is that no information exists regarding 
the functions of these ubiquitous proteins. 
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1.8. Aims of the Thesis 
To date, all current information regarding the characterisation of members of the PI-
PLC enzyme family has focussed on six sub-classes, with each sub-class having a 
different number of isoforms; PLCδ (δ1-δ4), PLCβ (β1-β4), PLCγ (γ1 and γ2), PLCε (ε1 
and ε2), PLCζ and PLCη (η1 and η2). Owing to the the importance of these enzymes in 
cell signalling, their molecular structures, tissue distributions, mechanisms of 
activation and disparite physiological functions have been extensively investigated 
over the past 50 years with over 20,000 manuscripts currently published in the 
scientific literature. In contrast, PLCXDs have received less attention with information 
only available for bacterial PLCXDs, generally regarded as virulence factors, and the 
PLCXD, known as VSG lipase, present in Trypanosoma brucei and Trypanosoma cruzi.   
The aim of this thesis are: 
 To further characterise the putative European eel PLCXD gene indentified in 
the previous microarray by elucidating its full-length sequence, tissue 
distribution and mRNA/protein expression in the intestine of the different 
developmental stages of the European eel (Yellow and silver) following salinity 
transfer. 
 To confirm the presence of three mammalian PLCXD isoforms (PLCXD1-3) and 
characterise their tissue distribution (mouse and human) and cellular 
localisations (HeLa cells; human PLCXDs). 
 To characterise the mRNA and protein expression levels of PLCXDs in the 
cerebella and retinal samples from a mouse model of neurodegeneration (The 
Harlquin mouse) compared to control mice. 
 To define the optimal conditions required for the production of recombinant 
human PLCXD proteins and characterise the enzymatic and structural 
properties of these proteins in vitro. 
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2.1 Animals 
Prior to the onset of this project, adult freshwater “yellow” and “silver” eels were 
netted from rivers in the River Tay catchment area by Dr Gordon Cramb in 
collaboration with a local supplier based in Blairgowrie, UK. Briefly, fish were 
transported to the Scottish Oceans Institute, University of St Andrews, where they 
were initially kept in holding tanks containing FW (0-10 mOsm kg-1) at ambient 
temperature (5-10 °C) on a 12h:12h light:dark photoperiod prior to the onset of 
experiments. Eels (n=6) were then transferred to separate experimental tanks 
containing 100 L of FW and salinity transfer was performed by reducing the water level 
of each tank to approximately 5% followed by a gradual re-filling (over a period of 1 h) 
back to 100 L with either SW (SW acclimation; 960-1020 mOsm kg-1) or FW (controls). 
Eels were kept at ambient temperatures (5-10 °C) under a natural photoperiod 
(12h:12h light:dark) in running aerated FW or SW water. After 6 months, groups of 
FW-maintained and SW-acclimated yellow and silver eels were killed, decapitated and 
pithed before the removal of tissues.  
Wild-type male mice on a B6CBA background and mice heterozygous for the X-linked 
harlequin mutation (Pdcd8Hq) on the same genetic background were bred and 
maintained by Dr Marisol Corrall-Debrinski at the Institut de la Vision, Paris, France, as 
described in Bouaita et al., 2011. Frozen cerebellar tissue samples and retinal RNA 
samples were prepared from 6-month old mice (n=6 wild type; n=6 Hq) by Dr Marisol 
Corrall-Debrinski and kindly sent to St Andrews for analysis of PLCXD expression.  
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2.2 Microbiology 
2.2.1 Growth of E. coli strains 
E. coli strains used in this thesis are listed in Table 2.1. The different medium and 
antibiotic supplements used for the growth of E. coli are listed in Tables 2.2 and 2.3, 
respectively. For the growth of bacterial cultures, single colonies were selected from 
freshly streaked selective agar plates and used to seed up to 10 mL of selective 
medium and grown at 37 °C with vigorous shaking (210 rpm) overnight (16-18 h). The 
following day, the overnight culture was used to extract plasmid DNA (Section 2.7.2) 
and/or to prepare glycerol stocks for long-term storage (Section 2.2.2). For protein 
expression, the overnight culture was diluted 1/1000 into a larger volume of selective 
medium and incubated at 37 °C with shaking (210 rpm) until an optical density at 600 
nm (OD600) of 0.6-0.8 was reached. These cultures were then used for expressed 
protein purification, according to Section 2.2.5. For growth on agar plates to obtain 
single colonies, the desired clone was streaked from a glycerol stock (Section 2.2.2) or 
a freshly transformed cell suspension (Section 2.2.4) onto a freshly prepared selective 
agar plate and the plates were incubated upside down (agar up) over night at 37 °C.  
2.2.2 Cryopreservation and resuscitation of E. coli cells 
For long-term storage at -80 °C, glycerol stocks were prepared for E. coli cell 
suspensions. 500 µL was removed from overnight liquid cultures of E. coli (prepared 
as above) and mixed thoroughly with an equal volume of filter-sterilised freezing 
media (LB, 30% v/v glycerol) and stored frozen at -80 °C. For the recovery of bacteria 
from a glycerol stock, an aliquot of frozen cells was streaked onto an LB-agar plate 
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containing the appropriate antibiotic to check for the presence of selective markers, 
and incubated as described above.  
 
Strain Description 
One Shot TOP10 (Invitrogen) Chemically competent E. coli. Used for high-
efficiency cloning and plasmid propagation. 
One Shot OmniMAX™ 2 T1R (Life 
Technologies) 
Chemically competent cell line used for 
cloning applications. TonA genotype for 
resistance against T1 and T5 phage 
infection. These were provided by the 
Oxford Protein Production Facility (OPPF). 
Rosetta™ (DE3) pLysS (Novagen) (DE3) indicates that the strain carries a 
chromosomal copy of the T7 RNA 
polymerase under the control of the IPTG-
inducible promoter, lacUV5. 
pLysS strains express T7 lysozyme which 
supresses basal expression of T7 
polymerase prior to induction. This plasmid 
also carries a chloramphenicol resistance 
gene. 
These strains were a gift from Dr Arif Sheikh, 
University of St Andrews. 
Lemo21 (DE3) competent E. coli 
(Invitrogen) 
Strains contain a chromosomal copy of T7 
lysozyme which is under the influence of an 
L-rhamnose-inducible promoter. When 
strains are grown without L-rhamnose they 
perform the same as a pLysS containing 
strain. Optional addition of L-rhamnose 
tunes the expression of the protein of 
interest. These were provided by the OPPF. 
OverExpress C43(DE3) plysS (Lucigen) Strains are lysogenic for the DE3 λ 
prophagend express the T7 RNA polymerase 
through IPTG induction controlled by the 
LacUV5 promoter. These strains also carry a 
chloramphenicol-resistant plasmid 
encoding the T7 lysozyme. These cells 
contain a mutations which confers toxicity 
tolerance and therefore they are used to 
express toxic proteins. These were a 
generious gift from Dr Arif Sheikh, University 
of St Andrews. 
Table 2.1: E.coli strains and their properties. 
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Media type Description 
Luria-Bertani broth (LB)-Lennox (Sigma-
Aldrich, Poole, Dorset, UK) 
Dissolve 20 g of powder in 1 L water. 
Autoclaved for 15 min at 121 °C 
LB agar (Sigma-Aldrich, Poole, Dorset, 
UK) 
35 g of powder was added to 1 L water 
and heated to boiling whilst stirring to 
fully dissolve the powder. Autoclaved 15 
min at 121 °C to sterilise. Was allowed to 
cool before making any additions, such 
as antibiotics. 30 ml poured into petri 
dishes and allowed to solidify. 
Terrific broth (TB) (Sigma-Aldrich, 
Poole, Dorset, UK) 
Dissolved 47.6 g and 8 mL glycerol in 1 L 
distilled water and autoclaved for 15 min 
at 121 °C. 
Power Broth™ (AthenaES™) 52 g dissolved in I L distilled water. 
Glycerol (4 mL) was added and then the 
solution was autoclaved for 15 min at 
121 °C. This was prepared by OPPF. 
Overnight Express™ Instant TB Medium 
(Millipore) 
Dissolved 60 g powder in 1 L distilled 
water, supplemented with 10 mL 
glycerol and then autoclaved for 15 min 
at 121 °C. This was prepared by OPPF. 
SOC Medium (Invitrogen) Supplied as 10 mL bottles of liquid 
medium used for the growth of bacteria 
in the final step of transformation. 
Table 2.2: The different media used to culture E. coli. 
 
Table 2.3: Antibiotics used for selective growth of bacteria 
Antibiotic Descirption 
Ampicillin sodium salt (Sigma-Aldrich, 
Poole, Dorset, UK) 
Stock concentration of 100 mg/mL prepared 
in MilliQ water. Working concentration of 
100 µg/mL. 
Kanamycin sulphate (Sigma-Aldrich, Poole, 
Dorset, UK) 
Stocks prepared at 50 mg/mL in MilliQ water 
and then diluted to 50 µg/mL working 
concentration. 
Chloramphenicol (Sigma-Aldrich, Poole, 
Dorset, UK) 
Stocks prepared at 34 mg/mL in 100% 
ethanol and used at a working concentration 
of 34 µg/mL 
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2.2.3 Preparation of chemically competent E. coli 
Within this thesis, only the Rosetta™ (DE3) pLysS and OverExpress C43 (DE3) pLysS 
strains were made chemically competent using the procedure described below; all 
other strains (Table 2.1) were purchased as chemically competent cells. A glycerol 
stock of Rosetta (DE3) pLysS and OverExpress C43 (DE3) pLysS strains were obtained 
from Dr Arif Sheikh and used to streak fresh LB-agar plates to obtained single colonies, 
as described in Section 2.2.1. These LB-agar plates contained 34 µg/µL 
chloramphenicol (prepared according to Table 2.2) to select for strains containing the 
pLysS plasmid. A single colony was then inoculated into 1 mL of LB medium 
supplemented with 34 µg/mL chloramphenicol and grown, as described in Section 
2.1.1. On the following day, the starter culture was diluted 1/1,000 to a final volume 
of 100 mL with fresh selective LB medium (Table 2.2) and incubated with shaking until 
an OD600 of 0.25-0.3 was reached. The culture was then chilled on ice for 15 min and 
the cells were harvested by centrifugation at 4,000 rpm for 10 min at 4 °C in 50 mL 
conical tubes using the Avanti J-26PI centrifuge with a JA-25.50 fixed angle rotor 
(Beckman Coulter, Inc.) The supernatant was discarded and the bacterial cell pellet 
was resuspended in 40 mL ice-cold sterile 0.1 M CaCl2 (powder obtained from Sigma-
Aldrich) and incubated on ice for 30 min. The cells were then harvested as above and 
the pellet resuspended in 6 mL 0.1 M CaCl2 containing 15 % glycerol (diluted from 100% 
stock in MillQ H2O; Sigma-Aldrich, Poole, Dorset, UK). The cell suspension was 
fractionated into 50 µL aliquots and stored frozen at -80 °C in sterile 1.5 mL Eppendorf 
tubes (Thermo Fisher Scientific, Loughborough, UK). 
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2.2.4 Heat-shock transformation of competent E. coli 
The ability of bacteria to directly uptake, incorporate and express exogenous genetic 
material from its surrounding is known as transformation. For transformation, 5-50 ng 
of plasmid DNA was added to a vial of chemically competent cells (50 µL), and the cell-
DNA mixture was incubated on ice for 30 minutes. This step was followed by a brief 
“heat shock”, which opens the pores of the cell membrane allowing entry of the 
plasmid. “Heat shock” was carried out at 42 °C for 30 s followed by immediate transfer 
to ice for 2 min. The transformed cells were then incubated with rotation for 1 h at 
37 °C in 200 µL of SOC media (Table 2.1) to allow the bacteria to recover from the heat 
shock and to express the antibiotic resistance gene present on the plasmid DNA.  A 
sample of the recovered bacteria (50-100 µL) was then grown and maintained on a 
pre-warmed selective agar plate, as described in Section 2.2.1. Single colonies were 
used to inoculate 10 mL of LB medium and grown overnight (Section 2.2.1) to prepare 
sufficient cells for plasmid purification, glycerol stock preparation (Section 2.2.2) and 
further growth for protein expression, as described in Section 2.2.5.  
2.2.5 Recombinant expression in E. coli 
Initially expression constructs were created for human PLCXD1, 2.1, and 3 (pETM11 
and pET22b+; Section 2.7.10.1) and used to transform Rosetta™ (DE3) pLysS and C41 
BL21 E. coli strains (Section 2.2.4). Towards the end of the project, human PLCXD1, 2.1 
and 3 were sub-cloned to the pOPIN expression vectors (Section 2.7.10.2) and 
transformed to Rosetta™ (DE3) pLysS and Lemo21 E. coli cells (Section 2.2.4). This 
latter work was carried out in collaboration with the Oxford Protein Production Facility 
(OPPF).  Small-scale expression experiments were carried out first to assess the effect 
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of different variables (Section 2.2.5.1) on the expression levels and solubility of 
recombinant proteins. Large-scale expression experiments were performed once the 
optimum expression parameters for a given target were obtained (2.2.5.2). 
2.2.5.1 Small-scale expression in E. coli 
Initially the levels of expression and solubilities of recombinant PLCXD isoforms were 
assessed in different E. coli host strains (Rosetta™ (DE3) pLysS and C41 BL21) using 
different induction temperatures (25 °C and 37 °C). Single colonies containing 
recombinant vector DNA for each clone were used to inoculate 10 mL of selective 
growth medium and grown overnight (Section 2.2.1). The following day, the starter 
culture was diluted 1/1,000 to a final volume of 50 mL with fresh selective TB medium 
and incubated with shaking until an OD600 of 0.6-0.8 was reached. Protein expression 
was induced by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG; 
Sigma-Aldrich, Poole, Dorset, UK) directly to the cell suspension. Expression was 
induced for either 4 h at 37 °C or 20 h at 25 °C with shaking at 210 rpm. Following 
incubations the cells were harvested by centrifugation at 4,000 rpm at 4 °C for 10 min 
using the Avanti J-26PI centrifuge with a JA-25.50 fixed angle rotor (Beckman Coulter, 
Inc.). Supernatants were decanted and bacterial pellets were weighted and then 
stored frozen at -20 °C until protein extraction (Section 2.8.5). 
Further small-scale expression trials were also carried out at the Oxford Protein 
Production Facility (OPPF), to test the effect of different fusion proteins on the level of 
soluble expression of recombinant of human PLCXD1, 2.1 and 3 in E. coli. Single 
colonies verified to contain recombinant vector DNA were used to inoculate 0.7 mL of 
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selective Power Broth (Table 2.2) the cultures were grown overnight in deep-well 
blocks (BD Falcon 353966) at 37 °C with shaking at 250 rpm. For the induction of 
protein expression in Power Broth, 250 µL of the overnight culture was diluted with 
fresh 3 mL Power Broth and incubated with shaking until an OD600 of 0.5 was reached. 
The cultures were then cooled by shaking at 240 rpm at 20 °C for 20 min and protein 
expression was induced following the addition of 1 mM IPTG to each well and growth 
overnight by shaking at 250 rpm at 20 °C. For auto-induction, individual colonies were 
picked and grown in Power Broth as before. A sample (0.25 mL) of this cell suspension 
was then diluted in 3 mL of Overnight Express Instant TB medium (Table 2.2) 
supplemented with the appropriate antibiotic as before. The cell suspension was 
incubated at 37 °C with shaking until an OD600 of 0.5 was reached. At this point, the 
temperature of the shaker was reduced to 25 °C and the cell suspension was incubated 
with shaking at 250 rpm for a further 20 h to induce protein expression. 
2.2.5.2 Large-scale expression in E. coli. 
For large-scale expression in E. coli, single colonies of each clone were picked and used 
to inoculate a 10 mL overnight culture, as described before. In-order to yield enough 
cells to seed a 12 L culture for protein expression, the starter culture was used to 
inoculate a further overnight culture of 200 mL. The following day, the second 
overnight culture was diluted 1/1,000 in fresh 1 L of selective TB medium (x12 for a 12 
L culture) and incubated at 37 °C with shaking (as before) until an OD600 of 0.6-0.8 was 
reached. Recombinant protein expression was induced and the cells were harvested 
and stored as described in Section 2.2.4.1. 
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2.3 Mammalian Cell Culture 
2.3.1 Maintenance of cell lines 
Adherent cell lines (ATCC) were maintained at 37 °C in a humidified atmosphere at 95% 
air/5% CO2 in the appropriate media (Sigma-Aldrich, Poole, UK) as shown in Table 2.4. 
Cells were grown in 75 cm2 flasks and seeded at a density of 10,000 cells per cm2. Cells 
were split into a new 75 cm2 flask once they covered ~80% of the bottom of the flask, 
as assessed by eye. The media was removed and the cells were washed twice with 10 
mL sterile 1 x Phosphate Buffered Saline (PBS pH 7.4; GIBCO). Cells were then detached 
from the plastic with 2 mL pre-warmed Trypsin-EDTA (Life Technologies, Paisley, UK). 
The cells were then suspended to homogeneity in 10 mL fresh media to inactivate the 
trypsin. An aliquot (0.5-2.5mL) of the cell suspension was added to a new 75 cm2 flask 
containing 15 mL of fresh media. 
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Cell type Origin Media used 
HeLa (ATCC) Immortalised cervical 
cells derived from 
Henrietta Lacks 
DMEM (Dulbecoos’ 
modified Eagles’s medium) 
supplemented with 10% 
(v/v) Fetal Calf Serum (FCS; 
Invitrogen), 100 units/mL 
of penicillin/streptomycin 
(Invitrogen, Life 
Technologies, Paisley, UK) 
HEK293T (Human 
Embryonic Kidney cells). 
Gift from Dr Jelena 
Andrejeva, University of 
St Andrews 
Immortalised cells 
transformed from 
human embryonic 
kidney cells. 
DMEM supplemented with 
10% (v/v) FCS and 100 
units/mL of 
penicillin/streptomycin 
mixture (Invitrogen, Life 
Technologies, Paisley, UK) 
Table 2.4: The maintenance of different mammalian cell lines. 
2.3.2 Storage and resuscitation of cell lines 
Following trypsinisation of a confluent 75 cm2 flask, the cell suspension was 
centrifuged at 1,000 rpm for 3 min at 4 °C. The cell pellet was then resuspended in 4 
mL freezing medium (Life Technologies) and 1 mL aliquots were added to cryovials 
(Thermo Fisher Scientific, Loughborough, UK). The cells were stored at -20 °C for 24 h 
and then -80 °C for 24 h and were stored under liquid nitrogen for long-term storage. 
Cells stored under liquid nitrogen were quickly thawed at 37 °C and added to 10 mL 
fresh growth media. The cells were harvested by centrifugation and resuspended in 25 
ml of fresh medium and transferred to a 75 cm2 flask and grown as previously 
described.  
2.3.3 Transient expression screen in HEK293 cells 
This work was carried out in collaboration with OPPF. The level of soluble expression 
of PLCXD1, 2, and 3 was tested in HEK293 cells by the transfection of pOPIN vector 
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constructs encoding PLCXDs tagged to different fusion proteins. Each PLCXD was sub-
cloned into 10 different pOPIN vectors as described later in Section 2.7.10.2. Cells (1 
mL; 1.5-2 x 105 cells/mL) were seeded in antibiotic-free DMEM (Invitrogen, Life 
Technologies, Paisley, UK) into 2 x 24-well plates, and incubated overnight as 
previously described. Following incubation, 1 mL of fresh DMEM with 2% FCS was 
added to each well of cells. A transfection cocktail was prepared containing 2 µL of 
1.33 mg/mL GeneJuice, 60 µL of serum-free DMEM and 1 µg of plasmid DNA and 
incubated at room temperature for 10 min. The transfection cocktail was added to 
cells and incubated at 37 °C for 3 days. 
2.3.4 Lentivirus-based overexpression in HeLa cells 
This work was carried out in collaboration with Dr Svetlana Kalujnaia, at the University 
of St Andrews. Briefly, over-expression of PLCXDs in HeLa was achieved by 
construction of recombinant lentiviral particles containing each PLCXD isoform. 
Lentiviruses were generated by co-transfecting HEK293T cells with the CMV 
(pCMVR8.91), VSV/G (pMD_VSVG) and pdlNotI’nPk’MCS’R plasmids (Section 2.5.4). 
The CMV plasmid encodes the viral proteins Gag, Pro-Pol, Rev and Tat which are 
controlled by the CMV promoter. The VSV/G plasmid encodes the viral envelop 
glycoprotein from the vesicular stomatitis virus under the control of the CMV 
promoter. The pdlNotI’nPk’MCS’R plasmid carried the target gene and the pac 
(puromycin N-acyl transferase) gene, both of under the control of the SFFV promoter 
sequence (Section 2.6.4). Only the pdlNotI’nPk’MCS’R plasmid carried the viral 
packaging signal sequence and therefore complete lentiviral particles will only carry 
target gene and the puromycin resistance gene. 
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Prior to transfection, HEK293T cells were passaged and 8 x 106 cells were seeded in a 
6 x 75 cm2 flask and incubated overnight. The following day, HEK293T cell confluence 
was assessed by eye and only flasks that had 80-85% confluence were used for virus 
preparation. Recombinant lentiviruses expressing each PLCXD isoform were prepared 
by transfecting the pdlNOT/PLCXD construct together with CMV (pCMVR8.91) VSV/G 
(pMD_VSVG) using FuGENE®6 (Promega, Southampton, UK) according to the 
manufacturer’s protocol. The culture medium containing the lentiviruses was 
removed two days after transfection and new medium was added to the cells and 
removed 24 h later. Medium from 2 and 3 days post transfection was pooled and 
centrifuged at 2,000 rpm for 10 min to remove cell debris. The supernatant was 
filtered through a 0.45 µm syringe filter unit (Millipore) and stored at -70 °C as the 
disabled lentivirus stock in 500 µL aliquots. HeLa cells were cultured in T75 cm2 to a 
confluence of 25-25%, as assessed by eye, and then incubated with 500 µL the 
lentivirus stock in the presence of 8 µg/mL polybrene (Sigma-Aldrich, UK). Two days 
after infection, the virus-containing media was replaced with media supplemented 
with 2.5 µg/mL puromycin (Gibco®). Stocks of stable cell lines were stored frozen at -
80 °C, according to Section 2.3.2. 
2.4 Insect cell culture 
2.4.1 Maintenance of Sf9 cell lines 
The maintenance of Spodoptera frugiperda-9 (Sf9; Life Technologies) cell lines was 
carried out by Ms Nahid Rahman at the Oxford Protein Production Facility. Briefly, 
these cells were maintained in Sf-900™ II medium (Life Technologies) at 27 °C in a non-
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humidified incubator. Suspension cultures were seeded between 3-5 x 105 cells/mL 
and grown at 27 °C (as above) with shaking at 120 rpm until they reached 2-3 x 106 
cell/mL (3-4 days) and then passaged. Adherent cultures were seeded at a density of 
2-3 x 106 cells/mL with 10 mL of Sf-900™ II medium in a 25 cm2 flask and incubated as 
above without shaking for 5-7 days. For storage, suspension cultures were grown to a 
density of 2-3 x 106 cell/mL and then centrifuged at 100 rpm for 5-10 min and the cell 
pellet was resuspended in the same volume of cell freezing medium (70% Sf900™ II/20% 
FCS/10% DMSO) as the original culture. 1.5 mL fractions of the cell suspension was 
added to each cryovial (Thermo Fisher Scientific, Loughborough, UK) and frozen at -
80 °C for 2-3 days. The vials were transferred to liquid nitrogen for long-term storage. 
For resuscitation, 3-4 vials of frozen cells were rapidly thawed in a water bath at 37 °C 
and added to a single 125 mL shake flask containing 25 mL of Sf900™ II media. The cell 
suspension was grown and passaged as described above. 
2.4.2 Baculovirus-based expression in Sf9 cells 
This work was carried out in collaboration with OPPF. The level of soluble expression 
of the different fusion constructs for PLCXD1, 2.1, and 3 was tested in Sf9 cells using 
the Baculovirus expression system. In-order to create the expression vector, the full-
length coding sequence of human PLCXDs was inserted into the pOPIN vector suite as 
described in Section 2.7.10.2. Co-transfection of linearized baculovirus shuttle vector 
or bacmid (BaculoGold™-Baculovirus DNA; PharMingen, BD) and the expression vector 
containing viral polyhedron sequences flanking the PLCXD insert allowed homologous 
recombination to take place (See vector map; 2.6.5). Sf-9 cells (500 µl; 5 x 105 cells/mL) 
were seeded in 24-well culture plates (Corning® Costar®cell culture plates; Sigma-
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Aldrich) and left to attach for 1 h at room temperature. An aliquot containing 250 ng 
of bacmid was gently mixed with 100-500 ng of expression vector DNA and 50 µL of 
Sf900II. To this mixture 0.75 µL FuGeneHD (Roche) was added and the mixture was 
incubated for 30 min at room temperature. The entire transfection mixture was added 
slowly to the appropriate well of Sf9 cells and incubated for 5-6 days as above. 
Following incubation, the baculovirus-containing media was removed (P0 virus stock) 
and was stored frozen at -80 °C. In-order to create P1 virus particles, Sf9 cells were 
seeded at 1 x 106 cells/mL in 24-well plates and left to attach as before. To each well, 
5 µL of the P0 virus stock (as prepared above) was added and the cells were incubated 
for 6 days as previously described. The media was removed (containing the P1 virus) 
and this was stored in 1 mL aliquots at 4 °C in the dark. For long term storage sterile 
BSA (Sigma-Aldrich) was added to 10% and the virus stock was stored frozen at -80 °C. 
Small scale expression screening was performed in suspension culture using 24 deep 
well plates (BrandTech Scientific, Inc., UK) with 5 mL of Sf-9 cells (1 x 106 cells/mL). To 
the cell suspensions, either 5 or 50 µL of the P1 virus was added and incubated for 2-
3 days at 27 °C with shaking at 250 rpm. A 1 mL sample was taken from each well and 
centrifuged for 15 min at 5,500 rpm and the cell pellet was stored frozen at -80 °C for 
protein extraction and purification (described later in Section 2.8.9). 
2.5 Cell assays and treatment 
2.5.1 [3H] Inositol-phosphate release assays 
This assay was carried out in collaboration with Dr Svetlana Kalujnaia. HeLa cells were 
virally-transfected and maintained as previously described. Control, non-transfected, 
and PLCXD1, 2.1 and 3 overexpressing cell lines were seeded in 6-well plates (Sigma-
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Aldrich) until they reached 70-80% of confluence, as assessed by eye. The inositol 
phospholipid pools were then radio-labelled by incubating the cells in inositol-free 
DMEM (MP Biomedicals, IIIkrich, France) containing 1 µCi/mL myo-D-[3H]-inositol (GE 
Healthcare, Buckinghamshire, UK) for 24 h. The cells were then extensively washed in 
complete media and were incubated for 2 h at 37 °C in HEPES-buffered DMEM (MP 
Biomedicals, IIIkrich, France) containing 10 mM LiCl (inhibitor of endogenous inositol 
monophosphatases) to determine the rate of turnover of the phosphoinositide pool 
by the accumulation of [3H]-inositol phosphate in the cell cytosol. Incubations were 
also conducted in the presence of LiCl plus the calcium ionophore A23187 (Sigma-
Aldrich). The reaction was terminated by removal of the medium and the addition of 
1 mL 10 mM ice-cold formic acid (Sigma-Aldrich) to each well and incubating on ice for 
30 min. The soluble [3H]-inositol phosphates were isolated from the formic acid extract 
by passing the cell extract through a column of Dowex AG resin (prepared by addition 
of a 0.5 ml 50% slurry in water; Bio-Rad Laboratories, Hemel Hempstead, UK, to 2 mL 
plastic columns). The resin was washed with 0.5 mL water and 0.5 mL of 60 mM 
ammonium formate/ 5 mM sodium tetraborate before eluting the [3H]-inositol 
phosphates with 1 mL of 1 M ammonium formate/0.1 M formic acid. An 800 µL sample 
of the eluate was transferred into scintillation tubes and mixed with 2.5 mL Optiphase 
Hisafe 3 (Perkin Elmer Biosystems, Cambridge) and the activity was quantified with a 
MicroBeta2 scintillation counter (PerkinElmer Biosystems, Cambridge, UK). 
2.5.2 Immunocytochemistry and fluorescent microscopy 
HeLa cells exhibiting stable overexpression of Pk/V5-tagged hPLCXD1, 2.1 and 3 were 
created and grown (Section 2.3.1) to sub-confluence on sterile coverslips (R&D 
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Systems, Inc, Minnesota) in 6-well plates (Sigma-Aldrich). The media was removed and 
the cells were washed in PBS. The cells were fixed with 4% formaldehyde (Sigma-
Aldrich) in 1 x PBS for 10 min and were washed three times in 1 x PBS. To enable the 
antibodies to gain access to the cell interior, the cell were permeabilised with 0.5% NP-
40 (Tergitol®; Sigma-Aldrich) in PBS for 10 min and the cells were washed 3 times in 
PBS. The cover slips were then incubated with 1% goat serum (Cell Signalling 
Technology™) in PBS for 1 h at room temperature to block non-specific binding of 
protein. Cover slips were then incubated with 1/200 dilution of the mouse anti-Pk tag 
(Abcam antibody gifted by Dr Jelena Andrejeva, University of St Andrews) in 5% BSA in 
PBS for 1 h at room temperature followed by 3 washing steps in PBS. Secondary 
antibody (Alexa Fluor 633-labelled donkey anti-mouse polyclonal antibody; 
ThermoScientific) was diluted 1:1000 in 5% BSA in PBS for 1 h at room temperature 
followed by extensive washing in PBS. Cover slips were washed briefly in PBS and 
mounted in ProLong gold antifade reagent containing DAPI (Sigma-Aldrich) according 
to manufacturer’s instructions. Slides were examined with a Zeiss fluorescent 
microscope system with a 63x oil emersion objective. 
2.6 Vector Maps 
2.6.1 pCR® 4-TOPO® vector 
The pCR 4-TOPO vector was purchased from Invitrogen, Life technologies, Paisley, UK. 
Linearized vector is supplied with 3’-thymidine (T) overhangs for TA cloning. The vector 
contains ampicillin and kanamycin resistant genes for positive colony selection using 
100 µg/mL and 50 µl/mL of the antibiotic, respectively. Priming sites for M13 and T7 
primers which are present for sequencing reactions. 
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 Figure 2.1- Vector map of the pCR 4-TOPO vector showing the cloning site and primers 
sequences used to confirm the presence of a gene insert. 
 
2.6.2 pET M11 vector 
The pET M11 vector was provided as a 0.5 mg/mL purified stock from Dr Arif Sheikh, 
University of St Andrews. The pET M11 vector is derived from pET backbones 
(Novagen). The vector has an N-terminal (His)6-tag which is cleavable by Tobacco Etch 
Virus (TEV) protease and the functional multiple cloning site (MCS) starting with the 
NcoI recognition site. The NcoI has the start codon ATG that can be used for the 
expression of the protein of interest. The target gene is inserted downstream of the 
T7 promoter. 
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Figure 2.2- pETM11 vector map show the multiple cloning site and other elements 
responsible for the expression of a gene of interest. 
 
2.6.3 pET 22b+ vector 
The pET 22b+ vector was provided as a 0.5 mg/mL purified stock from Dr Arif Sheikh, 
University of St Andrews. The pET 22b+ is also derived from pET backbones (Novagen). 
It includes a C-terminal (His)6-tag which is not cleavable by any proteases. For protein 
expression without a signal sequence, the gene of interest is sub-cloned into the MCS 
using NdeI and XhoI restriction sites. This places the gene downstream of the T7 
promoter which allows for inducible protein expression through by the action of IPTG.  
 
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3- pET-22b+ vector map showing the multiple cloning site (MCS) 
2.6.4 pdlNotI’nPk’MCS’R 
The HIV-1-based lentiviral vector pdlNotI’nPk’MCS’R was provided as a 1 mg/mL stock 
by Dr Jelena Andrejeva, University of St Andrews. The vector was used to generate 
HeLa stable cell lines expressing N-terminally Pk/V5-tagged PLCXD-1, 2.1 and 3. The 
vector carries an ampicillin resistance gene for selection in E. coli and a puromycin 
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resistance gene (pac) for selection of transfected mammalian cells. Figure 2.4 
summarises the features of the vector used for protein expression in HeLa cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4- Vector map showing features of the pdINotI’nPk’MCS’R vector allowing for 
sub-cloning and expression of a gene of interest. 5’ and 3’ Long Terminal Repeats (LTF) 
for integration into the host genome; the psi viral packaging signal sequence; central 
polypurine tract (cPPT) which improves vector integration into the host genome; the 
spleen focus-forming virus (SFFV) promoter; internal ribosome entry site (IRES) for the 
initiation of translations; the woodchuck hepatitis virus post-transcriptional regulatory 
element (WPRE) for RNA processing and nuclear import. 
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2.6.5 pOPIN vector suite 
The pOPIN vector suite is a series of expression vectors for the fusion of the target 
protein at its N- and C-terminus with a number of different fusion partners. These 
plasmid vectors were originally constructed by Dr Louise Bird, Oxford Protein 
Production Facility. The pOPIN vectors utilised for the expression of PLCXD fusion 
proteins in this thesis are shown in Table 2.3. The pOPIN vectors allow for the parallel 
screening of protein expression in multiple hosts (E. coli, HEK293T cells and Sf-9 insect 
cells; Figure 2.5).  Each vector carries an ampicillin resistance gene for positive 
selection of colonies. 
The presence of a T7 polymerase promoter with lacO operator allows for inducible 
expression in E. coli strains containing the DE3 prophage. The vector also contains a 
number of elements necessary for the protein expression in eukaryotic cells. The 
cytomegalovirus (CMV) early enhancer element, chicken β-actin promoter and the 
rabbit β-globin poly A site sequences together drive the high level expression in 
eukaryotic cells. Initiation of translation in eukaryotic hosts is driven by the presence 
of a Kozak consensus sequence. The p10 promoter and the lef2/ORF 603 and the ORF 
1629 baculoviral recombination sites allow for insertion into the baculovirus shuttle 
vector and for transfection of Sf-9 insect cells (Bird, 2011; Figure 2.8) 
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Vector Fusion 
Protein 
Sense primer extension Anti-sense primer 
extension 
pOPINF (His)6-3C-POI AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA 
pOPINS3C (His)6-SUMO-3C-
POI 
AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA 
pOPINTRX (His)6-TRX-SC-
POI 
AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA 
pOPINMSYB (His)6-MSYB-3C-
POI 
AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA 
pOPINHALO (His)6-HALO7-
3C-POI 
AGGAGATATACCATG CAGAACTTCCAGTTT 
pOPINM (His)6-MBP-3C-
POI 
AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA 
pOPINTF (His)6-TF-3C-POI AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA 
pOPINNUSA (His)6-NUSA-3C-
POI 
AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA 
pOPINE* POI-(His)6 AGGAGATATACCATG GTGATGGTGATGTTT 
pOPINE-3C-
HALO7* 
POI-3C-HALO7-
(His)6 
AGGAGATATACCATG CAGAACTTCCAGTTT 
 
 
 
 
 
 
 
 
Figure 2.5: Features of the pOPIN vector suite allowing for parallel expression in E. 
coli, mammalian (HEK293T) and insect (Sf-9) cells. 
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2.7 Nucleic acid techniques 
2.7.1 RNA Extraction 
Total RNA was extracted from numerous animal tissues and cultured cells using TRIzol 
reagent (Invitrogen, life Technologies, Paisley, UK). The TRIzol reagent is a solution of 
phenol and guanidinium isothiocyanate that solubilises biological material and 
denatures proteins. Frozen tissue samples (50-100 mg) were homogenised with 6 x 2.8 
mm ceramic beads using a Precellys 24 homogenizer (4 X 20 s at 6,500 rpm; PeqLab, 
Fareham, UK) in ice-cold TRIzol. For cultured cells (25 cm2 flask), media was aspirated 
off, cells were then rinsed once with ice-cold 1X PBS and resuspended in 500 µL of ice-
cold TRIzol.  After tissue/cell disruption, homogenates were centrifuged at 10,000 rpm 
for 1 min at 4 °C to pellet insoluble particulate matter. The supernatant was removed 
and thoroughly mixed with chloroform:isoamyl alcohol (24:1 v:v) (0.2 ml per ml of 
TRIzol; Sigma-Aldrich) in a fresh tube, which was then centrifuged at 14,000 rpm at 
4 °C for 15 min in-order to separate the RNA-containing aqueous phase (top) from the 
organic phase (proteins and high molecular weight DNA being denatured at the 
interphase). The aqueous phase was then removed and RNA was precipitated by 
adding 500 µL isopropanol (Sigma-Aldrich). The sample was then centrifuged at 14,000 
rpm at 4 °C for 10 min and the RNA pellet was washed once with 75% ethanol (Sigma-
Aldrich) and left to air dry. The RNA pellet was resuspended in MilliQ- water to a final 
concentration of 2 µg/µl. The concentration and purity of RNA was determined by 
measuring its optical density (OD) at 260 nm (Nanovue; Section 2.7.3). RNA integrity 
was assessed by electrophoresis in 1 % agarose gels (Sigma-Aldrich; Section 2.7.8), 
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with samples containing well-defined 18S and 28S ribosomal bands being deemed 
acceptable (Figure 2.6). 
 
 
 
 
 
                                    
 
 
 
 
Figure 2.6- Purified RNA was electrophoresed (Section 2.6.8) to monitor the integrity 
of extracted RNA. A total of 2 µg of RNA was separated alongside the 1 kb New England 
Biolabs molecular markers (NEB; Lane 1) on a 1% agarose gel. Both the 28S and 18S 
RNA bands are visible in the intact RNA (Lane 3). Degraded RNA appears as a smear 
(Lane 2). This image is representative of all RNA extractions, with only intact RNA being 
used for further experimental manipulation. 
 
2.7.2 Plasmid DNA extraction from Escherichia coli. 
Bacterial colonies were picked grown as described in Section 2.2.1. Following 
incubation, the cells were harvested via centrifugation at 4,000 rpm at 4 °C for 10 min. 
Pelleted cells were washed once with ice-cold 1X PBS to remove excess culture media. 
Plasmid extraction and purification was then carried out using the QIAprep-Spin 
Miniprep kit (Qiagen, Mancester, UK) following the manufacturer’s instructions. The 
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concentration and purity of extracted plasmid DNA was then estimated, as described 
below. 
2.7.3 Measuring the concentration and purity of nucleic acids 
The concentration and purity of RNA and DNA was measured using a NanoVue Plus 
Spectrophotometer (GE Healthcare). The ratio of absorbance at 260 nm and 280 nm 
(A260/A280) was used as an indicator of the purity of RNA and DNA. A A260/A280 ratio of 
~2.0 and ~1.8 were accepted as “pure” for RNA and DNA, respectively. An aliquot (2 
µL) of the reference sample (same solution that RNA and DNA are suspended in) was 
used to blank the absorbance and then 2 µL of the appropriate RNA or DNA sample 
was used for quantification. 
2.7.4 First strand cDNA synthesis 
Prior to cDNA synthesis, RNA samples were DNase treated to remove any 
contaminating genomic DNA. To a 2 µg sample of RNA, 1 unit of DNase I enzyme 
(Promega, Southampton, UK) and 1.6 µL of 5 X DNase buffer (Promega, Southampton, 
UK) were added to a final volume of 8 µL with MilliQ H2O. This reaction was mixed 
thoroughly by flicking the tube and then incubated for 30 min at 37 °C. Heat 
inactivation of DNase I was then performed at 70 °C for 10 min. After DNase treatment, 
1 µL of MilliQ H2O and 1 µL of Oligo dT primer (500 µM) were added and the samples 
were incubated at 70 ° C for 5 min then placed on ice for 2 min. A volume of 5 µL First 
Strand Buffer (5X; Promega, Southampton, UK), 1.5 µL 10 mM dNTPs, 0.5 µL RNase 
inhibitor (RNAsin; Promega, Southampton, UK), 1 µL Moloney-Murine Leukaemia Virus 
reverse transcriptase (1 unit; M-MLV RT; Promega, Southampton, UK) and 7 µL MilliQ 
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H2O were then added and thoroughly mixed. The samples were then incubated in the 
following conditions: 42 °C for 50 min, 55 °C for 10 min, 70 °C for 10 min (inactivation 
of M-MLV) and 4 °C for storage. For semi-quantitative and real-time PCR, cDNA was 
diluted 1:20 with MilliQ H2O. In-order to clone and sequence the full-length of eel 
PLCXD-4, intestinal cDNA was synthesized using the Marathon cDNA Amplification Kit 
(Clontech, Saint-Germain-en-Laye, France) according to manufacturer’s protocol. 
2.7.5 Primers and primer design 
A number of different primers were used for PCR amplification and DNA sequencing. 
All primers were purchased from Eurofins MWG Operon. Primers were designed 
according the following specifications: sense and antisense primers were designed to 
have approximately the same melting temperature of 60-65 °C; and each primer had 
a GC content close to 50-60%. The melting temperature was calculated using the 
following equation: Tm = 4 x (G+C) + 2 x (A +T). For molecular cloning in E. coli, specific 
restriction sites were added to ends of the sense and antisense primer according to 
the cloning strategy. For relative quantitative PCR, primers of 18-24 nucleotides in 
length were designed across exon-exon boundaries to amplify fragments of 150-200 
bp in length. A full list of primers used in this thesis can be found in the Appendices A-
F. 
2.7.6 Reverse transcriptase Polymerase Chain Reaction (RT-PCR) 
RT-PCR selectively amplifies a specific region of cDNA using a pair of primers that bind 
to the target sequence. In this thesis, RT-PCR methods are used for the cDNA cloning 
of the PLCXD isoforms (Section 2.7.9), sub-cloning to different vectors (Section 2.7.10) 
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and to determine their tissue expression patterns. The sequence of sense and 
antisense primers used are shown in Table 2 (Appendices). All primers were designed 
to have an annealing temperature of between 63 and 65 °C. In general, RT-PCR was 
performed in a total reaction volume of 20 µL consisting of 1 µL of a diluted (1:20) 
cDNA, 300 nM each of gene-specific forward and reverse primers, 1 X Taq DNA 
polymerase buffer (Biogene; supplemented with 1.5 mM MgCl2), 200 nM dNTPs and 1 
unit of Taq DNA polymerase. The following PCR cycle was repeated for 35 cycles: 94 °C 
for 10 sec (denaturation), 60 °C for 30 sec (annealing), and 72 °C for 1 min (elongation). 
For the amplification of the full-length open-reading frames of PLCXD isoforms and 
sub-cloning into different vectors, the proof-reading DNA polymerase, Platinum Pfx 
(Invitrogen, Life Technologies, Paisley, UK) was used and the sequences were verified 
according to Section 2.6.9. 
For high-throughput PCR reactions performed at OPPF, RT-PCR was performed in a 
total volume of 50 µL consisting of 40 ng template DNA, 300 nM of each sense and 
antisense primer, 200  nM dNTP mix, 1 x KOD buffer (Millipore, UK; supplemented with 
1.5 mM MgCl2) and 1 unit of KOD Hot start DNA polymerase (Millipore, UK), made up 
to the final volume with MilliQ H20. The mixture was first heated to 98 °C for 30 sec to 
active the KOD DNA polymerase and then the following PCR cycle was repeated for 29 
cycles: 98 °C for 10 sec (denaturation), 60 °C for 30 sec (annealing), 68 °C for 1.5 min 
(elongation). The PCR products were then stored at 4 °C until further use. 
2.7.7 Rapid Amplification of cDNA Ends (RACE) 
5’-rapid amplification of cDNA ends (RACE) DNA fragments were amplified from RNA 
extracted 6-month SW-acclimated yellow eel intestine with a Marathon cDNA 
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amplification kit, as previously described (Section 2.5.3). 5’-RACE products were 
amplified in nested reactions using eel PLCXD-4 specific antisense primers (Appendix 
A) in combination with the Marathon kit AP1 and AP2 primers (Table 1; ClonTech, 
Saint-Germain-en-Laye, France), according to Section 2.5.4 using Pfx. PCR products 
produced by 5’-RACE amplification were cloned and sequenced as described in Section 
2.6.9. 
2.7.8 Detection of nucleic acids 
Gel electrophoresis was used to separate and visualise DNA/RNA. Agarose (1 g) was 
dissolved in 100 mL 1 x TAE buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 
8.0) by heating in a microwave until boiling. This solution was cooled and a stock 1 
mg/mL ethidium bromide (Life Technologies) was added to give a final concentration 
of 0.1 µg/ml. The agarose gels were then cast in a 10 x 20 cm gel tank (BioRad) with a 
24-well gel comb and allowed to set. Gel electrophoresis was carried out in a 
horizontal tank containing 1 x TAE as running buffer and run at 120 V for 1.5 h. Gels 
were imaged using the Gel Doc XR System (Bio-Rad). For estimation of fragment size, 
a 100 bp or 1 kb ladder (Invitrogen, Life Technologies, Paisley, UK) with known 
fragments sizes and concentrations was used. 
2.7.9 Molecular cloning in E. coli for sequencing 
2.7.9.1 Purification of PCR product 
When multiple PCR products are present following agarose gel electrophoresis, 
products within the expected size range were purified by gel extraction. DNA bands 
were excised from the gel as 100 mg agarose slices using a sterile scalpel blade. PCR 
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products were then purified using the QIAquick gel extraction kit (Qiagen) according 
to the manufacturer’s instructions. DNA was eluted from the QIAquick spin column 
upon addition of 30 µL of TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5). Where only 
a single PCR product was detectable following gel electrophoresis, the product was 
purified directly from the reaction mixture using SOPE resin (QuickStep 2 SOPE Resin; 
EdgeBio, UK) according the manufacturer's protocol. The concentration of DNA 
recovered was then quantified, as described in Section 2.7.3. 
2.7.9.2 Ligation of PCR fragments in pCR4- TOPO. 
For all sequencing reactions, PCR amplified fragments were cloned into pCR4-TOPO 
using the TA Cloning Kit (Invitrogen, Life Technologies, Paisley, UK), as per the 
manufacturer’s instructions. PCR fragments amplified with Platinum Pfx were SOPE 
cleaned and incubated with 10 mM dNTPs and 1 unit of Taq polymerase in 1x Taq 
buffer for 10 min at 72 °C to add 3’ deoxyadenosine (A) overhangs for TA cloning. A 5 
µL aliquot of the PCR product was added to 0.5 µL of the vector along with 1 µL of high 
salt solution and incubated at room temperature for 10 minutes. The entire TOPO 
cloning reaction was added into an aliquot (50 µL) of One Shot TOP10 chemically 
competent E.coli (Invitrogen, Life Technologies, Paisley, UK) and heat shock 
transformation conducted as previously described (Section 2.2.4).  
2.7.9.3 Selection of Colonies and sequencing 
Colonies were selected and used to inoculate 10 mL of selective LB medium and grown 
overnight, as described in Section 2.2.1. The following day, 5 mL of the overnight was 
used for plasmid extraction (Section 2.7.2) and the remaining cell suspension was used 
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to create glycerol stocks for each clone (Section 2.2.2). For sequencing, the PCR insert 
was amplified from the purified plasmid DNA (1 ng) using M13 sense and antisense 
primers (Appendix D). Amplified fragments were purified by SOPE resin (Section 
2.7.9.1) and 40-50 ng used for sequencing using the Big Dye di-deoxy chain termination 
method (Applied Biosystems, Foster City, CA), according to manufacturer’s protocol, 
using the nested T3 forward and T7 reverse primers (Appendix D).  
2.7.10 Molecular cloning in E. coli for protein expression 
Sequenced verified clones of hPLCXD1, 2.1 and 3 genes were selected and sub-cloned 
into a number of vectors for protein expression in E.coli, insect (Sf9) and mammalian 
(HeLa and HEK-293) cells.  
2.7.10.1 Sub-cloning of human PLCXDs in pET M11, pET 22 b+, pdl NotI 
The full-length sequences of human PLCXD-1, 2.1 and 3 were amplified with gene-
specific sense and antisense primers containing appropriate restriction sites for 
eventual insertion into either pET M11 (PLCXD 1 and 3), pET 22b+ (hPLCXD2.1) or pdl 
NotI. Details of the primer sequences and restriction sites are presented in Appendix 
A. The products of the PCR were first cloned in pCR4-TOPO for sequence verification, 
as described above. Plasmids containing the PLCXD isoforms and the target plasmids 
for protein expression were double digested with both restriction enzymes. All 
restriction enzymes were purchased from Promega. As a general protocol, 1 µg of each 
plasmid DNA was mixed with 1 unit of enzyme, 2 µg bovine serum albumin (BSA) and 
1 x buffer (Multi core B; Promega, Southampton, UK) made up to a final volume of 20 
µL with MilliQ water. For double digestions, a buffer was chosen which was optimal 
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for both enzymes. The samples were incubated at 37 °C for 2-3 h followed by 65 °C for 
10 min to inactivate the enzymes. After digestion, 4 µL of 6 x Gel loading buffer was 
added to each reaction and the samples were electrophoresed in 1% agarose gels, 
according to Section 2.7.8. Bands corresponding to the excised PLCXD product were 
gel extracted, purified and the amount of DNA quantified, as described previously. For 
the ligation of digested vector DNA and target insert DNA, a total of 100 ng of DNA 
(with a molar ratio of insert to vector of 3:1) was mixed 2 µL 10 X ligation buffer 
(Promega, Southampton, UK), 1 µL 1 unit T4 DNA ligase (Promega, Southampton, UK) 
and MilliQ H20 to to 20 µL. The samples were mixed gently with a micropipette, 
centrifuged briefly and then incubated at 16 °C overnight.  
2.7.10.2 In-Fusion cloning of human PLCXDs to the pOPIN vector suite 
PLCXDs were cloned from a HeLa cDNA library using primers designed for In-Fusion 
cloning, as described in Section 2.5.4. The PCR products were purified using AMPure 
XP Magnetic beads (Beckmann Coulter) according to the manufacturer's protocol. In a 
total volume of 10 µL,  100 ng of purified PCR product was mixed with 100 ng of the 
appropriate linearized pOPIN vector (depending on the primers used in amplification) 
and then transferred to a dry-down In-Fusion plate and mixed by pipetting. The entire 
reaction contents were then transferred to a clean 96-well PCR plate and heated at 
42 °C for 30 min. Once the incubation was complete, the In-Fusion reaction was 
transferred to ice and diluted with 40 µL of Tris-EDTA (TE) pH 8.0.  A 5 µL aliquot of the 
diluted In-Fusion mixture was then immediately transformed into OmniMaxII cells by 
the heat-shock method (Section 2.2.4) and 50 µL of transformed cells were grown on 
agar plates supplemented with antibiotic, 40 µg/mL X-Gal and 0.1 mM IPTG. White 
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colonies were selected and grown in 1.2 mL Power Broth in deep-well blocks at 37 °C 
overnight with shaking at 250 rpm. Glycerol stocks were prepared according to Section 
2.2.2, and the remaining cells were harvested following centrifugation at 4,000 rpm 
for 10 min. The media was decanted and the bacterial pellet was lysed and the plasmid 
purified according to the QIAquick Miniprep protocol (Qiagen) using a Bio-Robot 8000. 
2.7.11 Real-time quantitative PCR 
The relative expression of all PLCXD isoforms in different tissues was measured by 
quantitative RT-PCR using SYBR Green PCR Master Mix (Applied BioSystems, Foster 
City, CA) and amplification and analysis on an Applied Biosystems 7300 Cycler running 
propriatory SDS detection software (Applied Biosystems, Foster City, CA).  The PCR was 
carried in a total volume of 20 µL consisting of: 1 µL cDNA template (diluted 1/20; 
Section 2.7.4); 300 nM of each gene-specific sense and antisense primer (Appendices); 
1x SYBR green master mix (Applied BioSystems, Foster City, CA); MilliQ water to 20 µL. 
Amplification was started with an initial 10 min denaturation at 95 °C, followed by 40 
cycles of denaturation (95 °C, 30 s), primer annealing at the temperature appropriate 
for each primer (55-60 °C, 45 s) and primer extension (72 °C, 45 s) ending with melting 
curve analysis to validate the specificity of the PCR products. Template negative 
controls (NTC) were performed, using MilliQ water instead of template cDNA, to verify 
the absence of non-specific products or primer dimers. The relative abundance values 
for each target gene were expressed as standard quantity of gene of interest 
(determined from the cycle threshold (Ct) and the efficiency curve for the target gene) 
divided by the standard quantity of the reference (Rpl-P0; determined as for the target 
gene). The PCR efficiency estimates for each primer pair were performed using five-
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point, 5-fold, serially diluted template cDNA of the template cDNA ranging from 1/5- 
1/625. The Ct values (y-axis) were plotted against the log cDNA concentration (x-axis) 
and the primer efficiency was determined based on the slope of the standard curve. 
Slopes within the range of -3.60 to -3.10, correlating to efficiencies between 90-100%, 
were considered acceptable for real-time PCR. The threshold cycle (CT) for Rpl-P0 did 
not vary under different experimental conditions when equal amounts of RNA were 
used. 
2.8 Protein analysis 
2.8.1 Protein extraction from animal tissues and cultured cells 
Cytosolic and membrane protein fractions were prepared from tissues and cell 
homogenates for Western blotting analysis. Frozen tissue samples (100-150 mg) were 
homogenised with 6 X 2.8 mm ceramic beads using a Precellys 24 homogenizer (4 X 20 
s at 6,500 rpm; PeqLab, Fareham, UK) in ice-cold extraction buffer (50 mM Hepes, 1 
mM MgCl2, 0.25 M sucrose pH 7.4 containing 1 X EDTA-free cOmplete protease 
inhibitor cocktail (Roche Diagnostics Ltd., West Sussex, UK). For cultured cells, media 
was aspirated off and the cells were rinsed once with 1 X PBS. The cells were then 
trypsinised, as previously described in Section 2.3.1, and pelleted by centrifugation in 
15 mL falcon tubes at 1,000 rpm (Eppendorf Centrifuge 5810 R, swing-bucket rotor A-
4-62; Eppendorf, UK) at 4 °C for 1 min. The cell pellet was rinsed once in 1 X PBS to 
remove trypsin and resuspended in 0.5-1 mL ice-cold extraction buffer and 
homogenized with 0.7g X 1.7 mm ceramic beads as described above. After tissue/cell 
disruption, homogenates were centrifuged at 10,000 rpm (Eppendorf centrifuge 
5417C, fixed-angle rotor FA-45-30-11) for 10 s to pellet insoluble particulate matter 
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and the supernatant were re-centrifuged at 20,000 rpm (Eppendorf centrifuge 5417C, 
FA-45-30-11 rotor) for 40 min at 4 °C to gain the cytosolic fraction. The membrane 
pellets were resuspended in extraction buffer (0.2 x the original volume). The 
Bradfords method (Bio-Rad Laboratories, Hercules, CA, USA) was used to determine 
protein concentrations, according to the manufacturer’s protocol. Both the cytosolic 
and membrane protein fractions were aliquoted at 2 mg/mL and stored frozen at -
20 °C. 
HEK293T cells transiently transfected with pOPIN-PLCXD constructs were harvested 
after 3 days of growth to screen to monitor the expression of the different fusion 
constructs of PLCXDs. The media was removed from the cells and the 24-well plate 
was frozen at -80 °C for 30 min. The cells were then defrosted at room temperature 
for 10 min and lysed using 250 µL of lysis buffer (NP1-10, DNase, 1x Roche protease 
inhibitors). The mixture was pipetted up and down repeatedly to detach the cells from 
the plastic and the mixture was then centrifuged at 5,000 rpm for 30 min in 1.5 mL 
Eppendorf tubes (Thermo Fisher Scientific, Loughborough, UK) using an 5417C 
Eppendorf centrifuge with the FA-45-30-11 rotor (Thermo Fisher Scientific, 
Loughborough, UK). A 20 µL aliquot of the supernatant was then mixed with 20 µL of 
SDS sample buffer, denatured at 95 °C for 10 min and the proteins were separated and 
analysed by western blotting using anti-his primary antibody, as described below. 
2.8.2 Antibodies 
Studies described in this thesis utilised both commercially available and custom made 
primary antibodies alongside enzyme (HRP and AP) and fluorophore (Alexa Fluor)-
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conjugated secondary antibodies. These are detailed in Table 2.4. Custom-made 
primary antibodies were generated by Dr Gordon Cramb in collaboration with 
Pepceuticals, Leicester, UK. Briefly, a synthetic peptide was generated that reflected a 
sequence region sharing the lowest level of homology with other PLCXDs (See Table 
below). The synthetic peptide was conjugated to the keyhole limpet haemocyanin 
(KLH) carrier protein and then used to generate the specific polyclonal antisera in 
rabbits (Pepceuticals, Leicester, UK). Antibodies were subsequently affinity purified 
from a total of 20 mL of antisera using the specific peptide antigen cross-linked to 
activated thiol Sepharose 4B, following the manufacturers protocol (Amersham 
Biosciences).  
Table 2.5: List of antibodies used in this thesis. 
Antibody Species Antigen Source Experiment 
Pk/V5-tag Mouse Pk/V5-tag Dr Jelena  
Andrejeva 
Co-IP (Chapter 6) and 
Immunocytochemistry 
(Chapter 4) 
ePLCXD4 Mouse eelPLCXD4; aa’s 27-48-C-
LEKLDLPNGHEVNWMMSIDDET 
Pepceuticals, 
Leicester, UK. 
Western blotting 
(Chapter 3) 
α-tubulin Rabbit Mouse α-tubulin Abcam Western blotting 
(Chapters 3 and 5) 
hPLCXD3 Rabbit Human PLCXD3;aa’s 1-16- 
MASSQGKNELKLADW-C  
Pepceuticals, 
Leicester, UK. 
Lipid binding studies 
(Chapter 6) 
Alexa Fluor 
633 
Donkey Mouse IgG Invitrogen, 
Life 
Technologies, 
Paisley, UK 
Immunocytochemistry 
(Chapter 4) 
HRP-
conjugated 
Donkey Mouse IgG Abcam Western blotting 
(Chapter 3) 
AP-
conjugated 
Donkey Rabbit IgG Abcam Western blotting 
(Chapter 4 and 6) 
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2.8.3 SDS Polyacrylamide gel electrophoresis (PAGE) 
Extracted protein samples (2 mg/mL) were diluted 1:1 with 2 X SDS sample buffer (125 
mM Tris-HCl, 4% SDS, 20% glycerol and 90 mM β-mercaptoethanol, pH 6.8) and 
incubated at 95 °C for 10 min before being loaded (10 µg) onto NuPAGE precast 
polyacrylamide gradient gels (4-12%; Invitrogen, Life Technologies, Paisley, UK). 
Samples were separated at a constant voltage of 160 V for 1 h in a 1 x Mes running 
buffer (Invitrogen, Life Technologies). A sample (5 µL) of SeeBlue Plus2 pre-staining 
molecular weight standards (Invitrogen, Life Technologies, Paisley, UK) was used for 
molecular size estimation. Once electrophoresed, the gel was either stained with 
Coomassie blue (Section 2.8.3) or the proteins were transferred onto a PVDF 
membrane for Western blotting analysis (Section 2.8.4). 
2.8.4 Coomassie blue staining of proteins 
Within this study Coomassie blue dye was used to visualise proteins separated by SDS 
PAGE. Following electrophoresis the gel was incubated at room temperature with 
constant shaking in a solution of Coomassie brilliant blue stain (0.1% Coomassie 
Brillant Blue R-250, 50% methanol and 10% glacial acetic acid) for 5 minutes. The gel 
was then washed with a destaining solution (10% methanol, 10% glacial acetic acid) at 
room temperature with constant shaking for 10 minutes. This washing step was 
repeated several times to enable the visualisation of individual protein bands. 
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2.8.5 Western blotting analysis 
Proteins separated by SDS-PAGE were electroblotted onto PVDF membranes (VWR, 
Leicestershire, UK) for 1 h at 120 Volts in 1 x NuPAGE transfer buffer (Invitrogen, Life 
Technologies, Paisley, UK), supplemented with 10% methanol and 0.01% SDS. 
Immediately before transfer the PVDF membrane was incubated in methanol for 1 min 
prior to washing in water and then transfer buffer for 10 min. Following transfer, the 
membranes were incubated in blocking buffer (10% non-fat milk in PBS containing 0.2% 
Tween-20) for 1 h at room temperature with gentle rocking. Membranes were then 
incubated in 1% non-fat milk in PBS containing 0.5% Tween-20 and the primary 
antibody overnight at 4 °C. Primary antibody incubation was followed by washing for 
3 x 10 min in PBS, 0.2% Tween-20. Generally, the secondary antibody was diluted 
1/10,000 in blocking buffer, which was added to the membrane for 1.5 h at room 
temperature. This thesis used two types of secondary antibody: alkaline phosphatase 
(AP)-linked secondary antibodies and horseradish peroxidase-conjugated antibodies 
(Table 2.5).   For the former, bound antibodies were visualised by incubating 
membranes in Western blue phosphate substrate solution (Promega, UK) for 
approximately 5 min to allow the development of immunoreactive bands. For 
horseradish peroxidase-conjugated secondary antibodies, detection was performed 
using the ECL detection method, as described by the manufacturer (Pierce Dura ECL, 
Thermo Fisher Scientific, and Loughborough, UK). Densitmetric analysis was carried 
out using Aida Image analyser software. 
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2.8.6 Purification of recombinant proteins from E. coli 
Following expression recombinant proteins contained an N-terminal 6X His-tag.  Cell 
pellets were thawed on ice and resuspended in 10 mL of lysis buffer (50 mM Tris-HCl, 
500 mM NaCl, 10 mM imidazole, pH 8.0) per gram of wet cell pellet. The lysis buffer 
was supplemented with 1 X EDTA-free cOmplete protease inhibitor cocktail (Roche 
Diagnostics Ltd., West Sussex, UK) and 5 µg/mL DNAseI (New England Biolabs). The 
cells were mixed into a homogenous suspension in lysis buffer, and then sonicated six 
times for 10 s at 10 s intervals keeping on ice throughout. Total cell lysate was 
partitioned into soluble and non-soluble protein fractions by centrifugation for 30 
minutes at 20,000 rpm at 4 °C in 50 mL conical centrifuge tubes (Termo Fisher Scientific, 
Loughborough, UK) using the Avanti J-26PI centrifuge with a JA-25.50 fixed angle rotor 
(Beckman Coulter, Inc.). After centrifugation, the soluble fraction was filtered through 
a 0.22 µm syringe filter unit (Millipore) and the target protein was purified with a Ni2+ 
-affinity column (HisTrapTM HP column; GE Healthcare), according to the 
manufacturers’ instructions’, using the Akta Purifier chromatography system (UPC 10; 
GE Healthcare). Purification of target proteins was confirmed by SDS-PAGE and 
Coomassie staining. 
2.8.7 (His)6-tag cleavage 
Excess imidazole was removed following dialysis of pooled eluate samples in lysis 
buffer in the presence of dithiothreitol (DTT). TEV (Tobacco Etch Virus) protease was 
added (1 µg protease for 1 mg target protein at 4 °C overnight). Following digestion, 
the protein sample was analysed by SDS-PAGE to check the efficiency of TEV protease 
digestion. Protein samples were then loaded into the nickel column as before. 
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Successful cleavage of the (His)6-tag from the protein means that it should not bind to 
the column and therefore the target proteins should be eluted in the flow-through. 
The flow-through was then dialysed against 25 mM Tris-HCl containing 150 mM NaCl 
and concentrated using a Sartorius™ Vivaspin™ 20 centrifugal concentrator with a 
10,000 Da molecular weight cut-up (Thermo Fisher Scientific, Loughborough, UK) to 
prepare the samples for further purification by gel filtration column chromatography. 
2.8.8 Gel filtration column chromatography 
Gel filtration column chromatography is a method used to separate protein primarily 
based on molecular size. A sample volume of up to 5 mL was loaded onto a HiprepTM 
16/60 SephacrylTM S-200 column (GE Healthcare) according to the manufacturer’s 
protocol. Columns were run using the Akta Purifier chromatography system (GE 
Healthcare) and samples were collected into 1.5 mL fractions. Samples from the 
observed peaks were collected and analysed by SDS-PAGE. 
2.8.9 Pk-tag co-immunopreciptation (pull-down) 
Vector containing a PLCXD3 insert was virally transfected into HeLa as previously 
described. As a control, non-transfected wild-type HeLa cells were used. Transfected 
and control cells were seeded into 4 x 75 cm2 flasks each and grown until 80-85% of 
confluence as previously described. Cells were then washed twice in PBS and lysed 
with 500 µL of protein extraction IP buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM 
EDTA, 1% NP-40 and 5% glycerol) per flask for 10 min on ice. Samples from each of the 
4 flasks were transferred into a 1.5 mL microfuge tube and spun for 40 min, 14,000 
rpm at 4 °C using the Avanti J-26PI centrifuge with a JA-18.1 fixed angle rotor (Beckman 
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Coulter, Inc.). The supernatants were then pooled together (~2 mL) and transferred 
into two 1.5 mL microfuge (1 mL of supernatant in each) and a 10 µL sample was taken 
to assess the protein concentration by the Bradfords method. Prior to cell lysis, the 
primary Pk antibody was immobilised to Protein G Sepharose resin (GE Healthcare) 
using dimethylpimelimidate (DMP; Pierce). A 1 mL aliquot of protein G Sepharose was 
pelleted by centrifugation at 1,000 rpm for 3 min in a bench microfuge and 
resuspended and then washed three times with 1 mL PBS. The beads were 
resuspended with 500 µL of PBS and 20 µg of the anti-Pk primary antibody was then 
added to the Sepharose and incubated for 30 min on a rotary shaker at room 
temperature. The sample was centrifuged (as before) and the anti-Pk antibody-bound 
Protein Sepharose was then washed three times with crosslinking buffer (0.2M tris 
ethanolamine, 0.1 M sodium borate, pH 9) and incubated with 20 mM DMP in 
crosslinking buffer for 45 min with rotation at room temperature. The crosslinking 
reaction was stopped by washing 3 times in crosslinking buffer without DMP. The 
beads were then incubated with IP elution buffer (0.1 M acetic acid, 0.15 M NaCl, pH 
3.0) to wash away any Pk antibody that was not bound covalently to the beads. The 
beads were then washed three times with PBS and the bound antibody concentration 
was determined by the Bradford’s method. The beads were resuspended and stored 
in 500 µL PBS containing 0.02% azide at 4 °C until use. Extracted protein (0.5 mg) from 
both transfected and control HeLa cells was added to 100 µL of cross-linked bead slurry 
prepared above and incubated overnight at 4 °C with rotation. The beads were then 
washed three times with IP buffer and the protein was eluted using 3 x 20 µL of IP 
elution buffer (as above) and neutralised by adding an equal volume of Tris pH 8.0. 
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Protein concentration was quantified using Bradford’s method and samples were 
checked by SDS-PAGE analysis followed by Western blotting. 
2.8.10 Ni2+ -NTA expression screen protocol 
Frozen Sf-9 or E. coli cells expressing the different fusion constructs for PLCXDs were 
completely resuspended in 210 µL of Lysis Buffer (50 mM NaH2PO4, 300 mM NaCl, 10 
mM imidazole, 1% v/v Tween-20, pH 8) containing 3 units/mL of benzonase and 1 
mg/mL lysozyme. The deep-well blocks were then incubated at room temperature for 
15 min with shaking at 500 rpm. The cell lysate was transferred to a 96 deep-well block 
and a 20 µL sample was added to 20 µL SDS loading buffer (whole cell expression). The 
remaining lysate was cleared of cell debris and insoluble material following 
centrifugation at 4,000 rpm for 30 min in a bench microfuge. Before the end of the 
centrifugation, 20 µL of Ni-NTA magnetic bead suspension (Qiagen, Mancester, UK) 
was pipetted into a flat-bottomed microtitre plate (Greiner 655101) and then washed 
3 times with lysis buffer. In between each wash step the plate was placed on a 96-well 
magnet (QIAgen) for 1 min to pellet the beads and the supernatant was removed. 
Following centrifugation of the cell lysate, the supernatant was then mixed with the 
pre-equilibrated Ni-NTA agarose beads and incubated for 30 min at room temperature 
with shaking at 600 rpm. The insoluble pellets were kept in case no soluble expression 
was observed. The plate was then placed on a magnet (as before) for 5 min to pellet 
the beads. The supernatant was removed and the beads were sequentially washed 
with 200 µL of lysis buffer, 200 µL wash buffer (lysis buffer with 0.05% v/v Tween-20 
and 20 mM imidazole) and then 60 µL elution buffer (lysis buffer with 0.05% Tween 
and 250 mM imidazole). The Ni-NTA beads were pelleted between each wash by 
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transferring the plate to the magnet. A 20 µL sample of the supernatant (eluate) was 
then mixed with 20 µL of SDS sample buffer and analysed by SDS-PAGE for the 
presence of soluble recombinant proteins. 
2.8.11 Detection of protein-lipid interactions by PIP strips™ 
PIP strips are hydrophobic membranes that have been pre-adsorbed with 100 pmol of 
all eight phosphoinositides (See Chapter 1) and seven other important phospholipids, 
including lysophosphatidic acid, lysophosphocholine, phosphatidylcholine, 
sphingosine 1-phosphate, phosphatidic acid, phosphatidylethanolamine and 
phosphatidylserine (Echelon Biosciences Inc). Membranes were blocked for 1 h at 
room temperature with PBS supplemented with 3% BSA and 0.1% Tween-20 (Sigma-
Aldrich, Poole, Dorset, UK; known as blocking buffer). The membranes were then 
incubated with 0.5 µg/mL of purified PLCXD-3 (Section 2.6.3) in the blocking buffer. 
For detection of protein-lipid interactions, membranes were incubated with 
monoclonal mouse anti-PLCXD-3 primary antibody (1/1,000 in blocking buffer) for 1 h 
at room temperature. The membranes were then washed in blocking buffer for 3 x 10 
min and then incubated with donkey anti-mouse HRP-conjugated secondary antibody 
for 1 h at room temperature. Following washing, as above, bound secondary antibody 
was visualised using the SuperSignal West Dura chemiluminescent substrate, as 
previously described (Section 2.8.4). 
2.8.12 PLCXD3 activity towards purified lipids 
This assay was conducted with help from Dr Tomas Lebl (Department of Chemistry, 
University of St Andrews). Recombinant PLCXD3 overexpressed in E. coli and HeLa cells 
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and purified as described previously (Sections 2.8.5 and 2.8.8).  Soluble homologues 
of phosphatidylinositol- 4,5- bisphosphate (PI(4,5)P2; 1 mg) and phosphatidylinositol 
(PI; 1 mg) containing truncated fatty acid chains (dCi8) were purchased from Echelon 
Biosciences. These lipids were resuspended to 1 mg/mL in 50 mM Tris-HCl pH 8.0, 
containing 150 mM NaCl and 1 mM MgCl2 and stored frozen at -20 °C until use. 
Samples for 31P-NMR were prepared with 250 µg of the substrate lipid, 1 µg of purified 
PLCXD-3 (prepared from HeLa pull-down assay and E. coli expression), 11% D2O, and 
same buffer as the lipids to a final volume of 600 µL in 5 mm NMR tubes (Norwell). 
Prior to the addition of purified PLCXD-3, a 1 dimensional 31P-NMR spectra was 
obtained for each lipid using a Bruker AVANCE III 500 with 1,000 scans for 
approximately 30 min. Purified PLCXD-3 was then incubated with each lipid for 30 min 
at 28 °C and the 1D 31P-NMR spectra was analysed as above. 
2.8.13 Protein Crystallisation 
Following gel filtration chromatography, purified proteins were concentrated to 10 
mg/mL using Vivaspin™ sample concentrators (GE Healthcare). A number of 
commercially available crystal screens were used to test the conditions required for 
crystal formation, including JCSG+ (Qiagen), Index (Hampton Research), Wizard I+II 
(Emerald Biosciences) and PEGs (Qiagen). These screens were kindly provided by Dr 
Stephen McMahon. School of Biology, University of St Andrews. Crystal plates were 
set-up using a nano-drop crystallisation robot (Cartesian HoneyBee, Genomic 
Solutions) with 150 nL of protein and 150 nL of buffer per well. Plates were then 
incubated at room temperature and regularly checked for the presence of crystals. 
Initial hits were optimised in the attempt to gain better quality crystals, and this was 
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achieved by varying the concentration of salt and protein in the appropriate screen 
and also varying the amount of precipitant used. 
2.8.14 X-ray crystallography 
Suitable crystals chosen for X-ray data collection were cryoprotected in the original 
crystallisation buffer containing 15-30% (v/v) of glycerol. The work was carried out by 
Dr Stephen McMahon, School of Biology, University of St Andrews. Briefly, protein 
crystals were picked using a crystal loop and then dipped in 5 µL of the cryoprotection 
buffer. The crystal was then exposed to X-rays at 100K using an in-house Rigaku/MSC 
MicroMaz-007HF rotating anode with a Saturn 944+ CCD detector at wavelength 
1.54178 A. 
2.8.15 PLCXD4 Immunohistochemistry in eel intestine 
The anterior, mid and posterior regions of the intestine were removed from a 3-month 
SW-acclimated silver eel and fixed overnight in 4% paraformaldehyde in PBS and 
stored at 4 °C in PBS. These tissues were mounted in paraffin and 4 µm sections were 
cut and mounted onto slides courtesy of Professor David Harrison, School of Medicine, 
University of St Andrews. Tissue sections were de-waxed by immersion in xylene 
(Sigma-Aldrich, Poole, Dorset, UK) for 10 min and then re-hydrated in graded ethanol 
solutions (100%, 80% and 50%) for 5 min each and then rinsing in running water for 5 
min. De-waxed and re-hydrated slides were subjected to heat-induced antigen 
retrieval for 15 min in a pressure cooker with boiling citrate buffer (10mM Sodium 
citrate, 0.2% Tween-20, pH 6.0) using a microwave at 700 w. Once full pressure had 
been reached (10 min), the pressure was maintained for a further 5 min before 
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removing the heat and rapidly cooling whilst releasing the pressure. The slides were 
then washed 3 x 5 min in wash buffer (1 x PBS, 0.2% Tween-20) with gentle agitation. 
The slides were incubated in 0.3% H202 (Sigma-Aldrich, Poole, Dorset, UK) in PBS for 
10 min and then washed 3 x 5 min in wash buffer. The slides were then incubated in 
blocking solution (Protein Block; Dako) for 30 min at room temperature. The slides 
were drained and excess blocking solution was removed from the sections with tissue 
paper. Droplets (30 µL) of the eel PLCXD4 primary PLCXD4 antibody (Table 2.4) was 
diluted 1/500 in antibody diluent (Dako) and incubated overnight at 4 °C in a 
humidified chamber. Following 3 x 5 min rinses with wash buffer, the sections were 
incubated for 1.5 h in droplets containing a 1/1,000 dilution of secondary, Alexa Fluor 
633-conjugated donkey anti-mouse antibody (Invitrogen, Life Technologies, Paisley, 
UK) in antibody diluent (Dako). Following extensive rinsing with washing buffer, 
sections were mounted with Prolong gold anti-bleaching medium containing DAPI 
(Sigma-Aldrich, Poole, Dorset, UK). Sections were viewed with a fluorescence 
microscope (Zeiss Axioplan, Welwyn Garden City, Hertfordshire, UK) and images 
collected and analysed using Ziess Axiovision Aoftware. Control sections were 
incubated with blocking solution without the primary antibody. 
Immunohistochemistry was also performed to investigate the distribution of PLCXD3 
in the retinas of wild type and Harlequin mutant mice (n=6 for each condition). This 
work was carried out in collaboration with Dr Marisol Corrall-Debrinski at the Institute 
de la Vision. Fixed retinal sections were prepared from both wild type and Harlequin 
mice (n=6 for each genotype) as described in Bouaita et al., 2011. These sections were 
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prepared for Immunohistochemistry using anti-PLCXD3 antibody sent from St 
Andrews by Marisol Corrall-Debrinski as described in Bouaita et al., 2011. 
2.9 Bioinformatics 
Available PLCXD amino acid sequences were obtained from NCBI and Esembl and 
amino acid identity and similarity were calculated using MatGat2.01 software. For the 
construction of the phylogenetic tree, amino acid sequences were aligned using 
ClustalW and automatically edited in the software. The Mega 5 software was used for 
tree construction and visualisation using the p-distance of the neighbour-joining (N-J) 
method (Tamura et al., 2011).  
2.10 Statistical analysis 
Values are presented as means +/- SEM. For RT-qPCR and Western blot analyses, 
statistical significance was determined using a nonpaired Student’s T-test and 
significanct differences were considered within P < 0.05. 
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CHAPTER 3:  Cloning, sequencing and characterisation of a 
PLC-like gene from the European eel (Anguilla anguilla) 
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3.1. Introduction 
The European eel (Anguilla anguilla; Anguillidae) is a euryhaline teleost fish and 
therefore is able to inhabit both freshwater (FW) and seawater (SW) environments. 
The life cycle of the European eel is complex and begins in the western part of the 
North Atlantic known as the Sargasso Sea. Following spawning, the eggs use oceanic 
currents to drift towards freshwater systems of Europe and North Africa, including 
rivers, ponds and brackish water (Van Ginneken and Maes, 2005). During this 
migration, the eggs hatch releasing larvae, which eventually develop into the 
transparent, leaf-shaped lepthocephali larvae. Once these larvae reach the continental 
shelf of Europe they undergo their first metamorphosis to form "yellow eels", so called 
due to their yellow, dark green pigmentation (Munk et al., 2010). In freshwater 
systems of Europe the "yellow eels" begin to feed on invertebrates, crustaceans and 
other fish. Towards the end of this phase of development (2-15 years for male; 4-20 
years for females), the eels undergo a second metamorphosis (also referred to as 
"silvering") to form the sexually mature “silver eels”, which begin the c. 6000 km 
migration back to the Sargasso Sea (Van Gubbeken and Maes, 2005). Physiologically, 
the differences between the "yellow" and "silver" stages are important for survival 
with physiological and anatomical adaptations linked to the transition between fresh 
and salt water, and preparation of the c. 6000 km migration back to the Sargasso sea 
to breed (Van Ginneken et al., 2007).  These adaptations include changes in expression 
of specific genes involved in the regulation of energy resources and initiation of the 
reproductive development (Durif et al., 2005). Numerous other changes occur during 
the silvering developmental transitions which are suggestive of “anticipation 
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adaptation” to life in the deep sea, including an increase in the ocular index, new 
retinal pigments, modification/recruitment of gill chloride cells, colour modification 
with the body turning silvery white and increased thickness of their skin (Van Ginneken 
et al., 2007).  
Previous microarray studies in this laboratory identified various genes exhibiting 
differential expression following the “yellow” to “silver” developmental transition of 
the A. anguilla. One gene identified as showing a decrease in expression during this 
developmental transition was denoted PLC-like in that the partial sequence obtained 
contained only an X-domain and was devoid of all other domains commonly found in 
eukaryotes PI-PLC isozymes.  Thus, investigations described in this chapter aimed to 
determine the full-length sequence of the PLC-like gene identified in the microarray 
and perform sequence comparisons with other known PI-PLCs to predict its cellular 
functions. Furthermore, quantitative analysis of the mRNA levels of the PLC-like gene 
were performed using tissues extracted from both “yellow” and “silver” eels to clarify 
the microarray data and strengthen a potential role of this gene in the development 
of the European eel.  
3.2. RT-PCR amplification and sequencing of the eel PLC-like gene from the European 
eel 
Prior to the onset of this project, a partial sequence for the PLC-like cDNA was cloned 
and sequenced by Dr Svetlana Kalujnaia (unpublished data; See Appendix A for 
sequence). As a starting point, cloning experiments were then performed in this 
project to obtain the full-length coding sequence of the eel PLC-like gene using the 
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Marathon 5’ RACE RT-PCR technique (Chapter 2, Section 2.7.6). Using the proof-
reading Pfx DNA polymerase, RT-PCR was performed using Marathon cDNA 
synthesised from the intestine of the yellow eel (Chapter 2, Section 2.7.4) using gene-
specific antisense primers designed near the existing 5’ end of the PLC-like cDNA 
fragment. Successive nested PCR reactions were then performed in combination with 
the kit AP1 and AP2 primers. Primers sequences are detailed in Appendix A.  For RACE 
1 reactions, amplifications were carried out with the AP1 Clontech kit primer and three 
gene-specific antisense RACE1 primers (AS1, 2 and 3, Figure 3.1). A fragment of 
approximately 480 base pairs was successfully amplified only with the gene-specific 
AS3 primer. This PCR product was used as a template and re-amplified with the AP2 
primer and the gene-specific antisense 1 and 2 RACE 2 primers (Lane 2 and 1 
respectively, Figure 3.1). Following the nested RACE reactions, a fragment of around 
280 base pairs (bp) was produced corresponding to the combined expected size 
difference between the RACE 1/RACE 2 and AP1/AP2 fragments (Figure 3.1; Lane 2). 
The 280 bp PCR product obtained by RACE 2 PCR reactions was subsequently sub-
cloned to pCR4-TOPO and the recombinant vector was transformed into TOP 10 cells 
for propagation of the 280 bp fragment (Chapter 2, Section 2.7.9).  Colony PCR was 
performed using M13 forward and reverse primers (Appendix E) to check for the 
presence of the gene insert and four positive colonies with the most intense bands of 
the expected size were selected and sequenced using T3 and T7 (Appendix E). The 5’ 
RACE eel PLC-like sequences were then aligned with the original partial fragment using 
GENE JOCKEY II software (Biosoft) and one continuous sequence was created. The 
derived amino acid sequence was then determined and an interleaved 
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nucleotide/amino acid sequence produced (Figure 3.2). The open-reading frame of the 
eel PLC-like cDNA consists of 959 nucleotides, which encodes a protein containing 319 
amino acids. The nucleotide sequence reported herein appears in the GenBank 
nucleotide database under accession number JX101676. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Results of the RACE 1 and RACE 2 RT-PCR reactions for the amplification 
of the 5’ end of the eel PLC-like gene. For RACE 1 reactions, amplifications were 
carried out with the AP1 Clontech kit primer and either the gene-specific antisense 1, 
2 or 3 primers (AS1, AS2 and AS3; Lane 1, 2 and 3 respectively). For the RACE 2 
reactions, the AP2 primer was used in combination with either antisense 1 or 2 gene-
specific primers (AS1/2).  
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     Met Glu Phe His Leu Cys Val Leu Leu Tyr Phe Val Ile Leu Phe Ala Gly Ser Glu Gly Asp Pro Tyr Phe Asn Asp Leu Glu Lys Leu Asp Leu Pro Asn Gly His Glu 37    
   1  ATG GAA TTC CAC CTG TGT GTT CTG CTG TAC TTT GTA ATA CTT TTC GCT GGC AGT GAA GGG GAT CCC TAT TTC AAT GAT TTA GAA AAG CTT GAT CTC CCA AAT GGT CAT GAA 
      Val Asn Trp Met Lys Ser Ile Asp Asp Glu Thr Leu Leu Ser Ala Val Thr Ile Pro Gly Thr Cys Gln Ser Met Lys Met Asn Thr Leu Asp Gln His Gln Ala Trp Thr 74       
  38  GTA AAC TGG ATG AAA AGT ATA GAT GAT GAA ACA CTT CTC TCA GCA GTC ACC ATT CCA GGC ACA TGC CAA AGC ATG AAA ATG AAT ACT CTT GAT CAA CAC CAA GCA TGG ACA 
      Val Thr Gln Gln Phe Thr Ala Gly Val Arg Phe Phe Asp Ile Ser Leu Asp Asn Ser Val Val Lys Asp Gly Ser Leu Thr Arg Arg Lys Phe Ala Asp Val Met Glu Lys 111         
  75  GTA ACA CAG CAG TTT ACA GCA GGG GTG CGA TTC TTT GAT ATC TCC CTG GAT AAT TCA GTT GTC AAA GAT GGT TCT CTT ACA CGT AGA AAA TTT GCA GAT GTC ATG GAA AAG 
      Met Arg Glu Arg Leu Ile Ala His Pro His Glu Val Ile Leu Ile Arg Leu Thr Pro Glu Asn Gly Lys Ala Glu Lys Glu Ile Glu Lys Phe Ile Gln Val Asn Asp Asn 148     
 112  ATG AGA GAA CGT TTG ATT GCT CAC CCT CAT GAA GTA ATT TTG ATA AGA TTG ACC CCA GAA AAT GGC AAA GCT GAA AAG GAA ATA GAA AAA TTC ATA CAA GTG AAT GAC AAT  
      Val Trp Lys Asp Lys Lys Val Pro Lys Met Lys Glu Val Arg Gly Lys Ile Val Leu Val Gln Ser Ser Lys Phe Ser Lys Gly Leu Pro Val Asp Leu His Val Gly Gly 185      
 149  GTG TGG AAG GAT AAA AAA GTG CCC AAA ATG AAA GAA GTA AGG GGT AAG ATA GTG TTG GTG CAG AGC AGC AAG TTC AGT AAA GGG CTC CCG GTG GAC CTT CAT GTG GGT GGG   
      Lys Glu Phe Lys Asp Lys His Ser Lys Lys Tyr Met Glu Ala Ile Tyr Asn His Phe Lys Asp Lys His Ser Lys Lys Tyr Met Glu Ala Ile Tyr Asn His Leu Lys Ala 222      
 186  AAG GAG TTT AAA GAT AAG CAC TCA AAA AAG TAC ATG GAA GCG ATT TAT AAT CAT TTT AAA GAT AAG CAC TCA AAA AAG TAC ATG GAA GCG ATT TAT AAT CAT CTA AAG GCA  
      Ala Glu Asn Ala Gly Asp His Ile Val Val Thr Glu Thr Ser Ala Tyr Phe Gly Phe Thr Lys Ser Ser Lys Asn Ala Ala Val Lys Ile Asn Pro Met Leu Gln Lys Tyr 259      
 223  GCA GAA AAT GCA GGT GAC CAT ATT GTA GTG ACT GAA ACA AGC GCA TAT TTT GGA TTC ACA AAA TCA TCA AAA AAT GCA GCT GTA AAA ATT AAT CCC ATG CTC CAA AAA TAC  
      Ile Asp Asn Gln Pro His Ala Asn Lys Pro Lys Gly Leu Gly Val Ile Val Met Asp Tyr Pro Gly Ile Asp Leu Ile Gln Lys Ile Ile Asp Ile Asp Ile Asn Pro Lys 296         
 260  ATA GAC AAC CAG CCG CAT GCT AAT AAA CCA AAA GGT TTG GGG GTG ATT GTC ATG GAC TAT CCA GGC ATT GAT CTC ATC CAG AAA ATC ATA GAT ATA GAT ATC AAC CCT AAA  
      Ser Glu Gly Ser Pro Glu Ser Ser Pro Glu Glu Gly Glu Asn Pro Pro Glu Thr Asp Gly Glu Pro Glu Stop 320     
 297  TCA GAA GGC TCA CCT GAA TCC TCC CCA GAA GAA GGT GAG AAC CCA CCT GAA ACT GAT GGG GAA CCC GAA TGA  
Figure 3.2: The interleaved nucleotide and derived amino acid sequences of the coding region of the PLC-like gene from Anguilla anguilla. Blue lettering 
denotes the predicted nucleotide and amino acid sequences of the X-domain. Numbers present on the left and right margins refer to the nucleotide and 
amino acid sequences, respectively. Underlined is a signal sequence predicted by the SignalP 4.0 server (Peterson et al., 2011).  
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3.3. Sequence analysis and comparison of PLCXD isoforms in the European eel with 
other species. 
The deduced 319-amino acid protein has a predicted molecular mass of 33.9 kDa and 
an isoelectric point of 5.84. An N-terminal signal peptide of 20 amino acids was 
predicted by the SignalP 4.1 Server (ExPASy; Petersen et al., 2011). The presence of a 
signal peptide suggests that the eel PLC-like gene may be targeted to the secretory 
pathway or a specific organelle within the cell; however this remains to be determined 
experimentally. The deduced amino acid sequence of the PLC-like gene was predicted 
to contain only a PI-PLC X-domain following sequence comparisons with the Prosite 
protein domain database (motif entry code PS50007, Gly35- Lysine278 region). The 
presence of an only an X-domain suggests that the PLC-like gene identified is more 
similar in primary structure to bacterial PI-PLCs (Chapter 1, Section 1.6). 
The deduced amino acid sequence of the PLC-like gene was searched against the 
complete non-redundant protein (nr) database on NCBI 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). BLAST analysis showed the greatest 
homology (33%) with a 33.4 kDa uncharacterised predicted protein from the bicolor 
damselfish (Stegastes partitus; probability with BLAST, 3 x 10-38). Other proteins which 
scored high in the BLAST search included 15 uncharacterised predicted proteins from 
zebrafish (Danio rerio; probabilities with BLAST between 7x10-36 and 2x10-20) and 
bacterial phosphatidylinositol-specific phospholipases from Listeria monocytogenes 
(GenBank accession no. AFA26313.1, 1 x 10-19 Bacillus thuringiensis (GenBank 
accession no. X14178.1, 2 x 10-10) and Bacillus cereus (GenBank accession no. X64141.1, 
2 x 10-10). All proteins identified from this BLAST search were of a similar molecular 
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size to the eel PLC-like protein (30-35 kDa) and only contained an X-domain. A second 
BLAST search was performed against the complete non-redundant protein sequence 
database in mammals. This search identified a number of homologous proteins which 
had previously been characterised as members of a distinct PI-PLC subtype which 
contain only the X-domain of the other multi-domained members of this enzyme 
family and hence known as mammalian phospholipase C X-domain containing proteins 
(PLCXDs). To date, BLAST analysis reveals the presence of three PLCXD isoforms 
(PLCXD1, 2 and 3) in the genomes of most mammals, including human and mouse. The 
deduced amino acid sequence of the eel PLC-like gene showed less than 20% sequence 
identity with mammalian PLCXD isoforms (Figure 3.3). With the aim of identifying 
further PLCXD sequences in A. anguilla, BLAST analysis against the recently sequenced 
eel genome was performed using the PLCXD1, 2 and 3 nucleotide sequences identified 
in humans. Eel PLCXD1, 2 and 3 homologues were identified and their full-length 
sequence reconstructed by Dr Svetlana Kalujnaia, University of St Andrews. The 
deduced amino acid sequence of the eel PLC-like gene identified herein displays 17.6%, 
17.3% and 19% amino acid sequence identity with the predicted eel PLCXD1, 2 and 3 
respectively. The sequences of eel PLCXD1, 2 and 3 are yet to be experimentally 
verified. Given the low sequence homology with other PLCXDs, the eel PLC-like gene 
and others identified in the first BLAST search were denoted PLCXD4. In-order to verify 
the presence of additional PLCXD isoforms in vertebrates, a phylogenetic tree was 
constructed with a number of the PLCXD amino acid sequences identified through 
BLAST searching. Phylogenetic analysis indicates that the vertebrate PLCXD proteins 
group into four distinctive clusters (Figure 3.3). The PLCXD-like sequences identified in 
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the first BLAST search were subsequently denoted PLCXD4 as they did not group with 
any of the PLCXD1, 2 or 3 sequences. 
Although functional characterisation of vertebrate PLCXDs has yet to be performed, 
PLCXD sequences found in prokaryotes such as Bacillus cereus and Bacillus 
thuringenesis have been shown to be active lipases involved in the hydrolysis of 
phosphatidylinositol (PI) and glycosylated phosphatidylinositol (GPI) substrates (Heinz 
et al., 1998). The catalytic mechanism of B. cereus and B. thuringiensis has been well 
characteristed and the invariant histidine 32 (His32), histidine 82 (His82) and arginine 
69 (Arg69) amino acids, present within the X-domain, have been shown to be essential 
for catalysis (Chapter 1, Section 1.4.3.1) Sequences corresponding to the X-domains of 
PLCXDs from different vertebrates were aligned with the X-domain sequences of B. 
cereus and B. thuringenesis to screen whether these key catalytic residues are 
conserved in the vertebrate PLCXD isoforms (Figure 3.4). Indeed, His32, His82 and 
Arg69 were found to be conserved in the X-domain sequences of vertebrate PLCXD 
enzymes including eel PLCXD1, 2 and 3 isoforms, suggestive of the retention of similar 
catalytic properties to the bacterial PI-PLCs. In contrast, these residues were not found 
to be conserved in the X-domain sequence of eel PLCXD4. 
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Figure 3.3: Phylogenetic analysis of PLCXDs. This tree was constructed using the 
neighbour-joining method, with each bar representing the p distance of the N-J 
method. NCBI/EMBL accession numbers are detailed in Appendix B. 
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 PI-PLC_Bacillus_cereus         SIPLARISIPGTHDSGTFKLQ---------------------------NPIKQVWGMTQEYDFRYQMDHGARIFDIRGRLTDD---NTIVLHHGPLYLYVTLHEFI 
 PI-PLC_Bacillus_thuringiensis  NIPLARISIPGTHDSGTFKLQ---------------------------NPIKQVWGMTQEYDFRYQMDHGARIFDIRGRLTDD---NTIVLHHGPLYLYVTLHEFI 
 PI-PLC_Listeria_monocytogenes  TTNLAALSIPGTHDTMSYNGDIT-------------------------WTLTKPLAQTQTMSLYQQLEAGIRYIDIRA---KD---N-LNIYHGPIFLNASLSGVL 
 PLCXD4_Anguilla_anguilla       ETLLSAVTIPGTCQSMKMN----------------------------------TLDQHQAWTVTQQFTAGVRFFDISLDN---------SVVKDGSLTRRKFADVM 
 PLCXD4_Takifugu_rubripes       ERPLSHVTMPGTHNTMALYGG--------------------------------VYAECQTWSLASQLRAGVRFLDIRVRHVKG---N-LTIHHGVSYQRAHFGQVL 
 PLCXD4_Oreochromis_niloticus   DRLLSEITMPGTHNTMALYGG--------------------------------VYAECQTWSLASQLRAGVRFLDIRVRHVNG---N-LTIHHGVSYQRAHFGDVL 
 PLCXD4_Stegastes_partitus      FRTLSLITIPGTHDSMALYGG--------------------------------PEAECQVLSLMDQLRAGIRFLDLRVFALGD---T-LYVMHGVMYQHSTFKDVL 
 PLCXD4_Danio_rerio             NMFISNITIPGTHDTMALHGG--------------------------------AAAECQSWSLENQLLAGIRYLDLRV--SGN---N-LKVVHGVISQHTTFADVL 
 PI-PLC_Trypanosoma_cruzi       EMAITQVCFVGSHDAASYGVSKDSPFGADAPGFLLGDSVFASLLRFLFRGICASWSRCQWMSVRAQLNHGVRYLDMRVATNPEDASRL-YTLHH-QIS-VPLADVL 
 PLCXD3_Homo_sapiens            SIPLTNLAIPGSHDSFSFYIDEASPVGPEQPETVQ---NFVSVFGTVAKKLMRKWLATQTMNFTGQLGAGIRYFDLRISTKPRDPDNELYFAHG-LFS-AKVNEGL 
 PLCXD3_Mus_musculus            SIPLTNLAIPGSHDSFSFYIDEASPVGPEQPETVQ---NFVSVFGTVAKKLMRKWLATQTMSFTGQLGAGIRYFDLRISTKPRDPDNELYFAHG-LFS-AKVNEGL 
 PLCXD3_Bos_taurus              SIPLTNLAIPGSHDSFSFYIDEASPVGPEQPETVQ---NFVSVFGTVAKKLMRKWLATQTMNFTGQLGAGIRYFDLRISTKPRDPDNELYFAHG-LFS-AKVNEGL 
 PLCXD2_Danio_rerio             GIPLTNLAIPGSHDSFSFYIDEASPVGPEQPETVQ---NFVSVFGTVAKKLMRKWLATQTMNFTSQLEAGIRFFDLRISTKPRDPDNELYFAHG-LFS-ATVREGL 
 PLCXD3_Anguilla_anguilla       NTPLTNLAIPGSHDSFSFYIDEASPVGPEQPETVQ---SFVSVFGAVAKKLMRKWLATQSMDFARQLEAGVRFFDLRISTKPRDPDGRLYFAHG-LYS-ATVREGL 
 PLCXD2_Anguilla_anguilla       PLPLKYLAVPGSHDSFSFWVDEKAPVGPDQKALVK---HLATAFHLVAKKVMKKWSMTQNLTFREQLEGGIRYFDLRVSSKPGEPGHEVYFIHG-LFG-HKVRDGL 
 PLCXD2_Xenopus_laevis          ALPLTNLAIPGSHNSFSYRVDEKSPVGPDQAAFIK---LLAKI--PLVKRSLKKWAVTQNLTFKEQLESGIRYFDLRVSSKPEEAGKEIYFIHC-LYG-IKVWVGL 
 PLCXD2_Homo_sapiens            NLPLSNLAIPGSHDSFSYWVDEKSPVGPDQTQAIK---RLARI--SLVKKLMKKWSVTQNLTFREQLEAGIRYFDLRVSSKPGDADQEIYFIHG-LFG-IKVWDGL 
 PLCXD2_Mus_musculus            NVPLSNLAIPGSHDSFSYWVDEKSPVGPDQTQAVI---RLARI--SLVKKLMKKWSVTQNLTFREQLEAGIRYFDLRVSSKPGDTDQEIYFIHG-LFG-IKVWDGL 
 PLCXD2_Bos-taurus              NVPLSNLAIPGSHDSFSYWVDEKSPVGPDQTPAIK---RLARI--SFVKKVMKKWSVTQNLTFREQLDAGIRYFDLRVSSKPGDADQEIYFIHG-LFG-IKVWDGL 
 PLCXD1_Anguilla_anguilla       DIPLYNLAIPGSHDAMSYCLDITSPLVRSESDSFR---LVDKFFYCLTRPIIYRWATTQERDVEEQLKEGIRYFDLRIASKQQDPFDKLYFTHV-IYTSSTVLETL 
 PLCXD1_Danio_rerio             DIPLWNLAIPGSHDSMTYCLDKQSSVSNSTPRVVQ---VLDKYFPCIVRPCIMKWATTQEGAISNQLDLGIRFLDLRIAHKIKDPDEVFYFAHG-VYSLLTVKEAL 
 PLCXD1_Xenopus_tropicalis      DIPLYNISIPGSHDSMSYCLDKMSPLEPELPILLS---VLDKLVPCLARATILRWAKTQVLNVTQQLNAGVRYLDLRIAHRPDDPSPALYFAHG-LFTHITVKEAF 
 PLCXD1_Gallus_gallus           DTPLFNLSLPGSHDTMTYCLDKNSAVSGNESKLVK---FLNKCMPCIVRPIIMKWSITQVLTVTEQLEAGVRYLDFRIAHKSSDPSTNLYFVHM-VYTTVIVQDIL 
 PLCXD1_Mus_musculus            DVPLHHLSIPGSHDTMTYCLNRKSRISRASSWLLH---LLGRVVPFITGPVVMKWSVTQTLDVTQQLDAGVRYLDLRIAHAPEGSTRNLCFVHM-MYTKALVEDTL 
 PLCXD1_Homo_sapiens            DVPLHHLSIPGSHDTMTYCLNKKSPISHEESRLLQ---LLNKALPCITRPVVLKWSVTQALDVTEQLDAGVRYLDLRIAHMLEGSEKNLHFVHM-VYTTALVEDTL 
 PLCXD1_Bos_taurus              DVPLHQLSIPGSHDTMTYCLNKKSPISSKEPRLLH---LLCKVLPCVTLPMVLKWSTTQVLSVTEQLDAGVRYLDLRIAHVEDGSERNLHFVHM-VYTTALVEDTL 
                                         :  : . *: ::                                                  *.  * *  *.                             .  
 
 
                                          
 
 
Figure 3.4: Alignments of the derived X-domain amino acid sequences from a various vertebrate and non-vertebrate species. Symbols in the alignment 
are as follows: (*) indicates where there is a conserved amino acid; (:) indicates an amino acid position with conserved similarity; (.) indicates a semi-conserved 
amino substitution has occurred; (-) indicates spaces introduced to optimise the alignment. Conserved residues known to be important for the catalytic function 
of bacterial PI-PLC’s are highlighted in yellow. The NCBI Accession numbers where available in Appendix B.
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3.4. Tissue expression of eel PLCXD isoforms 
Quantitative RT-PCR (Chapter 2, Section 2.7.11) was used to determine the 
distribution and relative levels of expression of all four PLCXD mRNAs in tissues 
extracted from one FW-maintained and one SW-acclimated silver eel. RNA isolation 
and cDNA conversion were performed using standard protocols (Chapter 2, Sections 
2.7.1 and 2.7.4) and cDNAs from the same tissue were pooled together from the FW 
and SW silver eel. The sequences of the primers used for amplifications are detailed 
in Appendix A. Normalised expression values were obtained for PLCXD1, 2, 3 and 4 in 
each tissue and were subsequently presented as a bar graph (Figure 3.5 A, B, C and 
D). PCR analyses clearly indicated that PLCXD1, 2, 3 and 4 mRNAs show distinct tissue 
expression patterns. The eel PLCXD1 homologue has a wide tissue distribution with 
the highest mRNA expression in the gill and oesophagus. Similarly, expression of eel 
PLCXD4 mRNA was found in most of the tissues tested, with the highest expression 
being found in the intestine. In contrast, the eel PLCXD2 homologue showed a 
narrower tissue distribution, with mRNA expression only detectable in the eye. 
Melting curve analysis and gel electrophoresis were performed after each 
amplification to test the specificity of the gene-specific primers. A single peak and a 
single band of the expected size were obtained following amplification of PLCXD1, 2, 
3 and 4 indicating that the results represent the amplification of the gene of interest 
(data not shown). No amplification was observed in the no-template and reverse 
transcriptase negative controls indicating no nucleic acid contamination in the PCR 
reactions (data not shown). It is important to note that due to problems obtaining 
sufficient eels for tissue extraction the mRNA expression values for each tissue were 
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obtained using a cDNA sample pooled from n=1 FW-maintained eel and n=1 SW-
acclimated eel. Further tissue extractions from a larger sample of European eel is 
therefore required to verify the observed mRNA expression patterns. 
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Figure 3.5: Relative expression of ePLCXD-1, 2, 3 and 4 mRNAs in selected eel tissues 
(A-D respectively). Expression of PLCXD mRNAs was determined from Ct values 
obtained and normalised to Rpl-P0 expression in each tissue as detailed in the 
Chapter 2, Section 2.6.11. For each tissue, cDNA was pooled from n=1 FW-maintained 
and n=1 SW-acclimated silver eels. For both the gene of interest and Rpl-P0, each PCR 
reaction was run in triplicate with the average Ct value being used to calculate the 
relative expression value. 
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3.5. Quantitative mRNA expression and protein expression of eel PLCXDs in FW- and 
SW-acclimated yellow and silver eel intestine 
The previous microarray study found the eel PLCXD4 to exhibit higher expression in 
the intestine of the yellow eel compared with that of the silver eel (unpublished). In-
order to further confirm this, quantitative RT-PCR was performed to test the levels of 
PLCXD4 mRNA in the intestine of FW-maintained and 3 month SW-acclimated yellow 
and silver eels. The primers used were the same as those for the determination of 
tissue distribution, and their sequences are detailed in Appendix A. RNA was isolated 
from six FW-maintained and six SW-acclimated for both yellow and silver eels and was 
subsequently converted to cDNA. Normalised levels of PLCXD4 mRNA were calculated 
for each fish and an average value for the six FW-maintained and six SW-acclimated 
yellow and silver eels obtained. PLCXD4 mRNA levels were found to be 30-fold higher 
in the intestine of yellow eels compared with that of silver eels and were unaffected 
by salinity transfer suggesting that PLCXD4 mRNA expression is dependent on the 
developmental stage of the eel (Figure 3.6).  
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Figure 3.6: Relative expression of eel PLCXD4 mRNA in the intestine of FW-maintained 
and 3-month SW-acclimated yellow and silver eels. A total of 12 silver eel and 12 
yellow eels (6 FW and 6 SW) were used. Ct values were averaged from 6 fish in each 
condition and expressed relative to Rpl-P0 (x 10-3). Samples were run in triplicate and 
the error bars represent SEM across fish. ** P< 0.01. 
 
In order to test whether PLCXD4 protein levels also change during developmental 
transitions, western blot analysis (Chapter 2, Section 2.8.5) was performed using 
supernatant protein samples extracted from the intestine (Chapter 2, Section 2.8.1) of 
FW-maintained and 3 month SW-acclimated yellow and silver eels.  Custom-made 
antibodies raised against the N-terminal 15 amino acid peptide antigen from ePLCXD4 
were generated, as described in Chapter 2, Section 2.8.2. In proteins samples 
extracted from yellow eels an immunoreactive protein band of the expected molecular 
weight (36 kDa) was detected in both FW-maintained and SW-acclimated fish. 
Western bot analysis also revealed the presence of a prominent lower molecular 
weight band of 34 kDa. The presence of these bands was highly variable among 
individual yellow eels with most fish containing both bands and some fish containing 
either the 34 or 36 kDa bands (Figure 3.7).  
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The intensity of the combined 36 and 34 kDa immunoreactive ePLCXD4 bands and α-
tubulin was determined in each sample by densitometry (Chapter 2, Section 2.8.5) and 
revealed no significance difference in ePLCXD4 levels between FW-maintained and 
SW-acclimated yellow eels (Figure 3.7B). Similarly, two immunoreactive protein bands 
(34 and 36 kDa) corresponding to ePLCXD4 were detected in the protein samples 
extracted from silver eel intestine. The intensity of the immunoreactive bands 
corresponding to ePLCXD4 appeared to be greater in SW-acclimated fish compared to 
FW-maintained fish and this was confirmed by densitometric analysis of the proteins 
blot (Figure 3.7). Immunoprecipitation of crude intestinal extracts, prepared from SW-
acclimated Silver eels, followed by mass spectrometry confirmed the specificity of the 
PLCXD4 antibody for the 36 kDa protein band. Matched peptides of eel PLCXD4 
identified by mass spectrometry are shown in Figure 3.7C.  
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MEFHLCVLLYFVILFAGSEGDPYFNDLEKLDLPNGHEVN
WMKSIDDETLLSAVTIPGTCQSMKMNTLDQHQAWTV
TQQFTAGVRFFDISLDNSVVKDGSLTRRKFADVMEKMR
ERLIAHPHEVILIRLTPENGKAEKEIEKFIQVNDNVWKDK
KVPKMKEVRGKIVLVQSSKFSKGLPVDLHVGGKEFKDKH
SKKYMEAIYNHLKAAENAGDHIVVTETSAYFGFTKSSKN
AAVKINPMLQKYIDNQPHANKPKGLGVIVMDYPGIDLI
QKIIDIN PKSEGSPESSPEEGENPPETDGEPE 
 
Figure 3.7: (A) Western blot analysis of the expression of ePLCXD4 
and α-tubulin in the intestines of FW-maintained and SW-acclimated 
yellow and silver eels (n=6 eels for each condition). 10 µg of protein 
was loaded to each well. (B) Densitometric analysis of western blot 
data. Results are expressed as the ration between ePLCXD4 and α-
tubulin (n=6 fish; mean +/- S.E.M.) The data was further analysed by 
Students T-test. * P<0.05. Samples FW1-6 and SW1-6 for both yellow 
and sliver eels are the same as in Figure 3.6. (C) Matched peptides of 
eel PLCXD4 indentified by mass spectrometry. 
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3.6. Cellular localisation of PLCXD4 protein by immunofluorescence light microscopy 
Immunohistochemistry (Chapter 2, Section 2.8.15) was used to determine the cellular 
location of PLCXD4 peptide in the anterior, middle and posterior intestine of a 3-month 
SW-acclimated silver eel and a FW-maintained yellow eel. PFA fixation and paraffin 
embedding procedures yielded good antigenicity and good structural preservation 
(Figures 3.8 and 3.9). In both the 3-month SW-acclimated silver eel and the FW-
maintained yellow eel, PLCXD4 immunoreactivity was restricted to irregular shaped 
cells that appeared randomly at the base and in between the more columnar epithelial 
cells where fluorescence was present throughout the entire cell. The precise nature of 
these cells awaits further investigation. Immunofluorescence studies showed high 
levels of consistency across the anterior, middle and posterior sections of both the 
FW-maintained yellow eel and the 3-month SW-acclimated silver eel. As expected, 
control sections incubated with only a secondary antibody showed no fluorescence. 
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Figure 3.8: Immunolocalisation of eel PLCXD4 in transverse intestinal sections from a 
FW-maintained yellow eel. PLCXD4 localises to irregular intra-epithelial cells. Eel 
intestine sections were taken from the middle gut and probed with the affinity-
purified mouse anti-ePLCXD4 primary antibody and the Alexa Fuor 633-labelled 
donkey anti-mouse polyclonal antibody. Scale bar indicates 100 µm. (A) Phase contrast 
image, (B) Fluorescence image, (C) merge. Goblet cells, GC; Lumen, L; Epithelium, E. 
Images are representative of at least 10 microscope fields of view for 3 sections taken 
from one fish. 
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Figure 3.9: Immunolocalisation of PLCXD4 in the middle intestine from a 3-month SW-
acclimated silver eel. As with the yellow eel, PLCXD- localises to irregular shaped intra-
epithelial cells in close proximity to goblet cells. Sections were probed with affinity-
purified N-terminal anti-ePLCXD4 antibody. Scale bar indicates 100 µm. (A) Phase 
contrast image, (B) Fluorescence image, (C) merge. Goblet cells, GC; Lumen, L; 
Epithelium, E. Images are representative of at least 10 microscope fields of view for 3 
sections taken from one fish. 
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3.6. Discussion 
Inositol phospholipids are integral components of increasingly complex signalling 
pathways found in all animal cells. A variety of extracellular signalling molecules 
including many hormones, neurotransmitters and growth factors responsible for the 
regulation of a wide range of metabolic processes within a spectrum of cell types, 
mediate their actions through co-ordinated changes in inositol lipid metabolism. A 
family of enzymes central to these signalling pathways are known as phospholipase Cs 
(PLCs). These enzymes are responsible for the hydrolysis of phosphatidyl inositol 4, 5 
bisphosphate (PIP2) producing DAG and IP3, both of which serve as second messengers 
within the cell. DAG is a potent activator of protein kinase C signalling pathway, and 
IP3 mediates the release of calcium from intracellular stores (See Chapter 1). To date, 
all current information regarding the characterisation of members of this enzyme 
family have focussed on six sub-classes of PLCs, with each sub-class having a different 
number of isoforms. As a result of the importance of these enzymes in cell signalling 
their molecular structures, tissues distributions, mechanisms of activation and 
disparate physiological functions have been extensively investigated (See Chapter 1). 
Previous microarray studies in this laboratory identified various genes exhibiting 
differential expression following the “yellow” to “silver” developmental transition of 
the A. anguilla. One gene identified as showing a decrease in expression during this 
developmental transition was denoted PLC-like in that the partial sequence obtained 
contained only an X-domain. In this study, the full-length sequence of the coding 
region of the PLC-like gene was obtained by 5’ RACE RT-PCR reactions using Marathon 
cDNA cloning. In silico analyses indicated the PLC-like gene as being a member of a 
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novel PI-PLC subtype which contain only the characteristic X-domain of the other 
multi-domained members of this enzyme family and hence are known as 
phospholipase C X-domain containing proteins (PLCXDs). Although the molecular and 
physiological functions of vertebrate PLCXD isoforms remain to be characterised, 
PLCXD homologues present within B. cereus and B. thuringiensis are considered to be 
virulence factors and are capable of hydrolysing the phosphodiester bonds found in 
both phosphatidylinositol (PI) and also glycosylphosphatidylinositol (GPI)-anchored 
proteins within mammalian cells (See Chapter 1; Heinz et al., 1998). The chapter 
details results of the initial characterisation of the amino acid sequence and 
homologies, tissue and cellular distribution and protein expression patterns. 
3.6.1 Sequences of eel PLCXD proteins 
The present study describes the isolation, full-length sequencing and characterisation 
of a PLC-like gene from the intestine of the European eel. Analysis of the deduced 
amino acid sequence of the PLC-like gene suggests that it’s a member of the 
phosphatidylinositol-specific phospholipase C (PI-PLC) superfamily of 
phosphodiesterases. Unlike other eukaryotic PI-PLCs (See Chapter 1), the PLC-like gene 
characterised herein is predicted to only contain an X-domain and is subsequently 
much smaller than other eukaryotic PI-PLCs with a predicted molecular weight of 33.9 
kDa. Screening of amino acid sequences from public databases (most notably the NCBI 
database) has identified homologues of the PLC-like gene in the genomes of a number 
of species from bacteria to humans. These proteins are members of a distinct PI-PLC 
subtype known as phospholipase C X-domain containing proteins (PLCXDs) as they 
only contain an X-domain. BLAST analysis and subsequent phylogenetic analysis within 
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this thesis has identified three PLCXD isoforms (PLCXD1, 2 and 3) in most mammals 
and at least four in teleost fishes. To date, eukaryotic PI-PLCs have been divided into 
six subtypes each of which contain a multi-domain structure, as previously described 
in Chapter 1. Given that PLCXDs only contain an X-domain, these proteins are more 
similar in primary structure to bacterial PI-PLCs and therefore potentially represent a 
seventh subtype of the PI-PLC superfamily of phosphodiesterases.  
From the structure of the complexes, supporting data from enzyme kinetics, and site-
directed mutagenesis, bacterial PLCXD isozymes are known to utilise general base/acid 
catalysis with the invariant His-32, His-82 and Arg-69 residues (present within the X-
domain) known to be essential for catalytic activity (Heinz et al. 1998). Alignments of 
the X-domain sequences of eel PLCXD1, 2, 3, and 4 with that of B. cereus and B. 
thuringiensis found the key catalytic residues (His32, His82 and Arg69) of bacterial 
PLCXD enzymes to be conserved in eel PLCXD1, 2 and 3 isoforms, suggestive of the 
retention of catalytic properties similar with the bacterial PLCXD enzymes. In contrast, 
none of these residues were conserved in the X-domain sequence of PLCXD4 
suggesting that this isoform may be an inactive phosphodiesterase or possess a yet 
uncharacterised catalytic mechanism unique from other phospholipase C enzymes. 
Indeed, site-directed mutagenesis of His32, His82 and Arg69 abolishes the catalytic 
activity of PI-PLC from B. cereus (Heinz et al., 1998). The conservation of these key 
catalytic residues within the X-domains of eel PLCXD1, 2 and 3 is highly suggestive of 
the retention of PLC-related catalytic functions. Future studies should aim to test the 
ability of recombinant proteins of all eel PLCXD isoforms to hydrolyse PI and PI(4,5)P2 
and also test their lipid binding properties.    
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3.6.2 Tissue expression of eel PLCXD isoforms 
Quantitative real-time PCR using RNA isolated from various tissues from the European 
eel was used to determine the tissue-specific expression of eel PLCXDs 1, 2, 3 and 4 
mRNA in A. anguilla. Previously we characterised the tissue distribution of human 
PLCXDs 1, 2 and 3 isoforms (Gellatly et al., 2012). Similarly with human PLCXD isoforms, 
eel PLCXDs 1, 2, 3 and 4 display distinctive mRNA expression patterns. Unlike the 
human PLCXD isoforms, the mRNA expression levels of eel PLCXDs 1, 2, 3 and 4 were 
not found predominantly in the brain. For eel PLCXD1, mRNA expression was found in 
virtually all the tissues tested with the highest level being found in the gill. The tissue 
distribution of eel PLCXD2 mRNA was restricted to the eye with no detectable signal 
being present in any other tissue. In contrast, a wider mRNA expression pattern for 
PLCXD2 was observed in human tissues. The tissue distribution of eel and human 
PLCXD3 isoforms was similar with expression primarily within the heart. Given that the 
European eel PLCXD1, 2, 3 and 4 isoforms have obvious tissue specificity, these 
proteins potentially have distinctive yet uncharacterised physiological roles. The lack 
of consistency in the tissue distribution of eel and human PLCXDs 1, 2 and 3 isoforms 
suggests that each PLCXD isoform may exhibit species-specific physiological functions. 
To our knowledge, this is the first report describing the tissue-specific mRNA 
expression pattern of any PLC subtype in the A. anguilla. 
3.6.3 Quantitative mRNA expression and protein expression of eel PLCXDs in FW- and 
SW-acclimated yellow and silver eel intestine 
Consistent with our previous microarray data, quantitative expression studies showed 
PLCXD4 mRNA levels to be significantly more abundant (30-fold) in the intestine of 
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yellow eels compared to silver eels and unaffected by salinity transfer. These results 
suggest that some, as yet unknown, developmental changes associated with the 
“yellow” to “silver” transition (also known as silvering) may be responsible for the 
changes seen in PLCXD4 mRNA expression in the eel intestine. Whether PLCXD4 mRNA 
expressed in other tissues of the A. anguilla is similarly affected by the yellow to silver 
developmental transition remains to be characterised. We further evaluated the 
expression of PLCXD4 protein levels in the intestine in both FW-maintained and SW-
acclimated yellow and silver eels using western blot analysis. Immunoreactive protein 
bands of 36 kDa (expected size) and 34 kDa were detected and confirmed by co-IP to 
be ePLCXD4. The presence of these bands were highly variable among individual 
yellow and silver eels with most fish containing both bands and some fish containing 
either the 34 or 36 kDa bands. Relative quantification of ePLCXD4 protein bands, 
normalised to α-tubulin, revealed similar levels of ePLCXD4 in the intestine of FW/SW 
yellow and FW silver eels. However, there was marked variability in the expression of 
the ePLCXD4 proteins between different fish with the same group, particularly FW-
maintained yellow eels, causing difficulties in the interpretation of the data. More 
accurate determination of ePLCXD4 protein levels requires an increase in the number 
of intestinal samples tested; however the declining population numbers of the 
European, close to the level of extinction has therefore made it difficult to gain 
sufficient eel samples for experimental purposes. In silver eels, densitometry revealed 
an almost 2-fold increase in the level of ePLCXD4 in the intestine of the SW-acclimated 
fish compared with FW-maintained fish. The increase in expression was not seen in 
the mRNA levels and therefore the observed increases in protein expression level is 
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likely due to as yet uncharacterised post-transcriptional changes. One explanation for 
the observed increase in ePLCXD4 protein level in SW-acclimated silver eels could be 
that this protein is involved in the molecular mechanisms underlying osmoregulation 
in the European eel. Given that no changes in ePLCXD4 protein levels were detected 
when yellow eels were transferred to SW, this explanation seems unlikely. A more 
likely explanation is that ePLCXD4 is linked to the series of morphological and 
physiological changes that occur late on during the silvering process as the eel enters 
the sea (See Section 3.1).  
3.6.4. Immunolocalisation of PLCXD-4 in middle intestinal sections 
In the previous section, western blot analysis revealed that PLCXD4 protein levels were 
detectable in the intestine using an affinity-purified N-terminal PLCXD4 antibody. In-
order to further characterise PLCXD4 protein expression in the intestine of the 
European eel and to shed light on possible physiological functions, 
immunohistochemistry was used to examine the localisation of PLCXD4 within the 
intestine. PLCXD4 immunoreactivity was restricted to irregular shaped cells that 
appeared randomly at the base and in between the more columnar epithelial cells. 
Immuno-fluorescence was present throughout the entire cell. No specific fluorescence 
was observed in the smooth muscle and connective tissue layers of the intestine. The 
intestinal epithelium is a single cell layer which consists mainly of absorptive columnar 
cells, referred to as enterocytes, with the inclusion of mucus-secreting goblet cells, and 
various intraepithelial endocrine /neuroendocrine cells and lymphocytes (Clarke and 
Witcomb, 1989). The presence of a various different cell types within the intestinal 
epithelium is thought to underlie the multifunctional nature of the gut which has been 
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shown to be involved in diverse functions in the eel including nutrient, water and ion 
uptake, and therefore osmoregulatory processes, as well as being the first line of 
defence against harmful agents entering the lumen (Grosell et al., 2010). The precise 
nature of these cells awaits further co-localisation experiments with antibodies 
recognise proteins specific for endocrine, neuroendocrine or immune cells. Although 
the precise functional role of PLCXD4 in the eel intestine is currently unknown, future 
experiments could characterise the expression, cellular localisation and effect of gene 
knockdown and over-expression in cultured primary epithelial cells from the intestines 
of European eels. These molecular approaches will offer a better comprehension of 
the cellular/potential physiological functions of PLCXD4 in the intestinal epithelium. 
Given that only very low PLCXD4 expression was detected in western blots using the 
intestine of FW-maintained silver eels, it would be interesting to carry out 
immunofluorescence studies of PLCXD4 protein expression using intestinal sections 
from this group of fish. Currently intestinal sections from the yellow eel are unavailable. 
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CHAPTER 4: Cloning, tissue distribution and 
characterisation of human and mouse PLCXD isoforms 
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4.1. Prediction and characterisation of human PLCXD genes 
With the goal of identifying human and mouse PLCXD isoforms, BLAST searching 
against the non-redundant NCBI protein database was used to identify sequences with 
homology to eel PLCXDs. Three genes, denoted PLCXDs 1, 2 and 3, were identified and 
their corresponding nucleotide sequences were submitted to the BLAT search engine 
on the Santa Cruz genome browser. In human, the PLCXD1 sequence is present on 
both X (Xp22.33) and Y (Yp11.32) chromosomes whereas PLCXD2 and 3 sequences 
mapped to positions 3q13.2 and 5p13.1 respectively. Interestingly, the Ensembl 
database predicted the presence of two transcripts for PLCXD2, designated 
ENST00000393934 and ENST00000477665, each containing an open-reading frame 
consisting of four exons. The predicted sequences of exons 1-3 were found to be 
identical, whereas the sequence of exon 4 is different. The presence of two different 
PLCXD2 transcripts may result from alternative splicing events within exon 4, and 
ENST00000393934 and ENST00000477665 were subsequently denoted PLCXD2.1 and 
2.2 (Figure 4.1).  
 
 
 
 
125 
 
 
Figure 4.1: Schematic diagram of exonic sequences present in different PLCXD2 mRNA isoforms. Boxes and lines represent the exons 
and introns, respectively. Human PLCXD2 is found on band q13.2 of chromosome 3. The location of each exon sequence on chromosome 
3 is indicated below each exon (See Esembl). The nucleotide sequences of PLCXD2.1 and PLCXD2.2 were originally obtained from the 
Esembl database and subsequently confirmed following sequencing of RT-PCR products cloned from HeLa first strand cDNA. PLCXD2.3 
was initially identified during RT-PCR amplification of PLCXD2.2 and its full-length sequence was later obtained using Marathon cDNA 
prepared from the HeLa cell line.The nucleotide sequence of Exons 1-3 are identical in each splice variant, whereas the sequence of Exon 
4 is different.  
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In-order to confirm the predicted sequences of all human PLCXDs, including the splice 
variants of PLCXD2, RT-PCR was used to amplify the entire open-reading frames of all 
human PLCXD transcripts from a HeLa cell cDNA pool (Chapter 2, Section 2.7.6). The 
sequences of primers used are detailed in Appendix C. PCR products of around 1000 
base pairs were obtained corresponding to the expected molecular sizes of PLCXD1 
and 3 (Figure 4.2). Following gel purification and TOPO cloning reactions (Chapter 2, 
Section 2.7.9), the predicted sequences of human PLCXD1 and 3 were confirmed. For 
PLCXD2, PCR products of around 1000 base pairs were obtained corresponding to the 
full-length open reading frames of PLCXD2.1 and 2.2 (Figure 4.2). Sequencing reactions 
confirmed these sequences to be identical to those present within the database. 
Additionally, a larger band of just over 1000 base pairs was detected following 
amplification with primers specific to PLCXD2.2, which sequencing reactions and 
alignment analysis showed to be highly similar to PLCXD2.1 and 2.2 with differences 
only present at the 3’-end (Figure 4.1 and 4.2). Cloning and sequencing of this 
additional band was carried out in collaboration with Dr Taciana Kasciukovic, 
University of St Andrews. This additional band therefore represents a further PLCXD2 
transcript with a divergent 3’-end which was subsequently denoted PLCXD2.3.  
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Figure 4.2: RT-PCR amplification of human PLCXDs using cDNA synthesized from 
HeLa cells. Gel electrophoresis analysis with ethidium bromide staining shows the 
amplification of PCR products of the expected size for human PLCXD1, PLCXD2 and 
PLCXD3 (Lanes 1, 2 and 3, respectively). Included in the analysis was a predicted 
alternative splicing variant of PLCXD2, PLCXD2.2, shown in Lane 5. Interestingly, a 
larger band was also amplified alongside PLCXD2.2 which sequencing has confirmed 
as a further alternative splicing variant of PLCXD2, denoted PLCXD2.3. The molecular 
markers for size estimation is shown in lane 4. 
 
The presence of conserved protein domains was predicted using the SMART databases 
(Smart Architecture Research Tool; http://smart.embl.de/). Based on predictions by 
SMART, amino acids 30-206, 42-215 and 22-197 of PLCXDs 1, 2 and 3 respectively have 
homology with X-domain sequences of the normal X and Y catalytic domains found in 
all known eukaryotic PI-PLC. No other domain homologies were predicted using 
SMART databases. Previous phylogenetic analysis of PLCXD proteins from different 
species showed PLCXD1, 2 and 3 sequences to cluster into separate groups with each 
isoform being highly conserved across species, suggestive of conserved functions. 
Additionally, previous sequence alignments of PLCXD proteins from different species 
including the functionally characterised bacterial PLCXD homologs revealed the 
conservation in all human PLCXDs of two key catalytic histidines and an arginine 
residue suggestive of the retention of similar catalytic properties in human proteins 
(Chapter 3, Figure 3.5). 
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4.3. mRNA expression and tissue distribution of mouse and human PLCXD1, 2 and 3 
Quantitative RT-PCR (Chapter 2, Section 2.7.11) was used to determine the 
distribution and relative levels of mouse PLCXD1, 2 and 3 mRNAs in a range of different 
tissues. Primer sequences used are detailed in Appendix D. As shown in Figure 4.3A, B 
and C, PCR analyses clearly indicated that PLCXD1, 2, 3 mRNAs show distinct tissue 
expression patterns. For all PLCXD isoforms, the highest mRNA expression levels were 
observed in the brain. PLCXDs 1 and 3 mRNAs were observed in virtually all tissues 
tested indicating potential fundamental roles in cell function. 
In the case of human PLCXD isoforms, mRNA expression levels were analysed using 
semi-quantitative RT-PCR in a restricted number of tissues (Figure 4.3D). Human 
PLCXD1 mRNA expression levels were observed in virtually all tissues tested. Although 
PLCXD3 mRNA expression was detectable in most of the tested tissues, a particular 
strong signal was found in the heart. PLCXD2 mRNA expression levels (probe for all 
spliceforms) was restricted to the leukocytes and thymus. 
 
 
 
 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Relative expression of mPLCXD-1, 2.1 and 3 transcripts in a range of mouse tissues (A-C) taken from n=1 mouse. 
Relative levels were calculated using Rpl-P0 as the normalizing gene, as detailed in the materials and methods. PCR amplifications were 
run in triplicate and the mean values are reported. Mean values for brain samples (a), (b) and (c) are 1.0, 100 and 20, respectively. Values 
on the Y-axis indicate relative expression to Rpl-P0 (x10-3). (D) Semi-quantitaive expression levels of hPLCXD1, 2 and 3 transcripts by 
RT-PCR analysis from a restricted number of human tissues (1- leukocytes, 2- thymus, 3- heart, 4- small intestine, 5- colon, 6- kidney, 7- 
molecular weight markers, 8- lung and 9- skeletal muscle. 
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4.4. The distribution of PLCXD1, 2 and 3 in the mouse brain 
Analysis of the expression of PLCXD1, 2 and 3 in different areas of the mouse brain has 
been previously characterised by in situ hybridisation experiments and this data was 
accessed from the Allen Brain Atlas. This comprehensive analysis was undertaken by 
the Allen Institute for Brain Science (AIBS) and is the first large scale project to map 
the expression of approx. 20,000 genes in the mouse brain by in situ hybridisation. The 
expression of these genes was detected and quantified and subsequently stored in a 
database, allowing for comparisons of gene expression patterns. All data present 
within the database was taken from 8-week-old adult C57BL/6J male mice. In this 
chapter, the database was used to reveal the PLCXD1, 2 and 3 mRNA expression 
patterns in different brain regions to further characterise the predominant expression 
of these transcripts previously observed in the mouse brain (see Figure 4.4). The 
expression pattern of each PLCXD isoform is represented in a heat map, where the 
level of gene expression is indicated by different colours (blue: low, green: medium, 
red: high expression level), as determined by in situ hybridisation using digoxigenin-
labelled probes. For PLCXD1, a strong signal was present in the hippocampal formation, 
in particular the pyramidal cells of the regions CA1-3 and granule cells of the dentate 
gyrus (Figure 4.4). Additionally, a strong signal for PLCXD1 was evident in the purkinje 
layer of the cerebellum. For PLCXD2, a particularly strong signal within periglomerular 
cells and the mitral cells layer of the olfactory bulb (Figure 4.5). PLCXD2 staining was 
also evident in visual cortex and various regions of the mid-brain including the inferior 
colliculus, and the lateral posterior nucleus of the thalamus (Figure 4.7). Localisation 
observed in nervous tissues was in the nerve cell, but not in the glial cells as revealed 
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at higher magnification. Interestingly, no detectable expression was observed for 
PLCXD3, which is inconsistent with our previous findings. 
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Figure 4.4: Analysis of the expression of PLCXD1 in different regions of brain of 8-week-old adult C57/BL/6J male mice by in situ 
hybridisation. This data is stored within the Allen Brain Atlas (http://www.brain-map.org/). Expression is also represented as a heat map 
(Top left; blue: low, green: medium, red: high expression). Hippocampal formation: Cornu Ammonis area 1 and 3 (CA1 and CA3), 
dentate gyrus (DG), dentate gyrus polymorphic layer (DGpo), dentate gyrus granule cell layer (DGsg), dentate gyrus molecular layer 
(DGmo). Cerebellum: purkinje layer (pur. lay.) and granule cell layer (gran. lay.).
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Figure 4.5: Analysis of the expression of PLCXD2 in different regions of brain of 8-week-old adult C57/BL/6J male mice by in situ 
hybridisation. This data is stored within the Allen Brain Atlas (http://www.brain-map.org/). Expression is also represented as a heat map 
(Top left; blue: low, green: medium, red: high expression). Bottom left shows Nissl-staining. Glomerular layer (GLL), external plexiform 
layer (EPL), mitral cell layer (MCL), granule cell layer. 
 
134 
 
4.5. Sub-cellular localisation of PLCXD1, 2 and 3 isoforms in the HeLa cell line 
The most basic question of where human PLCXD isoforms are located within the cell 
can be investigated with immunofluorescence microscopy. HeLa cells stably 
expressing Pk/V5-tagged forms of PLCXD1, 2 and 3 were created in collaboration with 
Dr Svetlana Kalujnaia, University of St Andrews, using a lentiviral-based expression 
system, as described in the Section 2.3.4. Successful over-expression of each PLCXD 
isoform was confirmed by Western blot analysis (Figure 4.6) using the mouse 
monoclonal anti-Pk/V5 antibody (1/500 dilution; See Table 2.5) and a secondary 
alkaline phosphatase-conjugated donkey anti-mouse polyclonal antibody (1/10,000 
dilution; See Table 2.5). Wild-type cells (non-transfected) and HeLa cells exhibiting 
stable overexpression of Pk/V5-tagged hPLCXD-1, 2.1 and 3 were grown and prepared 
for immunocytochemistry and fluorescent microscopy, as described in Chapter 2, 
Section 2.5.2. When transfected HeLa cells were probed with an anti-Pk/V5 antibody 
followed by a secondary labelled Alexa Fluor 633-labelled donkey anti-mouse 
polyclonal antibody, the most prominent signals were present in uncharacterised 
cytoplasmic and perinuclear vesicles suggestive of endoplasmic reticulum and/or Golgi 
apparatus (Figure 4.7 B and D). In contrast, transfected PLCXD2.1 protein was found 
to be entirely nuclear (Figure 4.7C). No staining was observed in control non-
transfected HeLa cells, therefore confirming the specificity of both the primary and 
secondary antibodies. 
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Figure 4.6: Western blotting analysis of HeLa cells stably expressing Pk/V5-tagged 
PLCXD1, 2.1 and 3 (B, C and D respectively). Primary antibody: mouse anti-Pk/V5 tag; 
1/500 dilution. Secondary antibody: Alkaline phosphatase-conjugated donkey anti-
mouse. No bands were detected in control non-transfected cells (control; Lane A). 
Lane E: Standard protein marker (Fermentas). This image is a representation of 3 
separate experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Sub-cellular localisation of hPLCXD isoforms (red) in HeLa cell lines stably 
transfected with Pk-tagged hPLCXD1 (B), 2.1 (C) or 3 (D), respectively. Non-tranfected 
(Control) cell lines (A). DAPI stained nucleus is shown in blue. Photomicrographs were 
captured using a Zeiss Axiocam light microscope x40 objective. These images are 
representative of at least 10 microscopic fields of view for 3 separate experiments. 
Scale bar indicates 50 µm. 
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4.6. In vivo phospholipase C assays 
A cell-based [3H]-inositol-phosphate release assay was performed (Chapter 2, Section 
2.5.1) to investigate the potential role of hPLCXDs acting as functional PI-PLCs. This 
assay was carried out in collaboration with Dr Svetlana Kalujnaia, University of St 
Andrews. The relative [3H]-inositol phosphate (IP) content of non-transfected (control) 
HeLa cells and cells transfected with hPLCXD1, 2.1 and 3 was determined either in the 
presence or absence of the calcium ionophore A23187 (Chapter 2, Section 2.5.1). As 
shown Figure 4.8, HeLa cells transfected with hPLCXD constructs all exhibited 
significant (2.5- to 7-fold) increases in basal turnover of the phosphatidylinositol pool 
compared to the non-transfected control cells. Interestingly, compared with both 
PLCXD1 and PLCXD2.1 transfected cells, the turnover of PI-phospholipids was 
significantly higher in cells transfected with PLCXD3. Western blot analysis revealed 
hPLCXD1, 2 and 3 proteins to be expressed at similar levels in HeLa cells. The calcium 
ionophore A23187 increased PI turnover to the same extend in control and PLCXD1 
and PLCXD2.1 transfected cells but failed to enhance the already high turnover in cell 
over-expressing hPLCXD3. These data suggest that over-expression of all three hPLCXD 
isoforms increased endogenous phospholipase C activity in cultured HeLa cells in a 
calcium-independent manner.  
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Figure 4.8: Relative [3H]-IP content of non-transfected (control) HeLa cells and cells 
overexpressing hPLCXD1, hPLCXD2.1, hPLCXD3, following a 2 h incubation with 10 mM 
LiCl plus or minus the calcium ionophore A23187. Bars indicate the fold difference over 
non-transfected, control cells. Error bars indicate SEM for n=3 replicates. 
 
 
4.7. Discussion 
4.7.1. Identification of PLCXD homologs in the human genome 
Human and mouse sequences belonging to the PLCXD class of genes were identified, 
analysed and several important observations were made. Previous observations in the 
European eel showed PLCXD genes to be segregated into four groups (PLCXDs 1, 2, 3 
and 4) on the basis of sequence similarity, coincident with their position within a 
phylogenetic tree. Current investigations within this chapter have resulted in the 
identification of PLCXD1, 2 and 3 orthologues in humans and mice. In humans, the 
PLCXD1 gene is unusual, in as much as it is one of only 29 pseudo-autosomal genes 
that are present on both X (Xp22.33) and Y (Yp11.32) chromosomes. As with all 
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pseudo-autosomal genes that escape X-inactivation, this highlights PLCXD1 as 
potentially being linked to the variety of physical and mental disorders associated with 
sex chromosome aneuploidy, such as found in Triple X syndrome (Blaschke and 
Rappold, 2006).  
Sequence analysis has indicated that both mouse and human PLCXD isoforms have 
retained the amino acids known to contribute to the acid/base hydrolysis of 
phosphoinositides in B. cereus PI-PLCs as well as other mammalian PLCXDs, including 
His32, His 82 and Arg69 (B. cereus PLCXD sequence numbering; Figure 3.5, highlighted 
in yellow). Both mouse and human PLCXD isoforms also have a conserved arginine 
residue (Figure 3.5, highlighted in yellow), which is homologously positioned to Arg69 
in the calcium-independent bacterial PI-PLCs. As mentioned previously (Section 
1.4.3.1), Arg69 is important for stabilisation of the Ins (1:2cyc) P substrate 
intermediate in the active site of bacterial PI-PLCs whereas mammalian PI-PLC utilise 
a calcium ion to fulfil this role (Heinz et al., 1998). This difference is thought to be the 
reason that bacterial PI-PLCs can only catalyse the first step of the two-step reaction 
(Section 1.4.3.1) and therefore release Ins(1:2cyc)P as the principal product of 
phosphoinositide hydrolysis; in contrast, the principal product of mammalian PI-PLCs 
is the acyclic inositol phosphate (Heinz et al., 1998). As with eel PLCXD-1, 2 and 3, these 
data are suggestive of the retention of similar catalytic properties of mammalian 
PLCXD proteins to their homologues in bacteria. Further characterisation of the 
catalytic activity of human PLCXD is described in Chapter 5.  
As a result of in silico analysis and subsequent RT-PCR and sequencing reactions, we 
have identified and confirmed the existence of at least three splicing variants of the 
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PLCXD2 isoform derived from a single gene that differ in their C-terminal sequences. 
Alternative splicing variants have been previously reported for several other PI-PLC 
isozymes including rat PLC-β1 (Bahk et al., 1994), human PLC-β2 (Sun et al., 2007), 
human PLCε (Sorli et al., 2005) and mouse PLC-η (Hwang et al., 2005). Differences in 
tissue distribution and catalytic properties have been reported for most spliced 
variants of PI-PLC iszoymes (Rebecchi and Pentyala, 2000). The presence of splicing 
variants of PLCXD2 may therefore have important physiological and potential 
pathological consequences. Future work should aim to characterise and compare the 
tissue distribution and cellular localisations of the different alternative splice variant 
of PLCXD2 in a range of different tissues and cell lines.  
Recently the crystal structures of eukaryotic and prokaryotic PI-PLCs have been 
determined both in complexes with substrates thus enabling comparisons of the 
enzymes in substrate-specificity terms. Prokaryotic PI-PLCs and the catalytic domain 
of eukaryotic PI-PLCs consist of alternating α- helices and β-strands that resemble an 
incomplete triose phosphate isomerase α/β-barrel (TIM-barrel; Section 1.4.1.4). The 
first half of the barrel displays large structural similarity between the prokaryotic and 
eukaryotic PI-PLCs, however the enzymes display a much weaker similarity in the 
second half of the barrel. The higher degree of structure conservation in the first half 
of the barrel correlates with the presence of all catalytic residues, including the two 
catalytic histidine residues, in this portion of the enzyme. The second half of the TIM-
barrel contains the amino acid residues contributing to the substrate binding pocket. 
The distinctive nature of the second half of the TIM-barrel in prokaryotic and 
eukaryotic enzymes is known to contribute to their different substrate preferences 
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(Heinz et al. 1996; Heinz et al., 1998). In-order to predict whether mouse and human 
PLCXD proteins contain amino acids enabling interaction with inositol containing 
substrates, a structural model of mammalian PLCXDs was constructed using the known 
structures of B. cereus PI-PLC and the catalytic site of mammalian PLC-δ1. Due to low 
amino acid sequence homology this model was not robust and therefore whether 
mammalian PLCXDs have retained the amino acids known to contribute to the binding 
of either PI(4,5)P2 or PI is currently unknown.  
4.7.2. mRNA expression of PLCXD1, 2 and 3 in different mouse tissues and regions of 
the mouse brain 
Analysis of the tissue-specific mRNA expression patterns of the different PLCXD 
isoforms in mice and humans show PLCXD1, 2 and 3 to have distinct tissue 
distributions. Indeed the distribution of other mammalian PI-PLC subtypes and their 
different isoforms is well characterised and has similarly been shown to be tissue- and 
organ-specific (Suh et al., 2008). For instance, northern blot analyses of mouse tissues 
and EST sequence analyses using human UniGene database showed the highest level 
of PLC-γ1 mRNA to be present in the brain and embryonic tissues whereas PLC-γ2 
mRNA is expressed mainly in the lymph nodes (Mizuguchi et al., 1991). These 
differences in tissue distribution patterns are thought to serve as an explanation to the 
predominant role of PLC-γ1 in embryonic cell development and the role of PLC-γ2 in 
immune responses (Wang et al., 2000; Hashimoto et al., 2000). Given the specificity in 
distribution of PLCXD1, 2 and 3 in mouse and human tissues, it may be that each PLCXD 
isoform bears a unique function in the modulation of physiological responses.  At least 
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in mice, the highest mRNA expression of PLCXD1, 2 and 3 was found within the brain 
suggestive of a fundamental role in nerve cell function.  
The tissue-specific localisation of all three PLCXD isoforms was further described based 
on the data provided by the Allen Brain Atlas. PLCXDs 1 and 2 were found to have a 
widespread distribution in the brain with mRNA being detected within most brain 
regions. PLCXD1 was found to be particularly enriched throughout the hippocampal 
formation, with expression being detected in the neurons of the CA1-3 regions and the 
dentate gyrus, and the Purkinje layer of the cerebellum. The dentate gyrus appears as 
a V-shaped structure enveloping the end of the pyramidal cells of CA3 and is composed 
of three layers: molecular, granule and polymorph. PLCXD1 shows preferential 
expression in granule cell layer (DGsg) with little to no expression in the polymorph 
(DGpo) and/or the molecular (DGmo) layers. The hippocampal formation is known to 
play important roles in the consolidation of information from short-term memory to 
long-term memory and spatial navigation and neurons within this region have been 
extensively studied with regards to the cellular basis of “learning” (Jarrard, L.E, 1993; 
Izquierdo, I. and Medina, 1997). Neural circuit behaviour within and between neurons 
of the CA1-CA3 region and the denate gyrus is known to be modified in and 
experience-dependent manner involving changes in synaptic strength and neuronal 
excitability. These changes can be manifested in either long-term potentiation (LTP) 
and/or long-term depression (LTD) of neuronal transmission (Bruel-Jungerman et al., 
2007). Multiple receptors coupled to phospholipase C have been shown to be involved 
in the induction of LTD. Indeed, loss of PLC-specific signalling with inhibitors such as 
wortmannin, and more specifically, knock-out of PLCβ1 are known to impair LTD 
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(Reyes-Harde and Stanton, 1998). Similarly, the synaptic strength and neuronal 
excitability of Purkinje cells within the cerebellum is also known to be experience-
dependent and this is thought to underlie the memory processes in the cerebellum of 
behaving animals (Jorntel and Hansel, 2006). The mRNA expression data for PLCXD1 
may therefore be suggestive of a potential role in signal transduction in the 
hippocampus and cerebellum and potential association with learning and memory 
formation within these regions.  In-order to further assess the role of PLCXD1 in 
memory formation, future creation of a specific knock-out mouse model would be 
crucial. Using this model, learning tests and local measurement of synaptic 
transmissions in the hippocampus could be performed. Future experiments could also 
aim to study the expression, localisation and regulation of PLCXD1 in neurons cultured 
from the hippocampal formation. 
High mRNA levels of PLCXD2 were detected in the main olfactory bulb (MOB) and 
throughout the visual cortex (Allen Brain Atlas). Within the MOB, PLCXD2 mRNA 
expression was enriched in the mitral and periglomerular layers with little to no 
expression seen in the granule cell layer. These neurons are key elements of 
odor/pheromone processing and are directly involved in information processing to 
and from the olfactory epithelium, and the olfactory cortex and associated brain areas. 
Indeed, PLC-η2 (Nakahara et al., 2005) and PLC-β 1 (Watanabe et al., 1998) have also 
been shown to be expressed in the same neurons of the olfactory bulb. The presence 
of PLCXD2 mRNA within neurons of the MOB and the visual cortex suggests that 
PLCXD2 might specifically be involved in neural pathways underlying the transduction 
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and processing of sensory stimuli within higher brain regions. Further elucidation of 
the role played by PLCXD2 in sensory systems awaits the creation of PLCXD2 null mice. 
In summary, tissue-distribution analysis reveals PLCXD1, 2 and 3 to be predominantly 
expressed in the brain and further analysis (at least for PLCXDs 1 and 2) reveal this 
expression to be mainly restricted to neurons within specific regions of the adult 
mouse brain. Together, these data suggest that PLCXD isoforms may play fundamental 
roles in nerve tissue function. Further work is needed to clarify the cellular functions 
of PLCXD1, 2 and 3 by, for example, analysis of PLCXD-deficient or overexpressing cells 
and/or PLCXD knock-out animals. 
4.7.3. Cellular localisation 
In-order to further characterise the basic principles surrounding the molecular 
functions of human PLCXD proteins, the sub-cellular localisation of these proteins was 
determined following the transfection of tagged constructs into HeLa cells and 
subsequent visualisation by immunofluorescence. Western blotting analysis of 
wildtype, untransfected HeLa cell lysates probed separately with monoclonal 
antibodies raised against each human PLCXD isoform failed to detect a band 
corresponding to PLCXD1, 2 or 3. Given that endogenous protein expression was 
undetectable in HeLa cells, immunofluorescence experiments were performed using 
HeLa cells (over)-expressing each PLCXD isoform. PLCXDs 1, 2 and 3 were expressed as 
fusion proteins containing a Pk/V5-tag, thereby allowing detection using an anti-Pk 
primary antibody. PLCXDs 1 and 3 were found to be localised within uncharacterised 
cytoplasmic and perinuclear vesicles suggestive of endoplasmic reticulum and/or Golgi 
apparatus. This indicates that both proteins may be involved in unknown intracellular 
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functions rather than existing as part of extracellular signalling processes occurring at 
the plasma membrane. In contrast, transfected PLCXD2.1 was found to be associated 
with the nucleus. Interestingly, phosphoinositides have been shown to be enriched 
within the nucleus along with a number of enzymes that regulate phosphoinositide 
metabolism (Gonzales and Anderson, 2006). Although the lipid binding specificities 
and substrate specificities of PLCXD2 are currently uncharacterised, evidence detailed 
within this thesis suggests that this protein is able to influence phosphoinositide 
turnover in cultured HeLa cells. Whether PLCXD2 has a direct or indirect effect on 
phosphoinositide turnover remains to be fully characterised, however its association 
with the nucleus is suggestive of a potential regulatory role in nuclear 
phosphoinositide metabolism.  
Currently, this is the first attempt to characterise the sub-cellular localisation of any 
PLCXD isoform. The distinct nature of the sub-cellular localisations of PLCXDs 1, 2 and 
3 is highly suggestive of unique functions within cellular physiology. Most eukaryotic 
proteins are encoded in the nuclear genome and synthesized either in the cytosol or 
endoplasmic reticulum where they can be further sorted to other subcellular 
compartments. Depending on the destination, the sorting of proteins relies on the 
presence of a targeting sequence that is recognised by translocation machinery. 
Translocation of a protein to the nucleus requires a nuclear transport mechanism 
initiated by a nuclear localisation signal (NLS) sequence on the protein (Lange et al., 
2007) Such signals have been found in many nuclear proteins including PLC-β, where 
it is present as a cluster of basic residues at the C-terminus of the protein (Irvine, 2003). 
Interestingly, no classical nuclear localisation signal is predicted for PLCXD2.1. It is 
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possible that PLCXD2.1 could “piggyback” into the nucleus by binding to a nuclear 
protein however the exact mechanism of PLCXD2.1 nuclear remains to be 
characterised. Additionally, an interesting experiment would be to examine and 
compare the sub-cellular localisations of PLCXD2.2 and PLCXD2.3 splice variants and 
test whether they are also confined to the nucleus. This, however, awaits generation 
of HeLa cell lines stably expressing these proteins. At least for PLCXD1 and 3, future 
work should attempt to co-localise these proteins with various organelle-specific 
markers, including Golgi and endoplasmic reticulum markers. The sub-cellular 
localisation of PLCXD1, 2 and 3 described here need to be further verified in a cell line 
where endogenous protein expression can be detected with antibodies specific to 
each isoform. 
4.7.4. In vivo phospholipase C assay 
To investigate the potential of human PLCXDs acting as functional PI-PLCs, an in vivo 
phosphoinositide turnover assay was performed. All three hPLCXD isoforms were 
found to increase the endogenous phospholipase C activity in cultured HeLa cells in a 
calcium-independent manner. Although it is possible that the expressed PLCXDs 
mediate indirect increases in expression and/or activity of the endogenous HeLa cell 
PI-PLCs, given the sequence similarities with the bacterial PI-PLCs it is likely that 
PLCXDs have their own phospholipase C activity. In-order to determine whether the 
observed increases in PI turnover are due to PLCXDs having their own phospholipase 
C activity, the PI turnover assay could be repeated with mutant PLCXDs lakcing the two 
catalytic histidine residues. The increased activity in all cells seen with the ionophore 
could be accounted for by an enhanced activity of endogenous PI-PLCs, most of which 
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are stimulated by increasing calcium concentrations. All existing mammalian PI-PLCs 
have been shown to hydrolyse PI(4,5)P2 in a calcium-dependent manner whereas 
bacterial PI-PLCs show no metal-ion dependency and do not cleave multi-
phosphorylated forms of PI (Essen et al., 1997). Interestingly, the absolute increase in 
PI-phospholipid turnover in cells over-expressing PLCXD1 and PLCXD3 was lower in the 
presence of the ionophore, indicating a possible attenuation of PLCXD1 and 3 actions 
in the presence of excess calcium. With respect to the apparent lack of stimulation by 
calcium in vivo and the conservation of the Arg69 residue, known in bacterial PI-PLCs 
to occupy the location of Ca2+ in the eukaryotic enzymes, the human PLCXDs may be 
functionally more similar to bacterial PI-PLCs than other mammalian PI-PLCs. 
Alternatively the observed results may be due to the stress induced by protein 
overexpression. From this it is clear that the ability of the different human PLCXD 
isoforms to directly hydrolyse various PI and PI(4,5)P2 needs to be investigated and 
these experiments are described in Chapter 5. 
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CHAPTER 5: Expression analysis of PLCXDs 1, 2 and 3 in the 
tissues of Harlequin mice. 
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5.1. Introduction 
The Harlequin (Hq) mouse is a naturally occurring genetic mouse model of late-onset 
neurodegeneration. The phenotype of Hq mice is mainly characterised by progressive 
cerebella neuron defects, including the degeneration of granule and purkinje cells, 
which begins at 4 months of age and continues with progressive ataxia symptoms. In 
addition, progressive loss of retinal neurons is also evident in Hq mice, including 
ganglion and amacrine cells, which begins at 3 months and eventually leads to 
blindness (Bouaita et al., 2012). The Hq mouse carries an X-linked recessive mutation 
in the apoptosis-inducing factor (AIF) gene, identified as a retroviral insertion in the 
first intron, which severely reduces the expression of the AIF gene by 80% in mutant 
mice (Klein et al., 2002). AIF has nicotinamide adenine dinucleotide (NADH) oxidase 
activity and is found on the inner membrane of the mitochondria and plays a role in 
respiratory chain complex I biogenesis (Susin et al., 1999). Alternative splicing of the 
AIF mRNA precursor is known to give rise to four distinct isoforms (AIF1-4; Hangen et 
al., 2010). Reduced levels of both AIF1 and AIF2 is thought to increase the susceptibility 
of neurons to free radical damage leading to abnormal cell cycle re-entry and death of 
terminally differentiated cerebella and retinal neurons (Klein et al., 2002; Bouaita et 
al., 2012). 
Previously we proposed hypothetical functions for PLCXDs based on high levels of 
expression, relative to Rpl-P0, in the mouse brain. Furthermore, expression analysis 
revealed, at least for PLCXD2 and 3, detectable mRNA levels within the mouse eye and 
in situ hydridisation studies revealed the presence of PLCXD1 and 3 mRNA levels within 
the mouse cerebellum. Given these findings, it was of interest to further characterise 
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the mRNA expression levels and cellular localisation of all three PLCXD isoforms in the 
cerebellum and retina of both wild-type (WT) and Hq mutant mice to establish a 
potential role for PLCXDs in neurodegeneration. 
5.2. Analysis of mRNA expression levels and the cellular localisation of PLCXD isoforms 
in wild-type and the Harlequin mouse 
Previous studies have shown the mRNA levels of AIF1 and AIF2 to be reduced in the 
retina (~96%; Bouaita et al., 2012) of Hq mice compared to control animals (Bouaita et 
al., 2012). In addition, the mRNA-levels of Brn3a, which is a specific marker of retinal 
ganglion cells, has been shown to be reduced to ~50% of control values in Hq retinas 
(Bouaita et al., 2012). We obtained six retina and six cerebellum samples from both 
control and Hq mutant mice (Generous gift from Dr Marisol Corral-Debrinski, Institue 
de la Vision, Paris). As an important first step, RT-qPCR (Chapter 2, Section 2.7.11) was 
performed using gene-specific primers for AIF1 and 2, and Brn3a to confirm previously 
the observed down-regulations associated with the Hq phenotype. In the retina of Hq 
mutant mice, our analysis revealed suppression of both AIF1 and AIF2 mRNAs by 96%, 
and Brn3a mRNA by 43% to the control samples (Figure 5.1A). We also found the levels 
of AIF1 and AIF2 mRNA in Hq mice to be reduced by ~70% and ~60% respectively, in 
the cerebellum compared to control samples (Figure 5.1B). 
In-order to test whether PLCXDs 1, 2 and 3 are involved in the phenotypes associated 
with the Hq mutants, the cerebellar and retinal expressions of the gene transcripts and 
proteins were examined. Total RNA and protein was extracted from the cerebellum of 
six WT and six Hq mutant mice, as previously described. Unfortunately due to tissue 
availability only RNA was available from retinal samples of six WT and six Hq mutant 
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mice. RT-qPCR analysis of cDNA prepared from these tissues revealed PLCXD2 and 3 
transcript levels to significantly decrease in the retina of Hq mutant mice (Figure 5.2). 
In contrast, PLCXD1 levels were undetectable in both the cerebellum and retina 
samples from WT and Hq mutant mice (data not shown). No significant differences in 
PLCXD2 and PLCXD3 transcript levels were observed between cerebellar samples of 
control and Hq mutant mice (Figure 5.3A). Interestingly, western blotting analysis 
using a purified antibody against the N-terminus of PLCXD3, showed PLCXD3 protein 
levels to be undetectable in the cerebellum of Hq mutant mice compared to control 
mice where a band of 36 kDa was obtained, corresponding to the expected molecular 
size of mouse PLCXD3 (Figure 5.3B).  
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Figure 5.1: RT-qPCR analysis of the relative transcript levels of AIF1 and 2 and Brn3A 
in the retina (A) and the cerebellum (B) of control and Hq mutant mice. Total RNA was 
prepared from a total of six retina and six cerebellar samples from control and Hq 
mutant mice (mean +/- SEM presented). Values on the Y-axis represent relative 
expression to Rpl-P0. * P< 0.05, **P< 0.01 
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Figure 5.2: Quantification of PLCXD isoform expression in the retina. RT-qPCR assays 
were performed with total RNAs from retinas to determine the levels of PLCXD2 and 
3 mRNAs. Six independent RNA preparations of retinas were evaluated for both wild-
type and Harlequin (Hq) mutant mice (mean +/- SEM presented, ** p< 0.01 and * p< 
0.05). Values on the Y-axis represent relative expression to Rpl-P0.  
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Figure 5.3:  (A) Quantification of PLCXD2 and 3 transcript levels in the cerebellum of 
Hq mutant and control mice. Total RNA was extracted from the cerebellum of six 
control and six Hq mutant mice and cDNA conversions and RT-qPCR assays 
subsequently performed. Relative levels were calculated using Rpl-P0 as the 
normalizing gene. (B) Western blot analysis of PLCXD3 protein levels in cerebellar 
lysates from five control and five Hq mutant mice. 10 µg of total protein was loaded 
per each lane. A standard western blotting procedure was carried out using a purifed 
antibody raised against the N-terminus of human PLCXD3. Alpha-tubulin was included 
as the loading control. Lanes 1-5 represent Hq mutant mice, and lanes 6-10 represent 
control mice, in both blots. 
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5.3. Immunofluorescence analysis of retinal nerves from Control and Harlequin mice 
To further elucidate the functional role of PLCXD3 in the mouse retina, its subcellular 
distribution in retinal sections was analysed by immunostaining. This work was carried 
out in collaboration with Dr Marisol Corral-Debrinski, Institut de la Vision, Paris, France. 
Retinal sections were obtained for both wild-type and Harlequin mutant mice (n=6 for 
each) and were probed with an N-terminal affinity purified anti-hPLCXD3 antibody, as 
described in Section 2.8.4. Cells immuno-positive for PLCXD3 (green; Figure 5.4A, B 
and C) were found in the ganglion cell layer (GCL) and the inner nuclear layer (INL), 
with a decrease in the numbers of PLCXD3 positive cells in Harlequin mutant mice. To 
further characterise the PLCXD3 positive cells, immunolocalisation was performed for 
a variety of cell type-specific markers, including Brn3A (retinal ganglion cells; red 
Figure 5.4B), calretinin (amacrine cells; red Figure 5.4A) and paralbumin (bipolar and 
retinal ganglion cells; Red Figure 5.4C). Antibodies for these markers were kindly 
provided by Dr Marisol Corrall-Debrinski. It clearly appeared that PLCXD3 (green) 
expression is found in amacrine cells specifically labelled with an antibody against the 
calcium-binding protein calretinin (red), within the INL and GCL (Figure 5.4A). PLCXD3 
positive cells were found to be negative for Brn3A and paralbumin (Figure 5.4B and C 
respectively). Elucidation of the immuno-localisation of PLCXD2 in retinal sections 
awaits antibody preparation. 
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Figure 5.4: Immunofluorescence analysis of retinas from control and Hq mice. (A, B, C) 
Immunostaining for PLCXD-3 (Green) and Calretinin (Red; A), BRN3A (Red; B) and Paralbumin 
(Red; C) in the retina from control mice aged 6 months; PLCXD-3 expression was restricted to 
the ganglion cell layer (GCL) and the inner nuclear layer (INL). Brn3A immunostaining has been 
reported as a reliable and simple method for identifying retinal ganglion cells (RGCs) in retinal 
cross sections; paralbum is specific for RGCs and bipolar cells; Calretinin is specific for amacrine 
cells. PLCXD-3 positive cells were also found to be positive for calretinin suggesting that PLCXD-
3 is confined to amacrine cells. Hq mice experienced a decrease in PLCXD-3 expression. In the 
control sections, a 3-fold zoom was included to better visualise potential co-localisations.  GCL, 
galnglion cell layer; IPL, Inner polar layer; INL, Inner nuclear layer; OPL, outer polar layer; ONL, 
outer nuclear layer.  
 
5.4. Discussion 
Harlequin (Hq) mutant mice represent a reliable genetic model for age-related 
neurodegeneration. Aging Hq mutant mice experience progressive retinal and 
cerebellar cell degeneration, which eventually leads to blindness (Bouaita et al., 2012). 
The Hq phenotype is caused by an ecotopic proviral insertion into intron 1 of the 
apoptosis-inducing factor (AIF) gene, resulting in a reduction in transcript and protein 
levels (Klein et al., 2002). Interestingly, AIF was first discovered as a caspase-
independent apoptotic effector, which in dying cells, relocates from the mitochondria 
to the nucleus where it is thought to mediate chromatin condensation and large-scale 
DNA fragmentation (Modjtahedi et al., 2006). Recent elucidation of the crystal 
structure of both murine and human AIF proteins reveals that, in addition to a DNA 
binding domain, AIF contains an oxidoreductase domain, with a similar fold to the 
eukaryotic glutathione reductase family of enzymes (Mate et al., 2002) New work has 
been conducted to shed light on the molecular mechanisms by which mutant AIF 
results in neurodegeneration. Klein et al., 2002 have shown that cerebellar granule 
cells and retinal neurons from Hq mutant mice are more susceptible to hydrogen 
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peroxide-mediated cell death than their wild-type counterparts, a response that can 
be rescued following retroviral transduction of wild-type AIF. The mechanisms 
underlying AIF-mediated protection from peroxide insult in neurons are as yet unclear, 
with scavenging of hydrogen peroxide or maintenance of normal mitochondrial 
respiration being proposed (Klein et al., 2002). 
Previously, we have shown mouse PLCXD isoform transcripts to be predominantly 
expressed in the brain, with expression also being detected in numerous other tissues 
including the eye. Given that the phenotypes associated with the Hq mouse mutant 
are mostly restricted to neurons within the cerebellum and retina, we were interested 
to further characterise the expressions of PLCXD isoforms in these tissues from both 
wild-type and mutant mice. Towards this aim, we examined the expression levels of 
PLCXD transcripts and protein in the cerebella and retinas of six wild-type and six Hq 
mutant mice. In the Hq mutant mice, PLCXD2 and 3 transcript levels in the retina were 
found to be 50-60% of their wild-type counterparts. Although protein samples from 
the retinas of wild-type and Hq mutant mice are currently unavailable, 
immunofluorescence suggested a reduction in PLCXD3-specific staining in retinal 
sections from Hq mutant mice. Although reductions in immunofluorescence were 
observed, this would need to be confirmed by quantitative immunofluorescent 
experiments.  Immunofluorescence revealed positive staining for PLCXD3 in the 
ganglionic cell layer (GCL) and the inner nuclear layer (INL) of the retina which, in most 
cases, also stained positive for the cholinergic amacrine cell-specific marker, calretinin. 
However, PLCXD3 positive staining did not fully co-localise with that of calretinin. 
Biochemical, histochemical and pharmacological studies suggest around 30 different 
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amacrine cell sub-types, to exist within the mouse retina (MacNeil et al., 1999; 
Kunzevitzky et al., 2013) and therefore PLCXD3 positive staining that did not co-localise 
with the calretinin marker, may represent the expression of PLCXD3 in more than one 
amacrine cell subtype. Alternatively, PLCXD3 may also be localised to retinal cells 
distinct from amacrine cells. Full elucidation of the localisation of PLCXD3 within the 
retina therefore requires further co-localisation experiments with various other cell-
specific markers. The transcript levels of PLCXD1 were undetectable in our assay 
conditions suggesting that this isoform is expressed at very low levels. Future 
experiments could aim to convert a higher concentration of mouse retinal RNA to 
cDNA in an attempt to obtain a detectable signal for PLCXD1.  
In the cerebellum of Hq mutant mice, the transcript levels of PLCXD2 and 3 isoforms 
were expressed at similar levels to that of wild-type mice. Interestingly, western blot 
analysis showed a complete disappearance of the expression of PLCXD3 protein 
expression in the cerebellum of Hq mutant mice. Very often mRNA changes are 
reflected in protein levels; however it appears that in this case the two parameters 
change independently. Therefore for PLCXD3, results suggest that there is a decrease 
in protein expression within the cerebellum of Hq mutant mice, which is due to as yet 
uncharacterised post-transcriptional changes, potentially affecting either mRNA 
transport and/or translation efficiency. 
In summary, we have demonstrated specific and significant decreases in mRNA 
expression of PLCXD2 and 3, and although no absolute quantitative studies have been 
carried out, preliminary immunofluorescence suggests a reduction in the number of 
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cells within the retina of Hq mutant mice that express PLCXD3 protein.  Additionally, 
western blot analyses indicates a > 99% fall in PLCXD3 protein levels in the cerebellum 
of Hq mutant mice. Retinal and cerebellar neurons of Hq mutant mice have reduced 
AIF1 and AIF2 levels and this is thought to predispose these cells to peroxide-mediated 
cell death. Furthermore, these cells could be rescued by retroviral transfection with 
AIF cDNA (Klein et al., 2002). How AIF can act to reduce oxidative stress in vivo is 
currently unknown.  Oxidative stress is thought to lead to neurodegeneration by 
inducing abnormal cell cycle re-entry in terminally differentiated neurons by an 
unknown mechanism. Further investigations into the role of PLCXDs in Hq pathologies 
are now needed to clarify the association between the disease phenotype and changes 
to PLCXD mRNA and protein expression. It would be interesting to determine whether 
PLCXD mRNA and protein levels are influenced by oxidative stress within neurons. This 
might be tested by RT-qPCR and western blotting analysis of primary neuron cultures 
in the presence and absence of chemically induced oxidative stress. More work is also 
required to establish whether a decrease in the levels of PLCXDs mRNA and/or protein 
are associated with the mechanisms underlying oxidative stress-induced aberrant cell 
cycle re-entry.  
In further support of a potential role for PLCXDs in neurodegeneration, three intronic 
SNPs in the PLCXD3 gene have recently been shown to be associated with increased 
risk of variant Creutzfeld-Jakob disease (CJD) (Bishop et al., 2013). Sequencing 
revealed that these SNPs were found at the junction of intron 1 and exon 2, close to 
the splice site motifs (Bishop et al., 2013). Interestingly, exon 2 encodes the X-domain 
of PLCXD3, including the two putative catalytic histidine residues. Whether the 
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presence of these SNPs in PLCXD3 alters the functioning of the spliceosome between 
intron 1 and exon 2, and therefore the expression and activity of PLCXD3 is currently 
unknown. Future experiments should measure both mRNA and protein levels of 
PLCXD3 in postmortem specimens from persons with CJD. Similarly with Hq mutant 
mice, the association of oxidative stress and abnormal cycle progression has been 
reported in various human neurodegenerative disorders, including Alzheimers disease 
(AD; Klein and Ackerman, 2003). Studies of AD found many cell cycle regulators to be 
expressed in terminally differentiated neurons of affected regions, which led to DNA 
replication and subsequent progression to apoptosis and not mitosis (Nagy et al., 
1998). Whether the accumulation of PrPSc causes abnormal cell cycle re-entry in 
terminally differentiated neurons is yet to be established. It would be interesting to 
test whether PLCXD mRNA and protein levels are altered in post-mortem specimens 
from persons with AD and other common neurodegenerative diseases.  
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Chapter 6: Recombinant expression, purification and 
characterisation of human PLCXD1, 2 and 3 
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6.1. Introduction 
As highlighted in Chapter 1, eukaryotic PI-PLCs play a central role in most signal 
transduction cascades through the regulated hydrolysis of PtdIns(4,5)P2 producing the 
IP3 and DAG second messengers which are responsible for Ca2+-mobilisation and 
protein kinase C-activation. By altering membrane levels of PtdIns(4,5)P2, PI-PLC 
enzymes are also known to affect the membrane association and activities of many 
other signalling proteins (Chapter 1, Section 1.3.2.) In contrast, bacterial PI-PLCs have 
much smaller molecular masses (30-35 kDa), consisting of only an X-domain, and are 
known to hydrolyse phosphatidylinositol (PI). From the crystal structures of rat PLCδ1 
and B. cereus PI-PLCs, it is possible that both mammalian and bacterial PI-PLCs have a 
similar catalytic mechanism, characterised by general acid general base catalysis. Two 
active site histidine residues (His32 and His 82 in B. cereus; His311 and His356 in PLCδ1) 
are strictly conserved in all catalytically active PI-PLCs. A striking difference between 
mammalian and bacterial PI-PLCs is the utilisation of calcium within the active site 
(Section 1.4.3.1.). In  the calcium-independent bacterial PI-PLCs, Arg69 functions 
analogously to that of Ca2+ in the mammalian PI-PLCs (Section 1.4.3.1). This difference 
in calcium dependency is thought to underlie the fact that bacterial enzymes only 
complete the first step in catalysis and produce mainly the cyclic product, Ins(1:2cyc)P; 
mammalian PI-PLCs mainly produce both cyclic and acyclic inositol phosphates. 
Based on the primary amino acid sequences, all cloned hPLCXD isoforms show features 
typical of PI-PLC enzymes and contain the two conserved His residues. In addition, 
similarly with bacterial PI-PLCs, hPLCXD isoforms have an arginine residue analogously 
positioned with Arg69 from B. cereus. Although bacterial and other mammalian PI-PLC 
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enzymes have undergone numerous biochemical and structural studies, no data exists 
describing the basic molecular functions of hPLCXD isoforms. Towards this aim, we 
have cloned full-length versions of hPLCXD1, 2.1 and 3 isoforms and expressed them 
as recombinant proteins in E.coli. This chapter describes initial attempts to express 
hPLCXDs as recombinant protein in E. coli for protein purification and subsequent 
biochemical and structural characterisation. 
6.2. RT-PCR amplification of human PLCXD1, 2 and 3 and sub-cloning to expression 
vectors 
In-order to express PLCXD proteins for biochemical and structural studies, large 
amounts of purified protein must be generated. Towards this aim, the nucleotide 
sequences of the coding regions of human PLCXD1, 2 and 3 were amplified from cDNA 
prepared from HeLa cells using standard PCR protocols (Chapter 2, Section 2.7.6.). For 
PLCXD1 and 3, the primers used were designed to create an NcoI and a HindIII site 5’ 
and 3’ to the initiation and termination codons, respectively, whereas primers used 
for PLCXD2.1 contained the restriction sites NdeI (sense primer) and HindIII (antisense 
primer). A table of primers is shown in Appendix C. As shown in Figure 6.1, the 
amplified products were all approximately 1kbp is length, which is in accordance with 
the length of the PLCXD1, 2 and 3 coding regions (971, 914 and 965bp respectively). 
These PCR fragments were purified and subsequently digested with the appropriate 
restriction enzymes allowing for insertion into the appropriate expression vector- pET 
M11 for PLCXDs 1 and 3; pET 22b+ for PLCXD2 (See Chapter 2, Section 2.6 for vector 
maps). The resulting constructs were used to transform TOP10 cells, as decribed in 
Chapter 2, Section 2.2.4. A number of colonies were selected and colony PCR was 
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carried out to check for the presence of each gene insert. A fragment of ~1200 bp was 
amplified using vector-specific sense and antisense primers (Figure 6.2; See Appendix 
E for primer sequences). Three colonies were selected for each PLCXD isoform, their 
plasmids purified and the sequence of the insert confirmed as described in Chapter 2, 
Section 2.6.9, using vector-specific primer sequences.  
 
 
 
 
 
 
Figure 6.1: Gel electrophoresis of PCR products following amplification of PLCXD1, 2 
and 3 using gene-specific primers. Total RNA was extracted from HeLa cells and 
converted to cDNA, which was used as a template in the amplifications. A 1kb DNA 
ladder molecular marker (NEB) was used for size estimation. 
 
 
 
 
Figure 6.2: Gel electrophoresis of colony PCR products amplified using vector-specific 
sense and anti-sense primers (pETM11 A/AS and pET22b+ S/AS; Appendix E). PLCXD1 
and 3 were inserted into the pET M-11 vector whereas PLCXD2 was inserted to pET 
22b+. A 100 bp DNA ladder molecular marker (M; NEB) was used for size estimation. 
1 kb ladder 
100bp ladder 
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6.3. Recombinant over-expression of hPLCXDs 1, 2 and 3 in E.coli 
Sequence-confirmed expression vector constructs for hPLCXDs 1, 2 or 3 were used to 
transform the E.coli expression host, Rossetta (DE3) pLys S (See Chapter 2, Table 2.1 
for more details). Initial expression trials for PLCXD1, 2 and 3 were conducted on a 
small scale (50 mL cultures) in order to assess the extent of induction and solubility of 
each PLCXD isoform when expressed as a recombinant protein in E.coli (Chapter 2, 
Section 2.2.5.1). Recombinant proteins were expressed following addition of 1 mM 
IPTG and the growth of cells at 37 °C for 4 hours (Chapter 2, Section 2.2.5.1.) Following 
induction of protein expression by addition of IPTG, bacterial cells were harvested and 
lysed using standard methods (Chapter 2, Section 2.8.6), and samples taken from the 
total lysate and the soluble extract. Equal amounts of protein (10 µg) from the total 
lysate and soluble extract fractions were separated and analysed by SDS-PAGE gel 
electrophoresis (as described in Section 2.8.3) and protein bands detected following 
Coomassie blue staining (as described Section 2.8.4) For hPLCXDs 1, 2 and 3, bands of 
the expected size (39.7, 37.8 and 39.4 kDa respectively) corresponding to (His)6-tagged 
versions of the protein of interest, were present in the total lysates of Rosetta cells 
following induction at 37 °C for 4 hours. In each case, however, no soluble expression 
was observed for hPLCXDs 1 and 2, and only limited soluble expression was observed 
for hPLCXD3 (Figure 6.3). In an attempt to optimise protein solubility, the induction of 
protein expression was conducted at a lower temperature of 25 °C and induction time 
was increased to 20 hours. Additionally, the resulting solubilities of expressed hPLCXDs 
1, 2 and 3 were determined following induction with the lower IPTG concentrations of 
0.5 mM and 0.2 mM. No improvements in the solubility of hPLCXD1, 2 and 3 were seen 
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either using lower IPTG concentrations or reduced induction temperatures (data not 
shown). The best soluble expression was seen with hPLCXD3 when induced with 1 mM 
IPTG at 37 °C for 3 hours in both E. coli strains and therefore this condition was chosen 
for scale-up purification. Further optimisation of hPLCXD1 and 2 inductions is required 
to enable reasonable scale-up purification experiments.
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Figure 6.3: SDS-PAGE analysis of recombinant expression of PLCXD1, 2 and 3 in E.coli cells. Total protein was extracted from E.coli prior 
to (non-induced; NI) and following induction of protein expression with IPTG at 37 °C for 4 hours. Protein samples in the total lysate (TL) 
of cells extracted following induction of protein expression were subsequently centrifuged to yield a soluble fraction (soluble extract; 
SE). 10 µg of protein was loaded into each lane and proteins were detected with Coomassie blue. Protein bands for PLCXD1, 2 and 3 
represent His-tagged versions. Similar results were obtained when human PLCXDs were expressed in Rosetta and C41 cells, with protein 
induction at 37 °C or 25 °C for 4 hours and 20 hours, respectively.  Western blotting analysis revealed  consistent results (data not 
shown).
KD 
KD 
KD 
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6.4. Scale-up purification of human PLCXD3 
The recombinant hPLCXD3 protein expression was scaled-up to a 30 litre culture using 
standard methods as detailed Chapter 2, Section 2.2.5.2. Bacterial cell pellets 
containing hPLCXD3 were harvested, pooled and re-suspended to homogeneity in lysis 
buffer containing a DNAse and EDTA-free protease inhibitor cocktail (Chapter 2, 
Section 2.8.6). Proteins were then extracted and (His)6-tagged hPLCXD3 was purified 
using nickel chromatography (Chapter 2, Section 2.8.6.). hPLCXD3 bound to the 
column was eluted using an imidazole gradient and fractions containing hPLCXD3 
identified by SDS-PAGE (Figure 6.4A). A protein of around 40 kDa was displaced from 
the Ni2+ column at 60 mM imidazole, corresponding to (His)6-tagged hPLCXD3. Samples 
containing the 40 kDa band were pooled and subsequently dialysed against two 
changes of lysis buffer to remove any extra imidazole. In-order to remove the (His)6-
tag from hPLCXD3, TEV was added to the dialysis tube containing (His)6-tagged PLCXD3 
(1 µg protease for 1 mg) and digestion was conducted overnight at 4°C (Chapter 2, 
Section 2.8.7.) Following dialysis and TEV digestion, the pooled eluate fraction was 
loaded onto the Ni2+ column, as before, and the flow-through was collected and 
analysed by SDS-PAGE (Figure 6.4B). A protein band of 35 kDa was detected which 
corresponds to hPLCXD3 devoid of the (His)6-tag. The flow-through was subsequently 
dialysed, concentrated to 3 ml and then loaded onto a gel filtration column. 
Corresponding fractions containing hPLCXD3 were identified and confirmed by SDS-
PAGE analysis (Figure 6.4D). A major protein band corresponding to the expected size 
of hPLCXD3 and two additional bands at 30 and 25 kDa were detected by SDS-PAGE 
analysis (Figure 6.4 C).  Fractions containing PLCXD3 were pooled and concentrated to 
10 mg/mL, aliquoted, flash frozen and then stored at -80°C 
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(A)                                                                                           (B)                                     (C)  
 
 
 
 
 
 
 
 
Figure 6.4: Expression and purification of human PLCXD3 protein using Ni2+ affinity chromatography and AKTA technology. (A) Comassie-
stained SDS-PAGE gel of the proteins present in various fractions following elution of the the first Ni2+ column with different concentrations 
of imidazole; M, molecular marker. (B) TEV cleavage of His-tagged PLCXD3. Uncut lane, dialysed eluted protein from first Ni2+ -affinity column; 
Cut lane, flow-through of the second Ni2+ -affinity column following TEV digested sample of PLCXD-3. (C) Comassia-stained SDS-PAGE gel of 
the eluted proteins following gel filtration chromatography of the dialysed TEV digested fractions. 
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6.5. Pk/V5-tag co-immunoprecipitation (co-IP) of human PLCXD3 from HeLa 
HeLa cell lines stably expressing N-terminal Pk/V5-tagged versions of PLCXD3 were 
previously created in collaboration with Dr Svetlana Kalujnaia using a lentivirus based-
transfection approach (Chapter 2, Section 2.3.4.). For co-IP assays, wild-type (control; 
non-transfected) and hPLCXD3 transfected cells were grown and maintained in 4 x 75 
cm2 culture flasks, according to Sections 2.3.1 and 2.8.9. The anti-Pk/V5 antibody 
(Chapter 2, Table 2.5) was immobilised to Protein G sepharose resin, using a standard 
cross-linking protocol (Section 2.8.9). Pooled lysates were then prepared for each 
condition and 0.5 mg of cleared lysate was used for co-IP assays (Section 2.7.8.). The 
cross-linked antibody-resin slurry was then incubated with the cleared cell lysate, as 
described in Section 2.8.9. Following extensive washing, bound proteins were eluted 
from the resin into three 30 µL fractions using a glycine buffer of pH 2 (Section 2.7.8) 
and the eluates were immediately neutralised (Section 2.8.9) and tested for the 
presence of hPLCXD3 by western blotting analyses (Figure 6.5) using a rabbit anti-
hPLCXD3 primary antibody and a donkey anti-rabbit AP-conjugated secondary 
antibody (Chapter 2, Table 2.5). A band of around 38 kDa corresponding to the 
expected size of Pk-tagged hPLCXD3 was obtained in each eluate of HeLa cells 
transfected with hPLCXD3. These bands were absent from control, non-transfected 
cells (Figure 6.5).  
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Figure 6.5: Co-immunoprecipitation (co-IP) of hPLCXD3 from HeLa. Cells stably 
overexpressing PLCXD3 were created as described in Chapter 2, Section 2.2.4. Anti-
Pk/V5-tag antibody was conjugated to Protein G-sepharose resin, as described in 
Chapter 2, Section 2.2.4. Antibody-conjugated resin was then used to purify Pk/V5-
tagged hPLCXD3 from total cell lysates prepared from transfected HeLa cells, as 
previously described. Bound protein was eluted from the resin with a glycine buffer of 
pH 2.0 and the samples were neutralised and samples prepared for Western blotting, 
as described previously.  Western blotting was performed with an anti-PLCXD3 
primary antibody raised against the N-terminus of the protein and a donkey anti-rabbit 
alkaline phosphatase-conjugated secondary antibody (Abcam). This image is 
representative of 3 separate experiments. 
 
6.6. Interaction of purified hPLCXD3 with lipids 
Mammalian PI-PLCs are known to hydrolyse PI(4,5)P2 forming I(3,4,5)P3 and 
diacylglycerol (DAG), whereas bacterial PI-PLCs are known to hydrolyse 
phosphatidylinositol to cyclic inositol phosphate and DAG. The ability of hPLCXD3 
purified from E.coli and HeLa cells to hydrolyse soluble homologues of PI and PI(4,5)P2 
(diC4 PI and diC8 PI(4,5)P2 respectively) was tested by 31P NMR (Chapter 2, Section 
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2.8.12). For both phosphatidylinositol (PI) and PI(4,5)P2 the NMR signal spectrum of 
the phosphate group at position 1 in the inositol ring was monitored before and after 
the addition of either recombinant hPLCXD3 purified from E.coli (Chapter 6, Section 
6.4) or hPLCXD3 immunoprecipitated from HeLa cells (Chapter 6, Section 6.5), as 
detailed in the methods section (Chapter 2, Section 2.8.12). No changes in the 
chemical shifts patterns were seen following addition of 1 µg of hPLCXD3 purified by 
either of the above methods (Figure 6.7). Expected chemical shifts were observed 
following incubation of diC4 PI with 1 µg of PI-PLC commercially purified from B. cereus 
(Figure 6.6). 
To investigate whether a direct interaction of membrane lipids with human hPLCXD3 
could occur, hPLCXD3 purified from E. coli (Section 6.4 above) was used as a probe in 
a protein lipid overlay assay with a membrane lipid strip (Echelon) containing 15 
different spotted lipids (Chapter 2, Section 2.8.11). Following detection with hPLCXD3-
specific antibody, hPLCXD3 was seen to bind with varying extents to spots containing 
PI(3,4,5)P3, PI(4,5)P2, phosphatidic acid (PA), PI(3,5)P2 and PI(3,4)P2 (Figure 6.7 B). 
Control membrane strips incubated in the absence of hPLCXD3 resulted in low signals 
only with PA, indicating that the anti-hPLCXD3 primary and/or the anti-rabbit 
secondary antibodies displayed a slight non-specific interaction with this lipid.  
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Figure 6.6: 31P-NMR studies were performed to assess whether hPLCXD3 could 
hydrolyse short chain (diC8) PI and/or PIP2. Both hPLCXD-3 purified from E.coli and 
insect cells were tested (A) and PI-PLC purified from B.cereus (B). 500 µg of substrate 
and 1 µg purified from either E.coli or insect cells were used in each assay.  
 
 
 
    Phosphatidylinositol 
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Figure 6.7: 31P-NMR studies were performed to assess whether hPLCXD3 could hydrolyse short chain (diC8) PI and/or PIP2. Both 
hPLCXD-3 purified from E.coli and insect cells were tested (A) and PI-PLC purified from B.cereus (B). 500 µg of substrate and 1 µg 
purified from either E.coli or insect cells were used in each assay.  
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Figure 6.8: Overlay assay with hPLCXD3 incubated with membranes spotted with 100 
pmol of the phospholipids indicated (Lipid strips). Proteins were expressed in E.coli 
and purified by Ni2+ -affinity chromatography. Lipid strips were incubated with 100 
pmol of the recombinant protein overnight at 4 °C as detailed under “Experimental 
Procedures.” After washing, PLCXD3 was visualised using the polyclonal N-terminal 
anti-PLCXD3 antibody. (A), shows a schematic diagram of phospholipids impregnated 
on each individual PIP strip. (B), shows binding of the recombinant protein to the 
various lipids (100 pmol/spot). (C) represents the negative control PIP strip following 
incubation in the absence of recombinant protein.  
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6.7. Crystallisation and optimisation of hPLCXD3 
 
For crystallisation trials, a total of six different crystal screens were set up with the two 
concentrations (5 mg/mL and 10 mg/mL) of the recombinant protein. Crystal plates 
were set up using a nano-drop crystallisation robot, with 300 nL of buffer and 300 nL 
of protein per drop (Chapter 2, Section 2.8.13). A number of commercially available 
crystal screens were used to test the conditions required for crystal formation (See 
section 2.8.13). A single hit was obtained in the JCSG+ screen using 10 mg/mL of 
protein (Figure 6.8). hPLCXD3 protein crystals were picked, cryoprotected and exposed 
to X-rays at 100K, according to Section 2.7.13. The crystals diffracted X-rays to a low 
resolution of 10 A.  In an attempt to gain better quality crystals, the conditions that 
produced the initial crystal (above) were further optimised by varying the 
concentration of salt and proteins and also varying the type and amount of each 
precipitant used. Further optimisation did not yield crystals of sufficient quality for 
structure determination. 
 
 
 
 
 
Figure 6.9: Showing protein crystals obtained with hPLCXD3 purified from E. coli 
(Section 6.4; described above). Crystal plates were set-up according to Chapter 2, 
Section 2.7.12 using 150 nL of 10 mg/mL purified hPLCXD3. The crystals above were 
obtained following 1 days of incubation at room temperature. 
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6.8. Discussion 
6.8.1. Recombinant over- expression of hPLCXDs 1, 2 and 3 in E.coli 
Although high levels of hPLCXDs 1, 2 and 3 were found in the whole lysates of induced 
cells, the levels of soluble proteins were poor, with only hPLCXD3 showing any sign of 
soluble expression. The efficiency of recombinant protein expression in a bacterial 
host organism like E. coli depends on numerous parameters. Important factors 
associated with recombinant protein expression include the expression vector used 
for gene cloning (including the type of promoter used) as well as other factors linked 
to the nucleotide and amino acid sequence of the protein of interest (including mRNA 
and protein stability). Given that these parameters are predefined by the choice of the 
expression vector and the hPLCXD sequences, initial attempts to optimise soluble 
recombinant protein expression of hPLCXDs 1, 2 and 3 were performed by varying 
parameters affecting E. coli cell growth (growth/induction temperatures). Induction of 
the expression of hPLCXDs 1, 2 and 3 at a lower temperature and reducing the IPTG 
concentration failed to increase the solubility of any hPLCXD isoform. It is therefore 
clear that further optimisation of the recombinant expression of hPLCXD1, 2 and 3 is 
required, details of which are detailed in Chapter 6. 
The best soluble expression of the hPLCXD isoforms in E. coli was seen with hPLCXD3, 
which was therefore chosen for scale-up purification. In-order to gain enough soluble 
protein to enable structure determination by X-ray crystallography, a 30 litre E. coli 
culture expressing hPLCXD3 was grown. Standard affinity chromatography using nickel 
columns and gel filtration mainly yielded a single band of 35 kDa on SDS-PAGE. 
Additionally, hPLCXD3 purification contained minor contaminants which were 
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subsequently found by mass spectrometry to be polypeptides of 25 and 20 kDa 
molecular mass derived from the 35 kDa hPLCXD3. These degradation products were 
present at each stage during the purification process and may be due to the instability 
of hPLCXD3 and/or insufficient inhibition of the bacterial proteases. Fractions 
containing the 35 kDa hPLCXD3 enzyme were pooled together and concentrated to 10 
mg/mL. 
6.8.2. Interaction of purified hPLCXD3 with lipids 
The potential activity of PLCXD3 as a functional phospholipase C was tested in vitro 
using a phosphorus-based NMR assay. Whereas expected chemical shifts, indicative of 
phospholipase C activity, were observed for commercially purified B. cereus PI-PLC 
enzyme, no phospholipase C activity was observed for hPLCXD3 purified from E. coli 
or HeLa cells with either PI or PtdIns(4,5)P2 as the substrate. Due to expected chemical 
shifts being observed with PI-PLC purified from B. cereus, we believe the NMR assay 
used to be an appropriate test for phospholipase C activity. One interpretation of the 
results is that hPLCXD3 has no endogenous phosphodiesterase activity, at least to the 
substrates, PI and PIP2. Alternatively, the observed results may suggest that hPLCXD3 
can hydrolyse a substrate other than PI or PtdIns(4,5)P2. Indeed, phospholipase C 
enzymes with substrate specificity for phosphatidylcholine (PC) have been identified 
in both bacterial and mammalian cells, however they exhibit low homologies and 
different domain structures when compared with hPLCXD3 and therefore PC-specific 
activity seems unlikely for hPLCXD3. Given that hPLCXD3 enzymes purified from two 
different sources both failed to show any phospholipase C activity, we believe that the 
lack of enzyme activity is not an artefact of the purification procedure, however this 
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cannot be fully ruled out until recombinant hPLCXD3 is successfully purified from 
further sources. 
Enzymes that act on substrates such as lipid membranes often interact with more than 
one lipid substrate molecule. The enzymatic activity of the PI-PLC isolated from 
B.cereus has been shown to increase in the presence of organised lipid substrates, such 
as bilayers and micelles, containing certain phospholipids (Volwerk et al. 1994; Wehbi 
et al. 2003). Indeed numerous studies have demonstrated activation of mammalian 
PLC-δ1 and PLC-β1 following presentation of their substrate within a micelle or bilayer 
(Boguslavsky et al. 1994). Therefore, like other PI-PLCs, hPLCXD3 may exhibit 
interfacial catalysis in the presence of other, as yet unknown lipids, acting through 
allosteric means, required for enzyme activation. Evidence for the ability of hPLCXD3 
to associate with phospholipids in a non-catalytic manner was obtained following a 
lipid overlay assay. The hPLCXD3 enzyme purified from E. coli was able to interact with 
the poly-phosphorylated phosphoinositides PI(3,4,5)P3, PI(4,5)P2, PI(3,5)P2 and 
PI(3,4)P2.. A slight interaction was also seen with PA; however this was also observed 
in the negative control assay and therefore possibly indicates cross-reaction of the 
hPLCXD3 antibody with PA. Both mammalian and bacterial PI-PLC isozymes have been 
shown to interact with various non-substrate phospholipids and these interactions 
have been shown to be important for the regulation of sub-cellular localisation and 
enzymatic activity. The signalling phospholipid, PA, has been shown to bind to and 
stimulate PLC-β1 through a mechanism involving the C-terminal domain of PLC-β1 
(Ross et al. 2006). For PI-PLC isolated from the virulent bacteria B. thuringiensis, 
vesicles containing PI and PC displayed enhanced hydrolysis of PI compared with 
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vesicles containing only PI. PC is thought to allosterically bind and activate PI-PLC by 
helping the enzyme anchor to the membrane in a more active conformation (Zhou et 
al. 1997; Qian et al. 1998). The observed lipid binding specificities of hPLCXD3 may 
indicate that the catalytic function of the enzyme requires allosteric activation from 
non-substrate phospholipids and may explain the lack of enzyme activity observed in 
previous NMR studies. The ability of hPLCXD3 to hydrolyse PI and PtdIns(4,5)P2 when 
presented in mixed micelles containing different phosphoinositides requires future 
investigation. The amino acid residues involved in PLCXD3 lipid binding are yet to be 
characterised. Lipid hydrolysis and binding specificities for PLCXD1 and 2 awaits 
recombinant expression optimisation, as detailed in Chapter 7. 
6.8.3. Crystallisation 
Important discoveries have been made concerning the functional characterisation of 
eukaryotic and prokaryotic PI-PLC family members that include the crystal structures 
of the B. cereus (Heinz et al. 1995), B. thuringiensis (Shao et al. 2007) PI-PLCs and 
mammalian PLC-δ1 (Essen et al. 1996). Comparison of the crystal structures shows that 
prokaryotic PI-PLCs to be structurally similar to the X-domain of eukaryotic PI-PLCs in 
that both enzymes containing a distorted (βα8)-barrel structural motif, with a 
particularly large similarity for the first half of the barrel, in which all the catalytic 
residues, including two essential histidine residues, are located. The fact that 
eukaryotic enzymes, but not prokaryotic PI-PLCs require Ca2+ is explained by the 
observations that, in the bacterial enzymes, an arginine residue occupies a location 
close to that of the Ca2+ cofactor in the eukaryotic enzymes. Significant advances on 
the interactions of these enzymes with both substrate and non-substrate lipids have 
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been made and these have been described in the previous section. Given the 
conserved nature of PI-PLC family members, derivation of the crystal structure of 
human PLCXDs and subsequent comparative analysis from bacteria to man would 
really give some idea of the functions of these proteins. 
In this chapter, we describe the initial attempts to obtain the crystal structure of 
human PLCXD3. Although positive hits were obtained for hPLCXD-3 with one of the 
crystallisation conditions tested, these crystals diffracted at an insufficient resolution 
for further structure determination. Additionally, crystals were obtained following 
optimisation of the initial crystallisation condition through variation in the 
concentration of hPLCXD3, precipitant and the salt; however, as with previous crystals, 
they diffracted to an insufficient resolution. Producing protein crystals suitable for 
structure determination is often a challenging task, which benefits from high-
throughput screening to identify initial positive crystallisation conditions with further 
optimisation often required. Attempts to gain diffraction quality hPLCXD3 crystals 
appear to be challenging and further optimisation is clearly required. Furthermore, 
given that the purified fraction of hPLCXD3 was not homogeneous, with the presence 
of breakdown products, further optimisation of protein expression and purification 
protocols to gain soluble homogeneous protein may help to obtained crystals suitable 
for structure determination. With the aim of obtaining crystals suitable for structure 
determination, attempts to further optimise the expression of human PLCXDs in 
different host organisms have been made and are described in the next chapter. 
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CHAPTER 7: Small-scale recombinant expression screen of 
human PLCXD1, 2 and 3 isoforms using the pOPIN vectors 
in different host organisms 
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7.1. Introduction 
E. coli has been utilised as the expression system of choice by many laboratories 
involved in the production and purification of proteins for structural genomics. Many 
advantages are associated with the use of E. coli as an expression host including its 
well-known physiology, ease of genetic manipulation with advanced genetic tools, 
rapid growth and high-levels of recombinant protein production achieving up to ~30% 
of total cellular proteins (Baneyx 1999). The main disadvantage, particularly for 
eukaryotic proteins, is the tendancy for mis-folding and aggregation into inclusion 
bodies as a result of lack of eukaryotic chaperones, specialised post-translational 
modifications and/or ability to form complexes with stabilising binding partners 
(Hannig and Makrides 1998). In recent years, other expression systems, utilising 
different host cells including the baculovirus-insect cell and HEK cell expression 
systems, have been used for the production of recombinant eukaryotic proteins. The 
expression of eukaryotic chaperones, existence of post-translational modification 
pathways and ability to target proteins to sub-cellular localisations are among the 
many advantages of the use of these expression systems for the recombinant 
production of eukaryotic proteins (Nettleship et al., 2010). In addition, the level of 
soluble expression of a target protein can also be altered by the addition of an N- or 
C-terminal fusion protein, such as maltose-binding protein (MBP), thioredoxin (Trx) 
and glutathione S-transferase (GST; Nettleship et al., 2010).  
Previous attempts to express hPLCXD1, 2.1 and 3 isoforms as recombinant proteins in 
E.coli resulted in little soluble expression due to the aggregation of the highly 
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expressed proteins into inclusion bodies. Several strategies to enhance the folding of 
hPLCXD1, 2.1 and 3 into a native state in E.coli were tested, including lowering the 
temperature during induction or inducing expression with lower concentrations of 
IPTG, but these strategies proved unsuccessful (Chapter 6). It was therefore clear that 
further optimisation of hPLCXD1, 2.1 and 3 recombinant expression was required. The 
Oxford Protein Production Facility (OPPF) provides specialist facilities and knowledge 
for high-throughput cloning, expression in different host organisms and purification of 
target proteins for crystallography. To enable the optimisation of protein expression 
and solubility, the OPPF uses the pOPIN vector suite, which allows expression of a 
target protein with a number of different fusion tags (Chapter 2, Figure 2.5) and in 
multiple host organisms (E. coli, mammalian cells (HEK293T cells) and insect cells (Sf9 
cells)). This chapter details the high-throughput screen that was carried out at the 
OPPF to test the levels of soluble expression of recombinant PLCXD1, 2.1 and 3 when 
expressed as different fusion proteins (Chapter 2, Figure 2.5) in E. coli, HEK293T and 
Sf9 insect cells. 
7.2. InFusion cloning of human PLCXD1, 2.1 and 3 to the pOPIN expression vectors 
A total of 10 pOPIN vectors (Chapter 2, Figure 2.5) were used to create expression 
constructs for each hPLCXD isoform. To do this, the full-length coding sequences of 
hPLCXDs 1, 2.1 and 3 were amplified from a HeLa cDNA library (Created by Dr Svetlana 
Kalujnaia) using forward and reverse primers containing appropriate nucleotide 
extensions for InFusion cloning to the pOPIN vector suite (Chapter 2, Section 2.7.10.2). 
Primer sequences are detailed in Appendix C. A total of 10 amplifications were 
performed for each PLCXD gene using the KOD Hot start DNA polymerase (Chapter 2, 
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Section 2.7.6) and the products were analysed by gel electrophoresis. As shown in 
Figure 7.1, a PCR product of the expected size was obtained for PLCXDs 1 and 3, and 
almost all of the PLCXD2.1 amplifications. No PCR product for PLCXD2.1 was observed 
when amplified with primers containing extension for insertion to the pOPINM vector 
(lane 5).  
 
 
    
 
 
Figure 7.1: Gel electrophoresis analysis of PCR products following amplification of 
human PLCXDs 1, 2 and 3 with primers containing extensions for subsequent insertion 
into different expression vectors (1- pOPINF, 2- pOPINS3C, 3- pOPINNUSA, 4- 
pOPINMYSB, 5- pOPINM, 6- pOPINTF, 7- pOPINTRX, 8- pOPINHALO7, 9- pOPINE Neo, 
10- pOPIN- 3C- HALO7. M denotes molecular size marker. 
 
The PCR products were then purified using AMPure XP Magnetic beads, according to 
Chapter 2, Section 2.7.10.2. The purified PCR products were then inserted into 10 
different pOPIN expression vectors using the InFusion cloning method (Chapter 2, 
Section 2.7.10.2) and the expression constructs were transformed into OmniMaxII E. 
coli cells and grown on agar plates containing X-Gal for blue/white colony screening, 
as described in Section 2.7.10.2. Two white colonies were selected for each construct 
and grown for plasmid preparation, according to Chapter 2 Section 2.7.10.2. The 
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purified expression constructs were then used to express different fusion versions of 
PLCXD1, 2.1 and 3 in E.coli, HEK293 and Sf9 insect cells. 
7.3. Expression trials of hPLCXD1, 2.1 and 3 in E. coli 
The resultant 10 pOPIN expression vector constructs, made for each PLCXD isoform, 
were transformed into two different host strains - Rosetta (DE3) and Lemo 21 - and 
protein expression was induced by two expression regimes in 3 mL shaking cultures 
(Chapter 2, Section 2.2.5.1) giving rise to 40 samples for each hPLCXD isoform. 
Bacterial pellets were harvested and recombinant (His)6-tagged proteins were purified 
using magnetic nickel beads, according to Section 2.8.10. The level of soluble protein 
expression was assessed by visual inspection of SDS-PAGE gels of purified proteins and 
is shown in Figures 7.2, 7.3 and 7.4. The expected molecular sizes of the different 
fusion proteins are detailed in the Table 7.1. For each hPLCXD, little to no protein was 
purified when the expressed construct contained an N- terminal (His)6-tag, under any 
of the test conditions. However, with the exception of hPLCXD2.1, at least one fusion 
tag was found to increase the apparent solubility of the proteins when expressed in E. 
coli. For hPLCXD1, although limited success was experienced with most fusion 
constructs, the addition of an N-terminal trigger factor (TF) fusion tag  to the full-length 
protein gave the best soluble expression when expressed in Rosetta (DE3) cells using 
the auto induction method (Chapter 2, Section 2.2.5.1); however this was not 
consistent across the different expression conditions (Figure 7.2). For hPLCXD3, 
expression of the protein with a C-terminal (His)6-histidine tag increased solubility, 
however no soluble expression was seen with an N-terminal HIS6- histidine tag (Figure 
7.3). Additionally, expression of hPLCXD3 with either an N-terminal small ubiquitin-like 
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modifier (SUMO) or thioredoxin (TRX) fusion tag, also gave an increase in solubility, 
however only when expressed in the Lemo 21 host with IPTG induction. When the 
same constructs were expressed in Lemo 21 cells with auto-induction, only the SUMO 
fusion tag was seen to increase solubility (Figure 7.4).  
 
 PLCXD1 (kDa) PLCXD2.1 (kDa) PLCXD3 (kDa) 
(His)6-3C (Lane 1) 38.8 36.9 38.5 
(His)6-SUMO-3C 
(Lane 2) 
50.4 48.5 50.0 
(His)6-NUSA-3C 
(Lane 3) 
93.7 91.8 93.3 
(His)6-MSYB-3C 
(Lane 4) 
53.2 51.3 52.8 
(His)6-MBP-3C (Lane 
5) 
82.2 80.3 81.8 
(His)6-TF-3C (Lane 6) 87.0 85.1 86.7 
(His)6-TRX-3C (Lane 
7) 
50.8 48.9 50.5 
(His)6-HALO-3C 
(Lane 8) 
71.8 69.9 71.5 
3C-(His)6 (Lane 9) 38.8 36.9 38.5 
3C-HALO7-(His)6 
(Lane 10) 
71.8 69.9 71.5 
 
Table 7.1: The expected Molecular sizes of the recombinant fusion proteins for 
PLCXD-1, 2.1 and 3, expressed using the pOPIN vector suite. 
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Figure 7.2: SDS-PAGE analyses of expression screens.  Full-length Homo sapiens 
phospholipase C X-domain containing protein 1.  A. Lemo 21 cells grown in Powerbroth 
with IPTG induction; B. Rosetta (DE3) cells grown in Powerbroth with IPTG induction; 
C. Lemo 21 cells with auto-induction using TB-Overnight express media; D. Rosetta 
(DE3) cells with auto-induction using TB-Overnight express media. N-terminal fusion 
tag: 1- (His)6-3C; 2- (His)6-SUMO-3C; 3- (His)6-NUSA-3C; 4- (His)6-MSYB-3C; 5- (His)6-
MBP-3C; 6- (His)6-TF-3C; 7- (His)6-TRX-3C; 8- (His)6-HALO-3C. C-terminal fusion tag: 9- 
3C-(His)6; 10- 3C-HALO7-(His)6. To maintain the same layout, some of the gels have 
been stitched together and this is denoted with a doted line. 
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Figure 7.3: SDS-PAGE analyses of expression screen. Full-length Homo sapiens 
phospholipase C X-domain containing protein 2.1.  A. Lemo 21 cells grown in 
Powerbroth with IPTG induction; B. Rosetta (DE3) cells grown in Powerbroth with IPTG 
induction; C. Lemo 21 cells with auto-induction using TB-Overnight express media; D. 
Rosetta (DE3) cells with auto-induction using TB-Overnight express media. Fusion tags: 
1- (His)6-3C; 2- (His)6-SUMO-3C; 3- (His)6-NUSA-3C; 4- (His)6-MSYB-3C; 5- (His)6-MBP-
3C; 6- (His)6-TF-3C; 7- (His)6-TRX-3C; 8- (His)6-HALO-3C. C-terminal fusion tag: 9- 3C-
(His)6; 10- 3C-HALO7-(His)6. To make it easier to view the molecular marker some of 
the gels have been stitched together and this is denoted with a doted line. 
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Figure 7.4: SDS-PAGE analyses of expression screen. Full-length Homo sapiens 
phospholipase C X-domain containing protein 3.  A. Lemo 21 cells grown in Powerbroth 
with IPTG induction; B. Rosetta (DE3) cells grown in Powerbroth with IPTG induction; 
C. Lemo 21 cells with auto-induction using TB-Overnight express media; D. Rosetta 
(DE3) cells with auto-induction using TB-Overnight express media. N-terminal fusion 
tags: 1- (His)6-3C; 2- (His)6-SUMO-3C; 3- (His)6-NUSA-3C; 4- (His)6-MSYB-3C; 5- (His)6-
MBP-3C; 6- (His)6-TF-3C; 7- (His)6-TRX-3C; 8- (His)6-HALO-3C. C-terminal fusion tag: 9- 
3C-(His)6; 10- 3C-HALO7-(His)6. To make it easier to view the molecular marker some 
of the gels have been stitched together and this is denoted with a doted line 
 
 
 
A
u
to
-i
n
d
u
ct
io
n
 
IP
TG
 in
d
u
ct
io
n
 
Lemo21 (DE3) Rosetta™ (DE3) 
193 
 
7.3. Expression trials of hPLCXD1, 2.1 and 3 in mammalian cells 
The same suite of recombinant pOPIN expression vectors previously constructed for 
each PLCXD isoform, were tested for soluble protein expression following transfection 
of human embryonic kidney cells (HEK293; Chapter 2, Section 2.3.3). The different 
PLCXD fusion proteins were transiently expressed in HEK293 cells according to Chapter 
2, Section 2.3.3. Following growth of cells for 3 days (Section 2.3.3) the cells were lysed 
(Section 2.8.1) and soluble protein expression was assessed by western blotting 
detection of (His)6-tagged proteins present in the total lysate (Figure 7.5A) and soluble 
fractions (Figure 7.6B). Immunoreactive bands of expected sizes were observed in the 
total lysate of HEK293 cells transfected with most of the PLCXD3 vector constructs, 
however the intensity of these bands were variable. Corresponding bands were also 
observed in the soluble protein extract for these constructs indicating soluble 
expression. For PLCXD3, the highest level of soluble expression was observed with N-
terminal SUMO and TRX fusion tags. Immunoreactive bands were not found to be 
present in either the total lysate or soluble extract fractions from HEK293 cells 
transfected with expression vector constructs containing either PLCXD1 or PLCXD2.1 
(data not shown). 
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(A) 
 
 
 
 
(B) 
 
 
 
 
 
Figure 7.5: Western blot showing the results of the HEK293 cell expression screen. 
Homo sapiens phospholipase C X-domain containing protein 3. Western blot 
performed using anti-His primary antibody (1/1000 dilution) with total cell lysate (A), 
and soluble extract (B). N-terminal fusion tags: 1- (His)6-3C; 2- (His)6-SUMO-3C; 3- 
(His)6-NUSA-3C; 4- (His)6-MSYB-3C; 5- (His)6-MBP-3C; 6- (His)6-TF-3C; 7- (His)6-TRX-3C; 
8- (His)6-HALO-3C. C-terminal fusion tag: 9- 3C-(His)6; 10- 3C-HALO7-(His)6. The 
expected sizes of the different tagged versions of PLCXD3 are detailed in Table 7.1 
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7.4. Expression trials of hPLCXD1, 2 and 3 in insect cells   
The suite of pOPIN vectors previously created for each PLCXD isoform were used to 
create recombinant baculovirus particles for protein expression in Sf9 insect cells, as 
described in Chapter 2, Section 2.4.2. Sf9 cells were transfected with either 5 µL or 50 
µL of recombinant P1 baculovirus and proteins were harvested 72 and 96 hours post-
infection (Section 2.8.1). As with recombinant expression in HEK293 cells, soluble 
recombinant protein expression was only observed for hPLCXD3 (Figure 7.6). The 
presence of hPLCXD-1, 2.1 and 3 was not tested in total lysates. The highest levels of 
soluble expression were seen when hPLCXD3 was expressed with only a (His)6-tag at 
either the N (pOPINF construct; Lane 1) or C-terminal (pOPINE Neo construct; Lane 9). 
This result was consistent across the different expression conditions tested.  
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Figure 7.6: SDS-PAGE analyses of insect Sf9 cell expression screens.  Small-scale trials 
were conducted to determine the optimal conditions for hPLCXD3 production in Sf9 
cells following infection with recombinant baculovirus (BV) containing the hPLCXD3 
coding sequence. N-terminal fusion tags: 1- (His)6-3C; 2- (His)6-SUMO-3C; 3- (His)6-
NUSA-3C; 4- (His)6-MSYB-3C; 5- (His)6-MBP-3C; 6- (His)6-TF-3C; 7- (His)6-TRX-3C; 8- 
(His)6-HALO-3C. C-terminal fusion tag: 9- 3C-(His)6; 10- 3C-HALO7-(His)6.  
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7.5. Scale-up purification and crystallisation trials of hPLCXD3 
Previously, small-scale expression trials were performed in E.coli, HEK293T and Sf9 
insect cells to test the effect of numerous fusion tags on the expression of soluble 
recombinant human PLCXD1, 2.1 and 3 proteins. Whereas no signs of soluble 
expression were detectable for hPLCXDs 1 or 2.1 under any of the conditions tested, 
hPLCXD3 expressed as a soluble protein with highest levels being obtained in the insect 
expression screen. The expression of N- and C-terminal (His)6-tagged hPLCXD3 was 
further optimisation in Sf9 cells by transfection with different titers of the recombinant 
P1 virus particles (5, 10, 15, 12 and 30 µL) created for each construct. Cells were 
transfected according to Section 2.3.2 and protein extraction was carried out after 1, 
2, 3 and 4 days post-transfection (Chapter 2, Section 2.8.1). The soluble expression of 
hPLCXD3 was analysed by western blotting. The work was carried out by Ms Nahid 
Rahman, Oxford Protein Production Facility. For N-terminal (His)6-tagged hPLCXD3, 
the best soluble, non-degraded expression was present in cells infected with 15-30 µL 
of recombinant P1 virus, that were harvested 3 days post-infection. For the C-terminal 
(His)6-tagged construct, the best levels of expression was present in cells infected with 
15-30 µL recombinant P1 virus that were harvested 1 day post-transfection. These 
conditions were then chosen for scale-up purification. 
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Figure 7.7- Western blot analysis of the expanded insect cell expression screen for 
hPLCXD3. Recombinant virus containing either the N- or C-terminal (His)6-tagged 
version of hPLCXD3 was used to infect Sf9 cells. The following volumes of virus were 
used for transfections: 5 µL, 10 µL, 15 µL, 20 µL and 30 µL (denoted 1, 2, 3, 4 and 5 
above). Cells were harvested at day 1, 2, 3 and 4 and western blotting analysis was 
performed on extracted proteins using an anti-His primary antibody. Molecular 
markers are present in the first and last lanes of both blots. 
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For scale-up, total culture volumes of 1 litre were grown for each hPLCXD3 construct 
and recombinant proteins expressed according to Chapter 2, Section 2.4.2. Insect cell 
pellets were disrupted and (His)6-tagged proteins purified from the cell lysate using 
standard affinity nickel-chromatography techniques, as detailed in Chapter 2, Section 
2.8.6. SDS-PAGE analysis revealed the presence of a band of ~38.5 kDa corresponding 
to the expected size of (His)6-tagged hPLCXD-3 in both the soluble extract (Lane 2; 
Figure 7.8A and B), and the affinity-purified eluate fractions (Lanes 6, 7 and 8; Figure 
7.8A and B). The highest levels of soluble expression were seen with the hPLCXD3, N-
terminal (His)6-tagged protein. For both N- and C-terminal (His)6-tagged hPLCXD3 
proteins, eluate fractions were pooled and prepared for further purification by gel 
filtration chromatography (Chapter 2, Section 2.8.8). For each construct, two clear 
protein peaks were observed (Figure 7.9 and 7.10). The first peak corresponded to 
higher molecular proteins of ~2500-200 kDa, but also contained a number of proteins 
below 200 kDa which presumably exist of dimers in solution. The second peak 
comprised proteins ranging in molecular weight from ~20 to 100 kDa, including the 
(His)6-tagged hPLCXD3. SDS-PAGE analysis of fractions spanning the second 
chromatogram peak revealed a band corresponding to the expected size of (His)6-
tagged hPLCXD3 (~38.5 kDa) for both preparations (Figure 7.9 and 7.10). For the N-
terminal (His)6 fusion protein, fractions containing the 38.5 kDa band were pooled and 
the histidine tag cleaved following incubation with the 3C protease, as previously 
described in Chapter 2, Section 2.8.7. Following cleavage of the N-terminal (His)6-tag, 
the solubility of hPLCXD3 was compromised and substantial precipitate was obtained 
after storage of the protein at 4 °C for 24 h. SDS-PAGE analysis revealed reduced levels 
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of the 37 kDa band in the remaining soluble fraction. For the C-terminal (His)6 fusion 
protein, no tag cleavage was performed and fractions containing hPLCXD3 were 
subsequently pooled and concentrated to 5 mg/mL, as described in Section 2.7.12. 
Mass spectrometric analysis of the purified protein showed no evidence of post-
translational modifications. An initial crystallization screen was carried out using the 
commercially available JCSG+ and Wizard I+II protein crystallisation screens and the 
un-cleaved C-terminal fusion protein (Chapter 2, Section 2.8.13). Crystal trays were 
incubated at room temperature and checked for the presence of crystals each day for 
6 months. No crystals were detected in any of the tested conditions. 
 
 
 
 
 
 
 
Figure 7.8: SDS-PAGE analysis, with Instant Blue staining, of the different stages 
purification of C-terminal (A) and N-terminal (B) (His)6-tag fusions of hPLCXD3 from a 
1 litre culture of sf9 cells. Affinity purification chromatography using Nickel-beads was 
performed in both cases. Lanes are as follows: 1- total lysate; 2- soluble extract; 3- Ni 
column flow through; 4- Ni column wash 1; 5- Ni column wash 2; 6- Ni column eluate 
fraction 1; 7- Ni column eluate fraction 2; 8- Ni column eluate fraction 3; M- molecular 
weight size markers. 
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Figure 7.9: Gel exclusion chromatographic analysis of the pooled eluate fractions of 
the C-terminal PLCXD3 (His)6-tag fusion protein expressed in Insect cells following 
affinity chromatography. (A) chromatographic analysis showing two protein peaks 
(Peaks 1 and 2) corresponding to proteins eluting from the first Ni2+ - affinity column 
chromatography and an imidazole peak (Peak 3). (B)  SDS-PAGE analysis of selected 
fractions from the two protein peaks.  
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Figure 7.10: Gel exclusion chromatographic analysis of the pooled eluate fractions of 
the N-terminal PLCXD3 (His)6-tag fusion protein expressed in Insect cells following 
affinity chromatography. (A) chromatographic analysis showing two protein peaks 
(Peaks 1 and 2) corresponding to proteins eluting from the first Ni2+ - affinity column 
chromatography and an imidazole peak (Peak 3). (B)  SDS-PAGE analysis of selected 
fractions from the two protein peaks.  
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7.6. Discussion 
Analysis of the data generated by the expression screens in the three different host 
organisms revealed a high level of variability in protein solubility, with PLCXD3 showing 
the highest levels of soluble expression in each host. In the E. coli screen the 
production of soluble PLCXD1 and 3 appeared to be a “hit-or-miss” affair with some 
fusion tags enhancing solubility but with little consistency across the different 
expression regimes tested, and no obvious increases in solubility of PLCXD2. The 
HEK293 mammalian expression screen was also met with limited success with soluble 
expression only experienced with some fusion tagged versions of PLCXD3. The 
baculovirus-insect cell expression system consistently showed the highest levels of 
soluble expression; however this was only the case for PLCXD3 with no soluble 
expression being seen for PLCXD1 or 2. The best levels of soluble expression were 
obtained for full-length versions of PLCXD3 containing an N- or C-terminal (His)6 tag 
and expressed in Sf9 insect cells and therefore these cells were chosen for scale-up 
purification. Given that the best levels of soluble expression were only observed for 
PLCXD3, further optimisation of the recombinant production of PLCXD1 and 2 is 
required. Future strategies to enhance soluble expression could include co-expression 
with chaperones and the screening of more fusion tags. An alternatively method may 
be to recover native recombinant protein from inclusion bodies through a process 
known as refolding. Indeed this strategy has already proven successful for a number 
of proteins with poor soluble expression in E. coli, however the optimal conditions for 
refolding are protein-dependent and cannot be predicted and therefore this strategy 
is often challenging (Tsumoto et al., 2003).  
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Scale-up purification of hPLCXD3 was performed using Sf9 cells in a total 1 litre culture 
volume, using the predetermined optimal growth conditions for the soluble 
expression of N- and C-terminally (His)6-tagged PLCXD-3. The highest levels of soluble 
expression were seen with an N-terminal hexa-His-tagged version of PLCXD3. 
Purification of both N- and C-terminal (His)6 tagged-PLCXD3 was successful from insect 
cells with the presence of a band of the expected size following affinity and gel 
permeation chromatography. Unfortunately, enzymatic cleavage of the N-terminal 
(His)6-tag from PLCXD3 resulted in complete protein precipitation, rendering the 
protein unsuitable for further biochemical and crystallographic studies. Interestingly, 
sequence analysis predicts an intrinsically disordered region (IDR) formed by the first 
10 amino acids within the N-terminal regions of hPLCXD3, which therefore suggest 
that the N-terminus of PLCXD3 does not assume a unique three-dimensional structure 
under physiological conditions. IDRs have generally been shown to be involved in a 
variety of functions including molecular recognition, molecular assembly and protein 
modification (Dunker et al., 2002). It is therefore possible that the inclusion of a (His)6-
tag at the N-terminus of PLCXD3 may cause a disorder-to-order transition within this 
region, which could be associated with enhanced solubility of purified PLCXD3. This 
opens up the possibility that under physiological conditions an N-terminal IDR may 
mediate interactions with other proteins, which act as binding partners to stabilise 
PLCXD3 or alternatively proteins involved in post translation modifications. Future 
experiments should aim to express and purify PLCXD3 lacking the predicted N-terminal 
IDR to assess its effect on the solubility of the protein. Also, future work could involve 
pull-down experiments and two-hybrid assays to characterise the existence of 
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potential binding partners of PLCXD3 and the effect of removal of the predicted N-
terminal IDR on protein-protein interactions.  
In-order to prevent potential precipitation of PLCXD3, cleavage of the C-terminal 
(His)6-tag was not performed. As expected, there were no signs of precipitation 
following purification and concentration (to 5 mg/mL) of the protein. Failure to cleave 
large affinity tags from purified proteins has been noted to make crystallisation and 
structure determination more of a challenge as multi-domain proteins are usually less 
conducive to forming well-ordered, diffracting crystals, presumably due to the 
conformational heterogeneity allowed by the flexible linker region (Smyth et al., 2002). 
The presence of a small affinity tag, such as the (His)6, is not expected to affect the 
structure of PLCXD3 as it does not significantly increase the size or charge. Due to these 
characteristics His-tagged proteins may be more conducive for structure 
determination, indeed more than 100 structures of (His)6-tagged proteins having been 
deposited in the Protein Data Bank (Carson et al., 2007).  
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Chapter 8: Conclusions and future directions 
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The work described herein suggests that PLCXDs are ubiquitous enzymes present in all 
species from bacteria to man. At least three tissue-specific PLCXDs (PLCXD1-3) were 
identified in most mammals and four (PLCXD1-4) in teleost fishes. PLCXDs only contain 
an X-domain in their structure and lack all other domain structures present in 
mammalian PI-PLCs. PLCXDs are therefore more similar in primary structure to 
bacterial PI-PLCs and possibly represent the evolutionary precursor of mammalian PI-
PLCs. As mentioned at the start of the thesis, “Science never solves a problem without 
creating 10 more”, therefore this Chapter discusses the questions raised by this thesis 
and suggests future experiments that could be conducted. 
8.1. Are PLCXDs active phospholipase C enzymes? 
Based on the multiple sequence alignments described in Chapter 3, key amino acids 
known to be essential for the catalytic functioning of bacterial PI-PLCs were found to 
be conserved in the X-domain sequences of all PLCXDs, with the exception of ePLCXD4. 
Bacterial PI-PLCs use these residues to catalyse the hydrolysis of PI by a mechanism 
involving general acid, general base catalysis. Based on this data, it is therefore 
speculated that PLCXDs may possess a similar catalytic mechanism to bacterial PI-PLCs 
and that the catalytic activity of ePLCXD4 may be distinct from other PLCXDs. Whether 
PLCXDs also contain residues that would enable them to interact with PI and possible 
PI(4,5)P2 was difficult to predict given the low overall sequence homologies with the 
bacterial PI-PLCs. The ability of human PLCXDs to catalyse the hydrolysis of PI(4,5)P2 
and PI was tested in this thesis. Although expression of human PLCXD1, 2 and 3 in HeLa 
cells was associated with a 3- to 7-fold increase in endogenous phospholipase C activity, 
it was found in Chapter 6 that purified hPLCXD3 was not able to hydrolyse either 
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PI(4,5)P2 or PI. One interpretation of this data is that human PLCXDs may function to 
increase the activity of other endogenous PI-PLCs and are themselves not catalytically 
active. Future experiments could screen the catalytic activities of individually purified 
mammalian PI-PLCs in the presence and absence of purified PLCXD3 to test whether 
PLCXD3 can increase the rate of PI(4,5)P2 hydrolysis. Alternatively, the observed 
results may suggest that our expression and purification protocols are not sufficient 
for the production of active PLCXDs. Indeed, we experienced great difficulties to 
express human PLCXDs as soluble proteins in E. coli, mammalian and insect cells with 
the recombinant proteins mainly being localised within insoluble inclusion bodies. 
Although our small-scale expression trials carried out at OPPF identified insect cells as 
giving the best soluble expression of human PLCXD3, this expression was found to be 
inconsistent following scale-up purification with repeated purification attempts failing 
to gain any soluble protein. Future experiments could further optimise the 
recombinant expression of PLCXDs to gain sufficient protein for enzymatic analysis and 
crystallography. Obtaining the crystal structures of human PLCXDs would prove useful 
in determining the substrate specificity of PLCXDs. This way we could model the X-
domain structure with that of known bacterial PI-PLCs and mammalian PI-PLCs 
structures to predict whether PI and/or PI(4,5)P2 would be able to interact with the 
active site of PLCXDs. 
8.2. What is the role of ePLCXD4 in the intestine of the eel during developmental 
transitions? 
Based on microarray data from the intestine of sexually immature yellow eels and 
sexually mature silver eels, a novel PI-PLC family member was identified which 
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exhibited differential expression following sexual maturation. The deduced amino acid 
sequence of the eel protein shares a maximum of 33% with an uncharacterised PLCXD 
from the bicolour damselfish (Stegastes partitus) and less than 20% with all other 
PLCXDs, including eel PLCXD1, 2 and 3. Subsequently, the eel PLCXD gene identified in 
the microarray was denoted as PLCXD4. The original microarray data was validated by 
real time PCR analysis which found a 30-fold decrease in the expression of PLCXD4 
mRNA in the intestine of silver compared to yellow eels. Immunofluorescence 
revealed PLCXD4 to be present in unknown epithelial cells and western blotting 
analysis found an increase in PLCXD4 levels in the intestine of SW-acclimated silver 
eels, contrasting the RT-qPCR data. This data therefore suggests that PLCXD4 protein 
levels are up-regulated by salinity changes in the gut associated with the ingestion of 
SW, but only in silver eels. Physiologically this may suggest a possible role for PLCXD4 
in osmoregulation in the intestine of eels; however this seems unlikely given that 
PLCXD4 protein expression levels were not affected by salinity transfer in yellow eels. 
Future experiments could test the effect of salinity changes on the expression of 
PLCXD4 in cultured epithelial cells from both the yellow and silver eels. Another 
possible explanation is that the observed increases in PLCXD4 protein levels are 
associated with the morphological and physiological changes that occur late on during 
the silvering process as the eel enters the sea. Further studies using cultured epithelial 
cells from the eel intestine involving PLCXD4 overexpression and knockdown are 
required to gain better insight into the physiological functions of ePLCXD4 in the 
intestine. 
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8.3. What is the role of PLCXDs in the brain? 
Data described within this thesis provides evidence that PLCXDs may be important for 
brain function. Quantitative PCR analysis using a number of mouse tissues found 
PLCXD1, 2 and 3 mRNA to be predominantly expressed in the brain. More specifically, 
in situ hybridisation data available within the Allen brain atlas revealed PLCXD1 and 2 
to have distinct expression profiles within the brain. PLCXD1 was particularly 
expressed in neurons within the hippocampal formation and the cerebellum 
suggesting that PLCXD1 could be involved in signal transduction in these brain regions 
and potential association with learning and memory formation. PLCXD2 mRNA was 
predominantly located in neurons within the main olfactory bulb and visual cortex 
suggesting that PLCXD2 might specifically be involved the neural pathways underlying 
the transduction and processing of sensory stimuli within higher brain regions. No in 
situ hybridisation data for PLCXD3 was available within the Allen brain atlas and 
therefore the localisation of PLCXD3 mRNA within the brain is currently unknown. 
More work is required to further characterise the significance of these results. The 
specific functions of PLCXDs within the brain could be assessed by the generation of 
knock-out mice. To investigate the functions of PLCXDs in neuronal function, the 
expression and localisation of PLCXDs in primary neurons could be characterised. 
Experiments could also study the effect of PLCXD overexpression and/or knockdown 
on the function of primary neurons.  
Expression analysis using a mouse model of neurodegeneration, known as the 
Harlequin (Hq) mouse, revealed a potential role for PLCXDs in neurodegeneration. The 
levels of PLCXD mRNA and protein were found to differ in tissues that were associated 
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with significant neurodegeneration attributed to the Hq mutation. Both PLCXD2 and 
PLCXD3 were found to be significantly down-regulated in retinal samples extracted 
from Hq mutant mice compared to control mice. Furthermore, immunofluorescence 
suggested that PLCXD3 is localised in amacrine cells within the retina and that protein 
levels are also be reduced in Hq mutant mice, although these reductions need to be 
confirmed by quantitative immunofluorescent experiments. In the cerebellum, 
although mRNA levels were consistent between control and mutant mice, levels of 
PLCXD3 protein were significantly reduced in Hq mutant mice compared to control 
mice. Taken together, although these results are compelling, further studies are 
required to clarify the association between the disease phenotype and PLCXD mRNA 
and protein expression levels. Future experiments are required to test whether 
increases in oxidative stress could reduce the levels of PLCXD2 and 3 mRNA in the 
retina and PLCXD3 protein in the cerebellum of Hq mice. This could be tested by RT-
qPCR and western blotting analysis of primary neuron cultures with or without 
chemically induced oxidative stress. Interestingly, a paper was recently published 
which suggested that three intronic SNPs within PLCXD3 were associated with an 
increased risk of variant CJD. Although we are yet to further characterise the 
importance of these SNPs with regard to the expression and catalytic activity of 
PLCXD3, this data may also suggest a potential role for PLCXDs in neurodegeneration. 
It is hoped that the worked described within this thesis would stimulate further 
research into the role of PLCXDs in neurodegenerative disorders. Experiments could 
use RT-qPCR and western blotting experiments to test whether PLCXDs show 
differential expression profiles in other neurodegenerative disorders, such as 
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Alzheimer’s disease (AD), Huntingdons disease (HD) and Parkinson’s disease (PD). 
Furthermore, primary neuron cultures could be used to test the functional impact of 
overexpression and knockdown of PLCXDs in neuronal function.  
8.4. Optimisation of the recombinant expression of PLCXDs 
A major focus of this thesis was to determine the optimal conditions required for the 
expression and purification of sufficient amounts of soluble PLCXD for enzymatic 
analysis and structurally analysis by X-ray crystallography. Although PLCXD1, 2 and 3 
were found to express well in E. coli, significant formation of inclusion bodies was 
found in all cases, with PLCXD3 showing the highest solubility. PLCXD3 was therefore 
chosen for scale-up purification however a 30 L culture was required to obtain 
sufficient soluble protein for crystallography. This prompted a visit to the Oxford 
Protein Production Facility to test the effect of fusion tags and different host organisms 
on the solubility of recombinantly expressed PLCXDs. Initial success was achievedd 
with PLCXD3 expressed in insect cells however this expression was found to be 
inconsistent with repeated attempst failing to obtain any expression at all. It is clear 
from work carried out in this thesis that further work is required to optimise to 
conditions required for soluble recombinant expression of human PLCXDs. One 
possibility is to recover native recombinant protein from inclusion bodies through a 
process known as refolding. Although this strategy has proved successful for a number 
of proteins with poor soluble expression in E.coli, the optimal conditions for refolding 
are protein-dependent and cannot be predicted making this strategy challenging. 
Another possible strategy is co-expression with chaperones in E. coli. Recombinant 
cells experience a high substrate load and therefore it is expected that the availability 
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of chaperones, which are critically important for protein folding, might be a limiting 
factor. Future experiments could express individual chaperones or chaperone sets, 
including GroEL, DNak and their associated co-chaperones (de Marco et al., 2007) 
along with PLCXDs. 
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Appendix A- Sequences of primers used for the amplification of eel PLCXDs 
 
Marathon adaptor primer 1 (AP1) 5’-CCATCCTAATACGACTCACTATAGGGC-3’ 
Marathon adaptor primer 2 (AP2) 5’-ACTCACTATAGGGCTCGAGCGGC-3’ 
Eel PLCXD4 AS1  5’-TGCCAGCGAAAAGTATTACAAAG-3’ 
Eel PLCXD4 AS2  5’-CTTCATGACCATTTGGGAGATCAAGC-3’ 
Eel PLCXD4 AS3 5’-CATGAGGGTGAGCAATCAAACG-3’ 
 
 
>Anguilla anguilla PLCXD4 protein mRNA, partial coding sequence. 
 
GTACTTTGTAATACTTTTCGCTGGCAGTGAAGGGGATCCCTATTTCAATGATTTAGAAAAGCTTGATCT
CCCAAATGGTCATGAAGTAAACTGGATGAAAAGTATAGATGATGAAACACTTCTCTCAGCAGTCACCAT
TCCAGGCACATGCCAAAGCATGAAAATGAATACTCTTGATCAACACCAAGCATGGACAGTAACACAGCA
GTTTACAGCAGGGGTGCGATTCTTTGATATCTCCCTGGATAATTCAGTTGTCAAAGATGGTTCTCTTAC
ACGTAGAAAATTTGCAGATGTCATGGAAAAGATGAGAGAACGTTTGATTGCTCACCCTCATGAAGTAAT
TTTGATAAGATTGACCCCAGAAAATGGCAAAGCTGAAAAGGAAATAGAAAAATTCATACAAGTGAATGA
CAATGTGTGGAAGGATAAAAAAGTGCCCAAAATGAAAGAAGTAAGGGGTAAGATAGTGTTGGTGCAGAG
CAGCAAGTTCAGTAAAGGGCTCCCGGTGGACCTTCATGTGGGTGGGAAGGAGTTTAAAGATAAGCACTC
AAAAAAGTACATGGAAGCGATTTATAATCATCTAAAGGCAGCAGAAAATGCAGGTGACCATATTGTAGT
GACTGAAACAAGCGCATATTTTGGATTCACAAAATCATCAAAAAATGCAGCTGTAAAAATTAATCCCAT
GCTCCAAAAATACATAGACAACCAGCCGCATGCTAATAAACCAAAAGGTTTGGGGGTGATTGTCATGGA
CTATCCAGGCATTGATCTCATCCAGAAAATCATAGATATCAACCCTAAATCAGAAGGCTCACCTGAATC
CTCCCCAGAAGAAGGTGAGAACCCACCTGAAACTGATGGGGAACCCGAATGA 
 
Figure 1/Table 1: Partial coding sequence of the sense strand of ePLCXD4, prior to 
the onset of this project. Primers used to amplify and sequence the 5’ end within this 
thesis were: AS1, AS2 and AS3. 
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Primer seqeunecs used for determination of tissues distribution by 
real-time quantitative PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sense (5’-3’) Antisense (5’-3’) 
PLCXD1 GCAGCATGGCTTGACTCCCACC’ CGTCGTCATCGTAGGACAGCACG 
PLCXD2 GTGCGTGACGGCCTCCATGAAATC CATCAGCCAGTGGGTGGTGGTAG 
PLCXD3 CGACGAGGCGTCGCCGGTG GAGGCCGTGCGCGAAGTAGAG 
PLCXD4 CGTTTGATTGCTCACCCTCATGA GAGCCCTTTACTGAACTTGCTGCTCT 
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Appendix B- Accession numbers for proteins in used in ClustalW and 
phylogenetic analyses.  
 
Protein Species EMBL Accession number 
PLCXD1 Homo sapiens AAH05028.1 
Mus musculus AAH39627.1 
Bos Taurus AA151475.1 
Danio rerio AAH93162.1 
Anguilla anguilla N/A 
Xenopus tropicalis AAMC01064598 
Gallus gallus AADN03001397 
PLCXD2 Homo sapiens AA1211156.1 
Mus musculus AA151060.1 
Bos Taurus DAAA02001335 
Anguilla anguilla N/A 
Xenopus laevis AAH42310.1 
PLCXD3 Homo sapiens CAH56160.1 
Mus musculus NP_796329.2 
Bos Taurus NP_001096774.1 
Anguilla anguilla N/A 
Danio rerio AAH91866.1 
PLCXD4 Anguilla anguilla JX101676 
Takifugu rubripes XP_003969411.1 
Oreochromis niloticus XP_003452509.2 
Stegastes partitus XP_008286913.1 
Danio rerio XP_005158485.1 
PI-PLC Bacillus cereus NP_833485.1 
Bacillus thuringiensis ZP_04103399.1 
Listeria monocytogenes CAA38438.1 
Trypanosoma cruzi CAA03904.1 
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Appendix C- Sequences of primers used for molecular cloning of PLCXDs in 
E.coli 
 
hPLCXD 
isoform 
Primer Pair (5’→3’) Extension Target 
Vector 
hPLCXD1 Sense- ATGGGTGGCAGGTGAGCGCTTC 
Antisense- TCAGCACCACAGCAGCTTCTGCATTGAG 
NcoI 
HindIII 
pET M11 
Sense- ATGGGTGGGCAGGTGAGCGCTTC 
Antisense- TCAGCACCACAGCAGCTTCTGATTGAG 
SpeI 
NdeI 
pdlNotI’nPk
’MCS’R 
Sense- ATGGGTGGGCAGGTGAGCG 
Antisense-TCAGCACCACAGCAGCTTCTGATTG 
See Table 
2.5 Chapter 
2  
pOPIN (N-
terminal 
fusion) 
Sense- ATGGGTGGGCAGGTGAGCG 
Antisense- GCACCACAGCAGCTTCTGATTGAGC 
See Table 
2.5 Chapter 
2 
pOPIN (C-
terminal 
fusion) 
 
hPLCXD-
2.1 
Sense- ATGCTAGCAAGTTAGGAAGGCCAGGAG 
Antisense- GGATCTTCTGCTGAATCTCAAAGG 
NdeI 
HindIII 
pET 22b+ 
Sense- ATGCTAGCAAGTTAGGAAGGCCAGGAG 
Antisense TCAGGATCTTCTGCTGAATCTCAAAGG 
SpeI 
NdeI 
pdlNotI’nPk
’MCS’R 
Sense- ATGCTAGCAGTTAGGAAGGCCAGGAGG 
Antisense- TCAGGATCTTCTGCTGAATCTCAAAGG 
See Figure 
2.5 Chapter 
2 
pOPIN (N-
terminal 
fusion) 
Sense- ATGCTAGCAGTTAGGAAGGCCAGGAGG 
Antisense- 
GGATCTTCTGCTGAATCTCAAAGGATAAACTGG 
See Figure 
2.5 Chapter 
2 
pOPIN (C-
terminal 
fusion) 
 
hPLCXD3 Sense- ATGGCCTCGTCTCAGGGGAAAACG 
Antisense- TCAAAGTGTTGGCTTCTCCTTCATCAAAG 
 
NcoI 
HindIII 
pET M11 
Sense- ATGGCCTCGTCTCAGGGGAAAAACG 
Antisense- TCAAAGTGTTGGCTTCTCCTTCATCAAAG 
 
SpeI 
NdeI 
pdlNotI’nPk
’MCS’R 
Sense- ATGGCCTCGTCTCAGGGGAAAAAC 
Antisense- TCAAGTGTTGGCTTCTCCTTCATCAAAG 
See Table 
2.5 Chapter 
2 
pOPIN (N-
terminal 
fusion) 
Sense- ATGGCCTCGTCTCAGGGGAAAAAC 
Antisense- GTTGGCTTCTCCTTCATCAAAGACATAG 
See Table 
2.5 Chapter 
2 
pOPIN (C-
terminal 
fusion) 
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Appendix D- Primers used for semi-quantitative and quantitative PCR 
experiments to determine tissue expression patterns 
 
Mouse PLCXD1 Sense 
Mouse PLCXD1 Antisense 
5’-GTACCTGGACCTGCGGATCGCGCAT-3’ 
5’-GGCCAGAGCTGATCATAACGGCTGACTGT-3’ 
Mouse PLCXD2 Sense 
Mouse PLCXD2 Antisense 
5’-GAGACACTGACCAGGAGATCTACTTCATC-3’ 
5’-GCTCGCTCACTCAGGGTGCTCTCCAAG-3’ 
Mouse PLCXD3 Sense 
Mouse PLCXD3 Antisense 
5’-CAGACGATGAGCTTCACTGGTCAGC-3’ 
5’-CTGTGGTAGAAGACCAGTACTTGATAGTG-3’ 
Mouse Rpl-P0 Sense 
Mouse Rpl-P0 Antisense 
5’-GAGTGATGTGCAGCTGATAAAGACTGG-3’ 
5’-CTGCTCTGTGATGTCGAGCACTTCAG-3’ 
Human PLCXD1 Sense 
Human PLCXD1 Antisense 
5’-CGCCCTGTCGTGCTGAAATGGTC-3’ 
5’-GATACAGGCGACCAGGTACTCGTG-3’ 
Human PLCXD2.1 Sense 
Human PLCXD2.1 Antisense 
5’-CGCTACTTTGACCTGCGTGTGTC-3’ 
5’-CGCAGCGTCAAACTTTCCACACTG-3’ 
Human PLCXD3 Sense 
Human PLCXD3 Antisense 
5’-GCGGAAATGGTTAGCCACTCAGAC-3’ 
5’-CAGCACTTGATAGTCCTTCTCCCAC-3’ 
Human Rpl-P0 Sense 
Human Rpl-P0 Antisense 
5’-GAGTGATGTGCAGCTGATCAAGACT-3’ 
5’-GTTCCTCTGTGATATCAAGCACTTCAG-3’ 
 
 
Appendix E- Sequencing primers for pCR 4-TOPO 
 
M13 sense  5’-GGAACAAACGGCATGTGAGC-3’  
M13 antisense  5’-AAGCAGTGGTAACAACGCAGAGTACGCGGG-3’ 
T3 sense  5’-ATTAACCCTCACTAAAGGGA-3’ 
T7 antisense 5’-TAATACGACTCACTATAGGG-3’ 
pETM11 Sense 5’-CCATGAAACATCACCATCACCATCACC-3’ 
pETM11 Antisense 5’-GCTAGTTATTGCTCAGCGGTGGCAG-3’ 
pET22b+ Sense 5’-CTTAAGAAGAGATATACCATGAAACATCAC-3’ 
pET22b+ Antisense 5’-AGCTTGTCGACGGAGCTCGAATT-3’ 
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Appendix F- Specific primers for RT-qPCR assays using cDNA prepared from 
Harlequin mice tissues 
 
Gene 
name 
Sense primer (5’-3’) Antisense primer (5’-3’) 
AIF1 GGGGGCAAAATGGATAATTC CTGTTCTCTTCTGGGGACAG 
AIF2 GTCATCTCCTAGGATCCCCTTC TTGGTCTTCTTTTATAGTTTTGTAGGC 
BRN3A GAGGCCTATTTTGCCGTACA CAGTAAGTGGCAGAGAATTTCA 
PLCXD
1 
GTACCTGGACCTGCGGATCGCGCAT GGCCAGAGCTGATCATAACGGCTGACTG
T 
PLCXD
2 
GAGACACTGACCAGGAGATCTACTTCAT
C 
GCTCGCTCACTCAGGGTGCTCTCCAAG 
PLCXD
3 
CTCAGGTGGTGCTGACACCCAAA GTACGGATCCACTGCATCATGGCG 
 
 
 
